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Abstract 
Rationale 
Cardiovascular disease (CVD) is a leading cause of mortality in patients with COPD.  
Aortic stiffness, measured using aortic pulse wave velocity (PWV), an independent, 
non-invasive, predictor of CV risk; and inflammatory markers are increased in 
COPD.  Screening tools for community based identification of increased CVD risk, 
and a proactive approach to addressing primary prevention of CVD is needed.  
Statins modulate aortic stiffness and are anti-inflammatory, but are not currently 
used for primary prevention in COPD.  
Objectives 
Proof of principle double-blind Randomised Control Trial (RCT) to determine if six 
weeks simvastatin 20mg od reduces aortic stiffness, systemic and airway 
inflammation in COPD.  Cross-sectional pilot study comparing a non-invasive 
measure of oxidative stress (skin  “AGE ?) in COPD and controls, to lung function and 
aortic stiffness. 
Methods 
Stable patients (n=70) were randomised to simvastatin or placebo treatment.  Pre- 
and post-treatment aortic stiffness, blood pressure, spirometry, circulating 
inflammatory mediators and lipids were measured; airway inflammatory markers 
were performed where possible.  Predefined subgroup analysis was performed 
where baseline aortic PWV >10m/s. 
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For the cross-sectional study stable COPD patients (n=84) and controls (n=36) had 
lung function, arterial stiffness and skin AGE measured.   
Results  
In the RCT the active group achieved significantly lower total cholesterol, but no 
significant drop in aortic PWV compared to placebo group: -0.7(95%CI -1.8,0.5)m/s, 
p=0.24; or inflammatory markers.  In those with higher baseline aortic PWV, n=22, 
aortic PWV improved in the active group compared to placebo: -2.8(-5.2,-0.3)m/s, 
p=0.03.   
Skin AGE was increased in COPD compared to controls, inversely related to lung 
function, and directly related to aortic stiffness.   
Conclusions 
We could not detect any significant difference in the change in aortic PWV in 
patients with COPD taking simvastatin compared to placebo.  We did, however, 
report a significant and clinically relevant reduction in aortic PWV in those with high 
baseline aortic stiffness, suggesting a potential for statins to reduce CV morbidity in 
high risk individuals.  The pilot cross-sectional study suggests there is an indication 
to assess the potential role of skin AGE in patients with COPD as a non-invasive 
measure of CV risk.    
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1 Introduction 
1.1 Definition 
Chronic Obstructive Pulmonary Disease (COPD) is a term used to encompass a 
spectrum of disease from chronic bronchitis and emphysema, usually as a result of 
a significant tobacco smoking exposure.  Both chronic bronchitis and emphysema 
can be present in isolation, without the presence of COPD.  The key factor for a 
diagnosis of COPD is non-reversible airflow obstruction, where the Global Initiative 
ŽŶ KďƐƚƌƵĐƚŝǀĞ >ƵŶŐ ŝƐĞĂƐĞ  ?'K> ) ŝŶŝƚŝĂůůǇ ĚĞĨŝŶĞĚKW ĂƐ  “Ă ĚŝƐĞĂƐĞ ƐƚĂƚĞ
characterised by airflow limitation that is not fully reversible.  The airflow limitation 
is usually both progressive and associated with an abnormal inflammatory response 
of the lungs to nŽǆŝŽƵƐƉĂƌƚŝĐůĞƐŽƌŐĂƐĞƐ ? (Pauwels et al., 2001).  More recently the 
definition has been extended to include extra-pulmonary effects and comorbidities 
which may impact on the severity of the condition (Decramer et al., 2013).  As the 
condition progresses it can result in chronic (type II) respiratory failure (Raherison 
and Girodet, 2009).   
The heterogeneity of COPD has chronic bronchitis at one end of the spectrum and 
emphysema at the other end.  Chronic bronchitis is defined clinically as a chronic 
productive cough for at least three months of two consecutive years, in the absence 
of other diseases recognised as causing sputum production (MRC, 1965).  Whereas 
emphysema is defined pathologically as the permanent, abnormal enlargement of 
the air spaces distal to the terminal bronchioles, accompanied by destruction of 
their walls and without obvious fibrosis (ATS, 1995), leading to the irreversible loss 
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of elastic recoil with collapsing of the small, distal airways (Snider, 1985).  As these 
changes can occur without resulting in airflow limitation, a diagnosis of chronic 
bronchitis or emphysema can be made without meeting the definition of COPD.  
The obstructive ventilatory impairment associated with chronic bronchitis is 
attributed to increased inflammation, changes in the epithelium and increased 
secretions in the small airways (Snider, 1985).  As tobacco smoking is the main 
contributing factor to both chronic bronchitis and emphysema the two conditions 
often occur simultaneously, giving rise to the disorder chronic obstructive 
pulmonary disease (Snider, 1985).   
1.2 Epidemiology 
According to the World Health Organisation (WHO) COPD is the fourth leading 
cause of death in the world, and it is expected to become the third leading cause of 
death worldwide by 2020 (Raherison and Girodet, 2009, Murray and Lopez, 1997).  
COPD is the second leading cause of smoking attributable mortality, behind 
cardiovascular disease (Ezzati and Lopez, 2003).  It is estimated that 2.75 million 
(4.8%) deaths/year worldwide are attributable to COPD, with 30,000 of these 
deaths/year in the United Kingdom (UK) (Raherison and Girodet, 2009).  COPD is a 
growing problem in both the developed and developing countries throughout the 
world.  The prevalence statistics of COPD vary widely depending on the definition 
and classification methods, as recently demonstrated by the Burden of Obstructive 
Lung Disease (BOLD) (Buist et al., 2007).  Over a million people are diagnosed with 
COPD in the UK (Raherison and Girodet, 2009), with a further 2 million un-
diagnosed.  Previously the prevalence of COPD has been greatest in males, due to 
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smoking habits, but recently the prevalence in females has increased, particularly in 
young females; and in the United States of America (USA) the prevalence and 
deaths from COPD in females has now exceeded that of males (Mannino et al., 
2002).   
KWŚĂƐĂŶĞŐĂƚŝǀĞŝŵƉĂĐƚŽŶƚŚĞƐƵďũĞĐƚƐ ?ƋƵĂůŝƚǇŽĨůŝĨĞĂŶĚŝƐĂŚƵŐĞĞĐŽŶŽŵŝĐ
burden. The disabling effects of COPD vary depending on the severity of the 
condition and the susceptibility of the subject (Raherison and Girodet, 2009).  
Economic burden is related to both the impact on the health service including 
hospital admissions and ambulatory care and the inability to work (Raherison and 
Girodet, 2009).  The most significant healthcare cost is that associated with 
exacerbations and hospitalisations  (Chapman et al., 2006).  Historical annual direct 
costs have been estimated to be over £819 per patient per year in the U.K. (Britton, 
2003), with total direct costs to the National Health Service (NHS) in England and 
Wales of over £4.9 million and indirect costs of £9.82 million (NICE, 2010a).  At 
present the cost to employers is high.  Health campaigns aimed at highlighting risk 
factors could lead to a reduction of new cases of COPD, reducing hospitalisation 
and improving out-patient services (Nurmagambetov et al., 2006).  
1.3 Aetiology 
There is a five-fold increase in COPD diagnoses in those with tobacco exposure, 
however there are also environmental and genetic causes, demonstrated by 4% of 
people world-wide with COPD being never smokers (Raherison and Girodet, 2009).  
Risk factors for COPD can be classed as either host factors, for example age, gender 
and genetics; or acquired factors such as social and economic factors, passive and 
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active smoking, occupational and environmental exposure and infections 
(Raherison and Girodet, 2009).   
1.3.1 Host Factors 
1.3.1.a Gender 
A study looking at a Caucasian population of either current or ex-smokers in 
Norway with 954 patients with COPD and 955 controls; reported that there are 
gender differences, which appear to make females more susceptible to the effects 
of cigarette smoking and consequent lung damage (Sorheim et al., 2010).  Females 
with COPD are younger, have a lower pack year smoking history compared with 
males, have more severe disease than males and an earlier age of disease onset 
(Sorheim et al., 2010).  More females than males were current smokers, however 
more males than females had reported occupational exposure to dust or gas 
(Sorheim et al., 2010).  Females may be more genetically susceptible to the 
detrimental effects of smoking because of the gender differences in smoke 
metabolism (Ben-Zaken Cohen et al., 2007).  In a study with 278 participants 
Benowitz et al. investigated nicotine metabolism, and concluded females have a 
faster plasma clearance of nicotine and cotinine and higher nicotine to cotinine 
conversion when compared to males  (Benowitz et al., 2006).  Animal studies have 
also demonstrated gender differences in the response to smoke.  The increased 
levels of toxic nicotine metabolites in females could be responsible for the 
increased inflammatory reaction and generation of oxidative airway stress (Forkert 
et al., 1996).  As female airways are anatomically smaller than males, each cigarette 
may therefore also represent proportionally greater exposure, leading females to 
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develop more airway-based COPD rather than the emphysematous phenotype 
which is seen more in males (Han et al., 2007).  Hormonal contribution (Becklake 
and Kauffmann, 1999), differing occupational exposure, second-hand smoke, 
inhalation pattern and subjective symptom reporting are other possible 
explanations for gender differences (Sorheim et al., 2010).   
1.3.1.b Genetics 
As not all smokers develop COPD there is evidence for other contributing factors to 
developing the condition, such as genetic predisposition (Wan and Silverman, 
2009).  The most described genetic disposition is Alpha- ? ĂŶƚŝƚƌǇƉƐŝŶ  ?ɲ1 AT) 
deficiency  W a common but often under-diagnosed autosomal, co-dominant 
hereditary condition (Ioachimescu and Stoller, 2005), representing between 1-3% of 
people diagnosed with COPD (Raherison and Girodet, 2009).  ɲ1 AT is a serine 
protease inhibitor protein (anti-protease) (Bartels et al., 2009), with its deficiency 
shown to be caused by mutations within the SERPINA1 (SERine Proteinase Inhibitor 
A1) gene.  dŚĞůŝŶŬďĞƚǁĞĞŶɲ1 AT deficiency and respiratory dysfunction was first 
described in 1963 by Laurell and Eriksson (Laurell, 1963), with lŽǁ ůĞǀĞůƐŽĨɲ1 AT 
now quantified as being less than 11 micromol/L (Ranes and Stoller, 2005).  ɲ1 AT 
deficiency increases the risk of developing panacinar emphysema at an earlier age 
than that which COPD usually presents; and is also associated with bronchiectasis 
(Parr et al., 2007) and liver dysfunction (Strange et al., 2006).   
If the balance between proteases and anti-proteases is disturbed, as with ɲ1 AT 
deficiency, anti-proteases no longer inhibit the actions of proteases, thus the lungs 
are not protected.  Proteases, for example neutrophil elastase, will then destroy 
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lung tissue and results in alveolar wall destruction.  Increasing levels of unopposed 
neutrophil elastase, an inflammatory protease that gets released in response to 
pathogens entering the lungs (Lee and Downey, 2001), results in elastin degrading 
normal host lung tissue (Ranes and Stoller, 2005).   
ɲ1 AT is a polymorphic molecule with approximately 100 alleles identified, of which 
more than 30 have been identified as resulting in ɲ1 AT deficiency (ATS/ERS, 2003).  
The most common deficient ɲ1 AT ĂůůĞůĞ ŝƐƚŚĞ  ‘ ?ǀĂƌŝĂŶƚ  W people who are PI*ZZ 
homozygotes have plasma ɲ1 AT levels approximately 15% of normal; therefore 
these people are the ones most at risk of developing lung disease.  Smoking acts 
synergistically with factors that decrease ɲ1 AT.  Other known genetic causes 
include matrix metalloproteinases, specifically MMP-12 (Hunninghake et al., 2009), 
MMP-1 and MMP-9 (Molfino, 2004).  
1.3.2 Acquired Factors 
1.3.2.a Social and economic factors 
Social and economic conditions contribute to the risk of developing COPD, with 
people living in poor socio-economic circumstances more at risk of poor lung 
function and developing the condition (Gershon et al., 2011).  Residential 
deprivation was reported from 30,445 individuals using the Townsend score as an 
index to identify material deprivation.  Social deprivation can result in overcrowding 
within houses, which could increase stress and therefore be an influencing factor 
for smoking uptake; whereas education may increase health-related knowledge and 
therefore influence people to lead healthier and more active lifestyles.  People 
living in deprived areas were found to have one and a half to two times the 
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likelihood of being a current smoker compared to those living in more affluent 
areas (Shohaimi et al., 2003).  A cross sectional study with 22,675 adult participants 
from the general population found that after controlling for smoking history where 
67% of males and 44% of the females were either current or ex-smokers, social 
class, education and living in areas of deprivation independently predicted impaired 
lung function (Shohaimi et al., 2004).  This is likely through a number of variables 
such as smoking habits, diet, occupational and environmental exposure and lifestyle 
which are discussed below.  
1.3.2.a.i Smoking  
The main risk factor especially in the developed world for developing COPD is active 
smoking.  Smoking habits vary depending on the physical environment, with 
Shohaimi et al. describing social class and educational background as predictors for 
smoking uptake (Shohaimi et al., 2003).       
There is a positive correlation between current and ex-smokers and COPD mortality 
(Enstrom and Kabat, 2003, Eisner et al., 2006).  There have been many suggested 
mechanisms as to how and why cigarette smoking causes such damage to lung 
tissue.  Cigarette smoke stimulates inflammatory cell recruitment into the lung 
parenchyma, leading to the release of elastolytic proteases, which then destroy 
lung extracellular matrix and result in air space enlargement  W these pathological 
changes represent the changes that occur as emphysema develops (Shapiro, 2003).   
Passive smoke exposure can increase the risk of getting COPD (Robbins et al., 1993).   
Passive smoking, in addition to active smoking, influences the outcome in COPD 
patients, and causes greater COPD severity and poorer health status (Eisner et al., 
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2006).  The smoke released from a lit cigarette together with the smoke exhaled 
from a smoker forms the gaseous mixture inhaled by a passive smoker (Janson, 
2004), and contains many potent respiratory irritants (Janson et al., 2001).  The 
European Community Respiratory Health Survey reported that passive smoking also 
increased respiratory symptoms such as nocturnal and exercise related chest 
tightness and breathlessness (Janson et al., 2001).  There are high rates of passive 
workplace smoke exposure in Europe, whereas New Zealand, Australia and America 
have low workplace smoke exposure (Janson et al., 2001).  Cotinine, a metabolite of 
nicotine, and measure of tobacco was increased in habitants of those living with a 
smoker.  A link between cotinine and forced expired volume in 1 second (FEV1) was 
also reported, with a 105ml difference in FEV1 between subjects with the highest 
and lowest passive tobacco smoke exposure (Carey et al., 1999).  Xu et al. reported 
passive smoking related to a small decline in lung function results, with an 
approximate decline in FEV1 of 100mls and Forced Vital Capacity (FVC) of 150mls 
(Xu and Li, 1995). 
1.3.2.a.ii Occupation 
Occupation offers a significant risk factor to developing COPD and has wide 
variation depending on geographical location, as illustrated by studies in Norway 
finding associations between airflow obstruction and exposure to ammonia, metal 
fumes and anhydrides; in contrast to New Zealand finding associations with 
cleaners, laboratory technicians and construction workers (Hnizdo et al., 2002).  
Occupational exposure to both organic and inorganic dust and chemical agents 
increases the risk of developing COPD, with increased odds ratios for 
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transportation-related occupations, machine operators and construction trades 
(Hnizdo et al., 2002).   
1.3.2.a.iii Environmental exposure 
Air pollution increases the likelihood of a subject developing COPD and can trigger 
exacerbations.  Particles with a diameter of 100nanometers (nm) or less are defined 
as ultrafine particles (Donaldson et al., 2001), with diesel soot being the most 
numerous (MacNee and Donaldson, 2000).  Cigarette smoking and environmental 
pollution causes lung inflammation, resulting in a systemic inflammatory response, 
which leads to endothelial activation and changes in atherosclerotic plaques typical 
of plaque instability; and these vascular changes contribute to the increased 
cardiovascular (CV) morbidity and mortality in people with COPD (van Eeden et al., 
2005).  Developing countries have increased risk from pollution inside homes, 
where smoke from cooking or heating accumulates in badly ventilated houses 
(Raherison and Girodet, 2009).  Approximately 50% of the population use biomass 
fuel as their primary source of energy, but in developing countries this increases to 
around 90% (Bruce et al., 2000).  A considerable amount of the biomass smoke 
constituents are known to be toxic or are an irritant to the respiratory system (Hu 
et al., 2010).   
1.3.2.b Early life factors 
Early life environment may be another potential factor for impaired lung function 
and increased risk of developing COPD in later life.  Lower birth weight has been 
associated with reduced adult lung function, where mean FEV1 at 59-70 years of 
age is higher by 0.06L for every 1lb increase in birth weight  W as recorded at the 
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time by a health visitor, independent of smoking habit and social class (Barker et al., 
1991).  A relationship between lower respiratory tract infections in early life and 
subsequent development of COPD has been shown; and Bronchitis or pneumonia in 
childhood has been related to a reduced FEV1 (Shaheen et al., 1995).  Those with a 
lower socio-economic status during childhood were more likely to have a poor diet, 
and this poor nutrition impacts upon growth.  An inverse relationship between 
height and COPD risk was linked with socioeconomic status, particularly in younger 
adults (Ward and Hubbard, 2009).  A cross sectional analysis of lung function data 
and information from early life has highlighted the impact of childhood 
disadvantage  W maternal, paternal or childhood asthma, respiratory infections and 
maternal smoking - as being as significant as that of heavy smoking (Svanes et al., 
2010).  Reducing early childhood lung growth could prevent people reaching their 
potential maximum lung function (Barker et al., 1991), and this lowered lung 
function has no rectification with age; but as socioeconomic standards are 
improving, the effect of early life influences may become less important (Ward and 
Hubbard, 2009).   
1.4 Pathology and Pathophysiology 
The characteristic pathological changes associated with COPD occur in the central 
and peripheral airways, lung parenchyma and pulmonary vasculature (Pauwels et 
al., 2001).  Enlargement of the mucous secreting glands and an increase in the 
number of goblet cells are responsible for the hyper-secretion of mucous 
associated with the chronic bronchitic element of COPD (Snider, 1985).  Chronic 
bronchitis is characterised by hyperplasia and hypertrophy of the sub-mucosal 
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bronchial glands, which causes mucous hyper-secretion (Snider, 1985).  The 
emphysematous component of COPD results in the destruction of lung 
parenchyma, causing dilation and destruction of respiratory bronchioles.  The 
destruction of alveoli is a key component; and subsequent loss of elastic recoil with 
the consequent collapse of small, poorly supported, distal airways (Snider, 1985).  
Associated physiological changes include ciliary dysfunction, pulmonary 
hyperinflation, gas exchange limitations, pulmonary hypertension and eventually 
cor pulmonale (MacNee, 1994).   
Expiratory airflow obstruction arises as a consequence of permanent parenchymal 
destruction and airway dysfunction.  People with COPD have a faster rate of decline 
in their lung function (Mannino and Davis, 2006).  Donaldson et al. demonstrated 
that in 109 patients with COPD, the ones with more frequent exacerbations had a 
faster rate of decline in FEV1 and Peak Expiratory Flow (PEF) (Donaldson et al., 
2002).  With emphysematous changes the lungs elastic recoil pressure is reduced, 
and subsequently the driving pressure for expiration is reduced.   
The bronchoconstricted airways in COPD have an increased resistance (K ?ŽŶŶĞůů
and Laveneziana, 2006).  Residual Volume (RV) is often the first static lung volume 
to increase, and is therefore the first sign of increasing airway closure.  
Subsequently, Functional Residual Capacity (FRC) increases as a result of expiratory 
airflow obstruction and alterations in the static lung mechanics (K ?ŽŶŶĞůů ĂŶĚ
Laveneziana, 2006).  Dynamic hyperinflation has many effects upon the respiratory 
system.  It leads to increases in the elastic load on the inspiratory muscles, and 
consequently increases both the work of breathing and the oxygen cost of 
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breathing (O'Donnell et al., 1997).  Tidal volume expands so there is a low 
inspiratory reserve volume, and becomes fixed on the upper less compliant 
extreme of the pressure-volume relationship.  This results in inspiratory muscle 
weakness by maximally shortening muscle fibres in the diaphragm (Sinderby et al., 
2001) and increased breathing frequency, leading to significant reductions in lung 
compliance (K ?ŽŶŶĞůůĂŶĚ>ĂǀĞŶĞǌŝĂŶĂ ? ? ? ? ?).  It can also cause a reduced ability 
to modify tidal breathing during exertion, which then also leads to mechanical 
ventilation limitation (O'Donnell et al., 2002).  The combination of effects as a result 
of dynamic hyperinflation contributes to the symptoms of dyspnoea and exercise 
limitation experienced by patients with COPD (K ?ŽŶŶĞůůĂŶĚ>ĂǀĞŶĞǌŝĂŶĂ ? ? ? ? ?).  
Peripheral airway changes include airway inflammation, the development of 
fibrosis and smooth muscle hypertrophy, which all contribute to the thickening of 
the airway wall; and goblet cell metaplasia can lead to mucus plugging and facilitate 
the occlusion of lumen (Saetta et al., 1985, Saetta et al., 2001).  Central airway 
changes include an increase in the number of macrophages and T-lymphocytes in 
the airway wall, and an increase in the number of neutrophils in the airway lumen 
(Di Stefano et al., 1996).   
An early pathological feature of COPD is the vascular changes.  The intima of 
pulmonary vessels becomes thickened and there is an increase in smooth muscle 
and infiltration of the vessel wall by inflammatory cells (Peinado et al., 1999).   
The surface epithelium of the central airways are infiltrated by inflammatory cells 
(Pauwels et al., 2001), characteristically neutrophils, macrophages, B cells, 
lymphoid aggregates, and CD8+ T-Lymphocytes (Chung, 2005).  There are increased 
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levels of CD8+ T- Lymphocytes, and an increased smooth muscle area in the 
peripheral airways of smokers with symptomatic COPD in comparison with 
asymptomatic smokers with normal lung function (Saetta et al., 1998).  The 
increased levels of CD8+ T- Lymphocytes in the central airways are also found in the 
peripheral airways.  It is this peripheral airways site which is responsible for the 
chronic airflow limitation and hence obstructive ventilatory impairment 
demonstrated in smokers (Saetta et al., 1998).   
Airway smooth muscle produces inflammatory cytokines, proteases and growth 
factors, which contribute to the airway wall remodelling process.  Airway wall 
remodelling causes airway thickening and airflow obstruction, and occurs in the 
small airways through the processes of tissue repair and epithelial metaplasia.  This 
airway remodelling could also include the release of growth factors from 
inflammatory cells (Chung, 2005).  Chronic inflammation within the peripheral 
airways leads to the continuous cycle of cell injury and repair of the airway wall.  
This repairing process of the airway wall then leads to structural remodelling, 
causing the airway lumen to become narrowed and results in fixed obstruction as a 
consequence of increased collagen content and scar tissue formation (Pauwels et 
al., 2001).  The pathogenesis of COPD is largely attributable to the important role of 
CD8+ T- Lymphocytes and airway remodelling (Saetta et al., 1998).   
Subjects with COPD also have a heightened persisting systemic inflammatory state.  
Levels of C-Reactive Protein (CRP), fibrinogen, leucocytes and Tumour Necrosis 
Factor-ɲ ?dE&-ɲ )ŚĂve been shown to be elevated in people with COPD (Gan et al., 
2004), which is not attenuated with smoking cessation (Gan et al., 2004).  Matrix 
15 
 
metalloproteinases (MMPs) are structurally related metalloendopeptidases, vital for 
homeostasis and extracellular matrix turnover in both health and disease (Lowrey 
et al., 2008).  Circulating MMP-9 levels have been previously shown to be elevated 
in clinically stable patients with COPD compared to healthy controls (Bolton et al., 
2009b).  This increase in MMP-9 seen in patients with COPD could be due to 
neutrophil activation (Bolton et al., 2009b) or released from monocytes (Aldonyte 
et al., 2003). 
There have been two proposed explanations for the associations between COPD 
and systemic inflammation.  At first it was thought the inflammation from the lungs 
 ‘ŽǀĞƌ-ƐƉŝůůĞĚ ? ŝŶƚŽ ƐǇƐƚĞŵŝĐ ĐŝƌĐƵůĂƚŝŽŶ ? ƌĞƐƵůƚŝŶŐ ŝŶ ůŽǁ-grade systemic 
inflammation.  However, lack of correlation between plasma and sputum 
concentrations of soluble TNF receptors and Interleukin-8 (IL-8) suggests there is 
ŵŽƌĞ ƚŽ ƚŚĞ ŝŶĨůĂŵŵĂƚŝŽŶƉƌŽĐĞƐƐ ƚŚĂŶƚŚĞ ƐŝŵƉůĞ  ‘ŽǀĞƌ ƐƉŝůů ? ƚŚĞŽƌǇ(Vernooy et 
al., 2002, Sapey et al., 2009).  The other explanation is to consider COPD as a 
systemic inflammatory disease, where pulmonary inflammation and lung disease is 
one component of the multi-organ compromise (Barnes and Celli, 2009).  A recent 
study by Rutten et al. has suggested a further significant contributor to systemic 
inflammation in stable moderate to severe COPD patients is abdominal fat mass.  A 
positive association between plasma CRP and both abdominal fat mass (FM) and fat 
mass index (FMI) was demonstrated (Rutten et al., 2010).   
1.5 Diagnosis 
There are several important stages in diagnosing COPD.  These are primarily taking 
an accurate history including exposures, clinical examination and lung function 
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testing, usually spirometry (Raherison and Girodet, 2009).  Spirometrically, COPD in 
the UK has until recently been confirmed as a forced expiratory volume in one 
second (FEV1) and forced vital capacity (FVC) ratio (FEV1/FVC ratio) <0.7 and an FEV1 
<80% predicted (Gomez and Rodriguez-Roisin, 2002, NICE, 2004); however, in 
recent years recognition of milder airflow obstruction is sufficient for mild COPD 
when accompanied by symptoms (NICE, 2010a).  Good quality spirometry 
measurements are key to aiding diagnosis and monitoring disease progression, 
requiring appropriately qualified and experienced health care professionals.  A 
diagnosis of COPD is made using post bronchodilator spirometry results to alleviate 
misdiagnosis due to a reversible obstructive component as seen with chronic 
asthma (Pearson et al., 1997).     
At diagnosis, in addition to spirometry, subjects should also have a chest x-ray, full 
blood count and have their Body Mass Index (BMI) calculated (NICE, 2010a).  
Subjects 40 years of age or older with a smoking history equivalent to 10 pack years 
or greater, presenting with cough and/or sputum production are at risk of 
developing COPD and a COPD diagnosis should be considered (Raherison and 
Girodet, 2009).  COPD often remains hidden, with many individuals having un-
diagnosed airflow obstruction (Coultas et al., 2001), highlighting the need to be 
more pro-active in diagnosis.  Bednarek et al. reported in an observational primary 
care study looking at current, ex- and never smokers that patients 40 years of age 
or older had a COPD prevalence of 9.3%, however only 19% of these had been 
diagnosed and treated before the study; demonstrating the significant airflow 
limitation and loss of lung function before diagnosis (Bednarek et al., 2008).   
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1.6 Investigations 
1.6.1 Spirometry 
The physiological measurement in lung function, which forms the basis of the 
spirometric assessment of airway obstruction, is FEV1, where with lower FEV1 there 
is greater airflow limitation.  This measure of expiratory airflow limitation has been 
found to strongly correlate with increased mortality, and is a risk factor for 
cardiovascular disease, stroke and lung cancer (Hole et al., 1996).  The inverse 
relationship between FEV1 and increased mortality as seen in COPD was also 
demonstrated in life-long non-smokers (Hole et al., 1996).  FEV1 is the key marker of 
respiratory function in monitoring the disease progression because it is objective 
and quantitative.  Recognition that other factors to assess severity is needed, as it is 
debateable how useful just FEV1 is at assessing disease severity and progression; it 
only accounts for airway obstruction, not other respiratory manifestations, neither 
does it account for any of the systemic effects of COPD, given that COPD is now 
recognised as having extra pulmonary manifestations (Oga et al., 2007).  Currently, 
slowing the rate of decline of FEV1 has only been achieved by smoking cessation 
(Hole et al., 1996).   
1.6.1.a Severity of airflow obstruction 
There have previously been several variations in the guidelines used to classify the 
severity of COPD.  The first guidelines on the management of COPD in the UK were 
produced by the British Thoracic Society (BTS) in 1997 (Pearson et al., 1997).  These 
guidelines suggested a three stage approach to categorising patients with either 
mild, moderate or severe COPD based on their FEV1 values (Pearson et al., 1997).  
18 
 
These were replaced with the 2004 NICE guidelines which reclassified the 
percentages of FEV1 used (NICE, 2004).  Revised NICE 2010 guidelines now suggest a 
4 stage approach based on post bronchodilator spirometry (NICE, 2010a); see Table 
1.1.      
In parallel with this, the GOLD strategy have a 4 stage approach (Decramer et al., 
2013).  Previous versions of GOLD guidelines had a GOLD 0 category, which was an 
at risk group of subjects with normal spirometry but having symptoms such as 
chronic cough and sputum production (Pauwels et al., 2001).  Studies have 
highlighted that GOLD stage 0 was not applicable to detect at risk patients (Vestbo 
and Lange, 2002).  This was a contentious issue because there are many in-patient 
admissions and out-ƉĂƚŝĞŶƚĂƉƉŽŝŶƚŵĞŶƚƐĨŽƌƚŚĞ ‘ĂƚƌŝƐŬ ?ŐƌŽƵƉŽĨƐƵďũĞĐƚƐďĞĐĂƵƐĞ
they are symptomatic, and no treatment recommendations exist for this GOLD 0 
group of subjects other than smoking cessation (Joo et al., 2008).  The GOLD groups 
are shown in Table 1.1, and have been used to classify airflow obstruction severity 
in my thesis.  The ATS/ERS had previously published guidelines suggesting a 5 stage 
categorising process based on post bronchodilator spirometry, where the first stage 
ŝƐ Ɛƚŝůů ĂŶ  ‘Ăƚ ƌŝƐŬ ? ĐĂƚĞŐŽƌǇ ǁŝƚŚ ĂŶ &s1/FVC ratio >0.7 and an FEV1 A?  ? ?A?but 
incorporating risk factors (Celli and MacNee, 2004).  See Table 1.2.  
The latest GOLD guidelines also includes a four category (A, B, C and D) risk 
assessment strategy using symptoms as assessed by the modified MRC or CAT 
score, GOLD classification of airflow limitation and exacerbation history (Decramer 
et al., 2013).   
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It is clear that with so many differing guidelines published over many years on 
staging COPD, severity confusion can arise and differences in classification can 
occur depending on the guideline used.   
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Table 1.1 Current COPD Airway Severity Classifications 
Classification Lung function results 
Stage Severity Post bronchodilator 
FEV1 / FVC ratio 
Post bronchodilator 
FEV1 % predicted * 
FEV1 % predicted # 
1 Mild < 0.7 A? ? ?A? A? ? ?A? 
2 Moderate < 0.7 50-79%  ? ?A?A?&s1 < 80% 
3 Severe < 0.7 30-49%  ? ?A?A?&s1 < 50% 
4 Very 
severe 
< 0.7 < 30% 
Or < 50% with 
chronic respiratory 
failure  
< 30% 
Or < 50% with 
chronic respiratory 
failure 
* NICE 2010 COPD severity classification (NICE, 2010a) 
# GOLD 2013 COPD severity classification  (Decramer et al., 2013) 
 
Table 1.2 ATS/ERS COPD Severity Classification (ERS, 2004) 
Classification Lung function results 
Severity FEV1 / FVC ratio FEV1 % predicted 
At risk > 0.7 A? ? ?A? 
Risk factors: smoking history, exposure to pollutants 
Symptoms: cough, sputum production, dyspnoea or 
family history 
Mild A? ? ? ? A? ? ?A? 
Moderate A? ? ? ?  ? ?A?A?&s1 < 80% 
Severe A? ? ? ? 30% < FEV1 < 50% 
Very severe A? ? ? ? FEV1 A? ? ?A? 
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1.6.1.b Other severity measures 
It is becoming increasingly important to stage COPD severity on measures other 
than purely FEV1 to account for the systemic effects of COPD and to better define 
the respiratory impairment.  It is highlighted that measures such as BMI (Vestbo et 
al., 2006), exercise capacity (Pinto-Plata et al., 2004), exacerbations (Donaldson et 
al., 2002) and quality of life (Stahl et al., 2005) contribute to disease progression, 
thus should be taken into consideration when assessing disease severity; as well as 
the use of the Medical Research Council (MRC) dyspnoea scale for prognostic 
evaluation.  Gas transfer, partial pressure of oxygen in arterial blood and cor 
pulmonale should then be investigated in secondary care (NICE, 2010a).  This allows 
for a more thorough assessment of the disease severity and allows the condition to 
be graded appropriately.  The COPD assessment test (CAT) questionnaire provides a 
reliable measure of COPD related health status which can be used for long term 
follow up of COPD patients (Jones et al., 2009).                                                                                                
1.6.1.c Measuring airway inflammation 
Airway inflammation can be measured in a variety of ways, including the fraction of 
exhaled nitric oxide (FeNO), which is a repeatable measure in stable COPD subjects 
(Rouhos et al., 2011), though the diagnostic use is not as fully understood as it is in 
asthma.  Increased nitric oxide measurements are well established in asthma, but it 
has also been suggested that FeNO may reflect neutrophilic inflammation in COPD 
(Silkoff et al., 2001). 
Sputum cell counts can help define the inflammatory phenotype  W where COPD 
sputum samples consist predominantly of neutrophils (Tsoumakidou et al., 2003).  
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Inflammatory markers in induced sputum have been shown to be stable and 
neutrophilic inflammation repeatable in moderate, clinically stable COPD patients 
(Beeh et al., 2003).  There is a negative correlation between sputum neutrophils 
and FEV1 (Peleman et al., 1999).  A study by Stanescu et al. investigating the rate of 
decline of lung function with airway inflammation found that sputum with 
increased neutrophils correlated with the decline in FEV1 in both male smokers and 
non- smokers over the 15 year follow-up (Stanescu et al., 1996).   
1.6.1.d Composite measures of disease severity 
There have been a number of composite measures explored - the BODE (BMI 
Obstruction Dyspnoea Exercise) index, has been shown to be highly predictive of 
COPD mortality and is commonly used to assess disease severity (Celli et al., 2004).  
It is a 10 point scale in which the higher the score the greater the risk of death.  This 
provides a systematic grading system to reflect the composite nature of COPD (Celli 
et al., 2004).   
The ADO (Age Dyspnoea Obstruction), a simplified scoring system which also 
represents the multidimensional aspects of COPD has been developed (Puhan et al., 
2009), but its implementation remains to be seen.  This index uses age, dyspnoea 
and obstruction to determine a score to aid prognostic assessment.  Dyspnoea is 
assessed with the  MRC dyspnoea scale and obstruction is measured with FEV1 
(Puhan et al., 2009).     
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1.7 Treatment 
1.7.1 Smoking Cessation 
Smoking cessation is the only current intervention able to slow the rate of lung 
function decline associated with COPD progression (Scanlon et al., 2000).  
Reluctance of people to accept smoking cessation help is often due to lack of 
awareness of services available to them.  Smoking cessation services therefore 
need to be appropriately publicised and promoted, particularly in more deprived 
areas, with emphasis on a personalised, non-judgemental service (Roddy et al., 
2006).  Nicotine replacement therapy and brief counselling has been shown to be 
an effective smoking cessation intervention in in-patients.  This intervention 
significantly increases the number of people who were still abstaining from smoking 
a year later (Molyneux et al., 2003).  Other therapies such as bupropion and 
varenicline are also effective in aiding smoking cessation (Jorenby et al., 2006).   
1.7.2 Pharmacology 
Current treatment for COPD concentrates on patient reported symptoms such as 
ďƌŽŶĐŚŽĚŝůĂƚŽƌƐ ĨŽƌ ďƌĞĂƚŚůĞƐƐŶĞƐƐ ?  ^ŚŽƌƚ ĂĐƚŝŶŐ ɴ2 agonists and anticholinergics 
are routinely prescribed for symptomatic relief of breathlessness, and can be used 
in combination (NICE, 2010a) as they can be synergistic (Dorinsky et al., 1999).  If 
patients remain symptomatic or have two or more exacerbations per year a long 
acting bronchodilator should be prescribed.   
Long acting anticholinergic bronchodilators, such as Tiotropium, have been shown 
using results from the UPLIFT (Understanding Potential Long-term Impacts on 
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Function with Tiotropium) study to improve lung function, health-related quality of 
life (HRQoL) and exacerbations (Tashkin et al., 2010).   
Inhaled corticosteroids (ICS) alone are not licensed, but they have been shown to 
reduce exacerbations and improve quality of life; and are licensed to be used in 
combination with long acting B2-agonists (Sin et al., 2003b, NICE, 2010a).  ICS are 
recommended in those patients with an FEV1 A?  ? ?A?ƉƌĞĚŝĐƚĞĚĂŶĚŚĂǀŝŶŐ ƚǁŽŽƌ
more exacerbations requiring oral corticosteroids or antibiotics per year (Calverley 
et al., 2006, NICE, 2004).     
Theophyllines are not mainstay treatment but are occasionally used (NICE, 2010a).  
There is no place for routine oral corticosteroid maintenance therapy (Rice et al., 
2000).  Long term oxygen therapy has been shown to improve survival by 40% 
when given to patients with chronic hypoxia (Stuart-Harris et al., 1981).   
During an exacerbation an increase in medication will be required, and severe 
exacerbations may ƌĞƋƵŝƌĞ ŚŽƐƉŝƚĂů ĂĚŵŝƐƐŝŽŶ ?  Ŷ ĞǆĂĐĞƌďĂƚŝŽŶ ŝƐ ĚĞĨŝŶĞĚ ĂƐ  ‘Ă
ƐƵƐƚĂŝŶĞĚǁŽƌƐĞŶŝŶŐŽĨ ƚŚĞƉĂƚŝĞŶƚ ?Ɛ ƐǇŵƉƚŽŵƐ Ĩƌom his or her usual stable state 
that is beyond normal day-to-day variations, and is acute in ŽŶƐĞƚ ? (NICE, 2010a).  
Such exacerbations may require oral corticosteroids (OCS), nebulisers, antibiotics 
and/or supplemental oxygen (NICE, 2004).  Hospital admissions may be due to the 
severity of exacerbation or because the patient is unable to cope at home.   
1.7.3 Non-pharmacological Treatment   
Pulmonary rehabilitation should form an integral component of the management of 
respiratory disease, including COPD patients (Bolton et al., 2013, Spruit et al., 2013).  
Rehabilitation programmes include education, breathing exercises and exercise 
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training; and have been shown to improve exercise tolerance, QoL, dyspnoea and 
improve psychological well-being (Griffiths et al., 2000).   
Vaccinations have been shown to reduce mortality due to influenza in COPD 
patients (MacNee and Calverley, 2003).  Influenza vaccination is therefore 
recommended annually (Hak et al., 1998).  Pneumococcal vaccination has been 
demonstrated to reduce episodes of pneumococcal pneumonia in COPD patients 
younger than 65 years old with severe airflow obstruction (Alfageme et al., 2006).  
The importance of health education programmes aimed at informing patients about 
their condition, and how to adapt their daily routine to deal with their disease is 
now recognised (Worth and Dhein, 2004).  These self-management programmes 
require a multi-disciplinary approach (Bourbeau et al., 2004), thus there is a need to 
establish new approaches in COPD care.     
 
COPD is a slow but continuously progressive condition, causing constantly changing 
symptoms.  It is estimated that two-thirds of COPD subjects have at least one co-
morbidity as a result of their condition (Raherison and Girodet, 2009). 
 
1.8  Comorbidities 
The systemic consequences of COPD include cardiovascular, musculoskeletal, 
psychological problems such as depression and anxiety, cancer, and endocrine 
problems such as diabetes and metabolic syndrome (Luppi et al., 2008).  It was 
previously thought that comorbidities only presented in the latter stages of COPD, 
26 
 
but recent studies have demonstrated a high proportion of patients with 
musculoskeletal and cardiovascular disease even in mild airway obstruction (Sabit 
et al., 2007, Malerba and Romanelli, 2009, Bolton et al., 2004).  
1.8.1 Depression and Anxiety 
Prevalence estimations for depression and anxiety vary widely (Hill et al., 2008).  De 
Godoy et al. detected anxiety prevalence in COPD patients of 53% using the Beck 
Anxiety Inventory and depression at 46% using the Beck Depression Inventory (de 
Godoy and de Godoy, 2003).  Depression and anxiety have been reported in 
patients with mild COPD and prevalence rates were higher among women (Di 
Marco et al., 2006).     
1.8.2 Lung Cancer 
Cigarette smoking is the major cause of lung cancer (Wasswa-Kintu et al., 2005).  An 
obstructive ventilatory limitation, as demonstrated by a reduced FEV1, increases the 
risk of developing lung cancer.  As lung function deteriorates and increases in 
severity, the risk of developing lung cancer also increases (Wasswa-Kintu et al., 
2005).  Airway inflammation could have an important role in the pathogenesis of 
lung cancer because it is thought chronic inflammation increases the progression of 
carcinogenesis (Ballaz and Mulshine, 2003), providing a possible link between COPD 
and lung cancer.  A second plausible explanation for the relationship between 
reduced lung function and lung cancer is that with greater airflow obstruction 
people are less able to clear carcinogens from the airway, making them more at risk 
of developing lung cancer (Wasswa-Kintu et al., 2005).    
27 
 
1.8.3 Body Composition 
1.8.3.a Cachexia 
Cachexia is defined by Kotler ĂƐ ƚŚĞ  ‘ĐůŝŶŝĐĂů ĐŽŶƐĞƋƵĞŶĐĞ ŽĨ Ă ĐŚƌŽŶŝĐ ƐǇƐƚĞŵŝĐ
ŝŶĨůĂŵŵĂƚŽƌǇƌĞƐƉŽŶƐĞ ?ƌĞƐƵůƚŝŶŐŝƐ loss of weight and muscle mass, due to the loss 
of both fat and non-fat components (Kotler, 2000), and occurs in 20-25% of COPD 
patients (Engelen et al., 1994, Wagner, 2008).  Loss of skeletal muscle mass and 
function leads to reduced health status and exercise endurance, fatigue, dyspnoea 
and impaired cardiac function; which in turn can result in immobility and increased 
mortality (van Eeden and Sin, 2008).  BMI is a surrogate measure and does not 
account for losses in specific tissue  W such as fat or skeletal muscle.    
Low BMI has been found to be an independent risk factor for COPD mortality, with 
strongest association in more severe COPD patients (Landbo et al., 1999, Schols et 
al., 2005).  Additionally, in severe COPD patients with a normal or low BMI, weight 
gain seems to be beneficial (Schols et al., 1998).   
There are several mechanisms to determine body composition including 
bioelectrical impedance analysis (BIA), dual energy x-ray absorptiometry (DEXA) and 
skinfold assessment.  They aim to differentiate fat mass (FM) and fat-free (muscle, 
bone and organs) mass (FFM).  DEXA has the additional benefit of measuring bone 
mineral density (BMD) measurement.  Patients with a normal BMI can have loss of 
fat free mass, i.e. hidden loss (Bolton et al., 2004).  This loss of FFM, irrespective of 
BMI, has been associated with increased morbidity, worsening quality of life (Shoup 
et al., 1997) and mortality (Schols et al., 2005).  Indeed, COPD patients with muscle 
atrophy have comparable mortality risk to those with cachexia (Schols et al., 2005).  
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Fat free mass index (FFMI) has been reported to be a stronger predictor for 
mortality in COPD patients than BMI (Schols et al., 2005).  
As airflow obstruction severity increases there is preferential loss of skeletal muscle 
mass, reflecting a continuous catabolic state (Eid et al., 2001).  Originally tissue 
wasting in COPD was thought to be caused by only the imbalance of calorific intake 
and expenditure; however, it is now perceived to be due to multiple factors:-  
1.8.3.b Likely causes of altered body composition 
Muscle wasting occurs due to the imbalance between protein synthesis and protein 
breakdown.  The exact nature in COPD remains to be elucidated, but it is likely that 
altered anabolic and catabolic mediators play their part (Schols, 2000).   
Nutritionally, many patients with COPD eat sub-optimally because of the alteration 
in breathing pattern that occurs during chewing and swallowing, and a subsequent 
decrease in oxygen saturations can occur (Schols, 2000).  Iatrogenic factors such as 
thrush, a side effect to some inhalation therapies, could also affect eating habits.  
Many patients with COPD also report loss of appetite and early satiety during 
exacerbations (Vermeeren et al., 1997).  A fundamental feature of cachexia is 
hypermetabolism, defined as elevated resting energy expenditure (Kotler, 2000).  
Between 30% - 50% of patients with COPD experience tissue wasting, a likely result 
of hypermetabolism  (Mannix et al., 1999).  COPD patients become very inactive as 
their symptoms increase and they become limited by their breathlessness, 
compared to healthy subjects of similar age.  It has been considered that this 
drastic loss of anabolic activity and deconditioning contributes to cachexia (Wagner, 
2008).   
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Cachexia and muscle wasting are influenced by hormonal factors (van Eeden and 
Sin, 2008).  There are many reasons for low Testosterone in patients with COPD, 
including hypoxic inhibition of Luteinizing Hormone (LH) (Semple et al., 1981), 
natural decline with age (Gray et al., 1991) and OCS therapy (Kamischke et al., 
1998).  There is differing evidence on the levels and impact of Insulin-like Growth 
Factor 1 (IGF-1) in patients with COPD.  Some studies have shown an increase in 
IGF-1 which is thought to be due to physiological stress as a result of chronic 
hypoxia and bronchoconstriction (Creutzberg and Casaburi, 2003); whereas other 
studies have reported a decrease in IGF-1 levels (Burdet et al., 1997).  Age and OCS 
are contributing factors leading to the down regulation of the growth hormone 
system (Creutzberg and Casaburi, 2003); which results in reduced stimulation for 
muscle growth, thus reduced muscle mass (Creutzberg and Casaburi, 2003).   
Ghrelin stimulates the secretion of growth hormone, and has been shown to reduce 
fat utilisation through a positive energy balance (Tschop et al., 2000).  Underweight 
(BMI < 20kg/m2) COPD patients have increased plasma ghrelin levels (Itoh et al., 
2004); and it is thought to be elevated in response to the cachectic state of these 
patients.  The role of leptin, an adipocyte derived hormone, include effects on 
energy balance and energy homeostasis, and the regulation of long term body 
composition (Kotler, 2000).   
The increased systemic inflammation seen in COPD is energy intensive, requiring 
large amounts of essential amino acids, which drives the loss of skeletal muscle and 
subsequent decreased muscle mass.  When the process is chronic the depletion of 
skeletal muscle mass contributes to increased mortality and morbidity (Kotler, 
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2000).  Inflammatory cytokines such as TNF-ɲ ĂŶĚ />- ?ɴ ĂƌĞ ĂƐƐŽĐŝĂƚĞĚ ǁŝƚŚ
increased metabolism and the subsequent increase in protein turnover, with 
prolonged exposure to increased TNF-ɲ contributing to weight loss and 
malnutrition (de Godoy et al., 1996).   
1.8.3.a Obesity 
KďĞƐŝƚǇ ?ĂƐŝŶĚŝĐĂƚĞĚďǇĂD/A? ? ?ŬŐ ?ŵ2, is a major problem.  Related to this there 
is an increased inflammatory state, associated with increased CRP levels in patients 
with COPD, suggesting adipocyte-induced systemic inflammation in COPD (Breyer 
et al., 2009).   
Overweight patients with moderate to severe COPD had a lower mortality risk than 
normal weight patients, as mortality in those with severe airflow limitation 
increased with decreasing body weight (Wilson et al., 1989).  Since then, in a study 
of over 2,130 patients with COPD, Landbo et al. ŚĂǀĞ ĚĞƐĐƌŝďĞĚ Ă  ‘h ? ƐŚĂƉĞĚ
relationship between BMI and mortality, where those with a low BMI had high 
mortality and those with a normal or high BMI had better survival with the 
mortality risk increasing again in the obese (Landbo et al., 1999), although the 
number in the obese group were small. 
1.8.4 Metabolic Syndrome and Diabetes 
Increased circulating C-reactive protein (CRP) and IL-6 levels are positively 
associated with metabolic syndrome in COPD patients; and Watz et al. reported in 
175 stable outpatients with COPD GOLD stage I-IV and 30 stable patients with 
chronic bronchitis, nearly half (47.5%) of all subjects had metabolic syndrome (Watz 
et al., 2009), using the International Diabetes Federation criteria (IDF, 2006).  
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The risk of developing type 2 diabetes is increased in COPD patients, and has been 
demonstrated in female adults through an epidemiological study of 121,700 
females with COPD or asthma, aged between 30 and 55 years (Rana et al., 2004).  
Glucose intolerance and type 2 diabetes mellitus are recognised complications to 
OCS treatment (Archer, 2009).  In addition, a further mechanism behind this 
increased risk of developing diabetes is thought to be due to the increased 
inflammatory mediators present in subjects with COPD (Bolton et al., 2007).  
Further research is required in this area to investigate the association with 
inflammation, because glucose intolerance and diabetes is evident even in people 
not taking OCS (Mannino et al., 2008).   
Insulin resistance has been assessed using the homeostatis model assessment 
(HOMA) which is the product of fasting serum insulin and fasting plasma glucose 
values (Bonora et al., 1998).  Systemic inflammation has been associated with 
increased insulin resistance using HOMA index, in patients with COPD compared to 
healthy controls, which Bolton et al. related to the increased levels of TNF-ɲƐŽůƵďůĞ
receptor I and IL-6 in 56 non-hypoxaemic COPD patients compared to 29 controls 
(Bolton et al., 2007).  TNF-ɲ ĂŶĚ />-6 block the signalling through the insulin 
receptor, therefore inducing insulin resistance and increasing the risk of type 2 
diabetes (Barnes and Celli, 2009, Spranger et al., 2003).  CRP and IL-6 are increased 
in subjects with type 2 diabetes mellitus (Pickup and Crook, 1998) and these 
inflammatory markers are also increased in COPD.   
Obesity, particularly abdominal obesity, in COPD patients is associated with 
metabolic and inflammatory abnormalities, such as increased insulin levels, raised 
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TNF-ɲ ĂŶĚ />-6 plasma levels, decreased adiponectin and decreased HDL 
cholesterol; which commonly leave the patient susceptible to developing diabetes 
and cardiovascular disease (Poulain et al., 2008).   
1.8.1 Osteoporosis 
There is wide variation in the prevalence of osteoporosis and osteopenia in COPD 
patients, with 68% of a COPD study population found to have either osteoporosis or 
osteopenia and a higher prevalence in females (Jorgensen et al., 2007).  Clinically 
stable COPD patients starting pulmonary rehabilitation with GOLD stage I-IV disease 
severity reportedly had a prevalence of osteoporosis of 21% and osteopenia is 41% 
(Graat-Verboom et al., 2009).  The different prevalence could be dependent on the 
way osteoporosis was diagnosed - there is an overall lack of awareness to look for 
osteoporosis until COPD progresses to severe disease.  Osteoporosis was first 
reported by Shane et al. in pre-transplant end-stage respiratory disease patients, 
where OCS treated COPD patients were more severely affected by osteoporosis 
(Shane et al., 1996).  Osteoporosis is now being recognised in even mild and 
moderate COPD (Bolton et al., 2004).  Many of the risk factors for osteoporosis also 
occur in COPD, including age, inactivity, poor nutrition, low BMI, and inhaled and 
oral corticosteroids (Barnes and Celli, 2009).  The risk of low bone mineral density 
and osteoporosis increases as the severity of COPD increases (Vrieze et al., 2007), 
with subjects from the general population and either a low BMI or frequent 
exacerbations having the highest risk (Sin et al., 2003a).  Limitations of this study by 
Sin et al. include the results coming from NHANES and therefore the results were 
collected 15 years previously; and the subjects had airflow obstruction so the 
sample was not exclusively COPD subjects.   
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Osteoporosis prevalence is higher in patients with COPD compared to matched 
controls, even in those with newly diagnosed COPD (Soriano et al., 2005).  There are 
increased fracture rates in people with COPD with both current and previous use of 
inhaled corticosteroids, and when oral corticosteroid courses are adjusted for the 
dose response relationship between ICS and hip fractures remains (Hubbard et al., 
2002).  Low bone mineral density is seen in patients with COPD independent of 
their respiratory medication (Sin et al., 2003a).  Contributing factors for this low 
bone mineral density include decreased activity levels (Biskobing, 2002), low BMI 
(Incalzi et al., 2000), smoking history (Ward and Klesges, 2001), reduced 
testosterone levels (Kamischke et al., 1998), hypercapnia (Dimai et al., 2001) and 
systemic inflammation, particularly TNF-ɲ(Bolton et al., 2004).  Further studies are 
needed to look into the causation of these factors.  Morbidity and mortality is 
further increased with vertebral compression fractures in COPD patients, because 
symptomatic compression fractures can further reduce already impaired 
respiratory function (Carter et al., 2008).  A study of 74 females reported a 10% 
decrease in FVC in those with vertebral fractures (Leech et al., 1990).  
1.8.2 Cardiovascular (CV) Disease 
1.8.2.a CV disease and lung function 
The association between lung function and cardiovascular disease has been shown 
in the general population.  FEV1 can be used as a marker of cardiovascular 
mortality, independent of age, gender, smoking history (Sin et al., 2005), and an 
independent predictor of all-cause mortality (Stavem et al., 2005).  Even modest 
reductions in FEV1 (Sin et al., 2005, Hole et al., 1996) are a significant risk factor for 
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cardiovascular disease.  In an epidemiological sample of 621 68 year old males, 
Engstrom et al. demonstrated a high occurrence of ventricular arrhythmia, which 
had an inverse relationship with airflow obstruction and was associated with 
increased mortality and CV events (Engstrom et al., 2001).  A prior population based 
cohort study by Engstrom et al. in 291 male smokers reported increased CV risk and 
mortality in those with a declining lung function; suggesting change in lung function 
may assess individual susceptibility (Engstrom et al., 2000); consistent with that of 
Tockman et al. where it was reported that in a population of white males without a 
history of CV disease, decline in FEV1 was related to CV mortality independent of CV 
risk factors (Tockman et al., 1995). 
1.8.2.b CV disease and COPD  
The importance of investigating and treating cardiovascular disease in patients with 
COPD is highlighted by Mannino et al., where it is reported COPD patients are more 
likely to die of CV complications than of respiratory failure (Mannino et al., 2006).  A 
placebo controlled RCT comparing different inhaled medications (salmeterol, 
fluticasone propionate and combination) in 6184 moderate-severe patients with 
COPD from 42 countries reported that 26% of deaths in patients with COPD were 
CV in nature across the arms (McGarvey et al., 2007).  In a retrospective cohort 
study with 11,493 COPD subjects and 22,986 controls, it was reported that patients 
with COPD have a significantly higher risk of congestive heart failure, arrhythmia 
and myocardial infarctions than the control group (Curkendall et al., 2006), and 
patients with COPD have a higher incidence of first time acute MI compared to the 
general population without COPD (Feary et al., 2010).   
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A population based cohort study looking at patients with COPD found statins to be 
protective against CV mortality, and reported statin use to be associated with 
improved survival irrespective of co-existent CVD (Sheng et al., 2012).   
The structural and functional relationship between the respiratory and CV system 
may explain why COPD is a risk factor for CV diseases  W as the one organ system 
becomes impaired, it impacts upon the function of the other; so as COPD impairs 
the respiratory system the CV system is negatively affected.  This may be as a result 
of common pathologies and risk factors such as smoking, age and sedentary 
lifestyles or conditions that result in impairment of the heart from primary lung 
disease (Barnes and Celli, 2009, Maclay and MacNee, 2013).   
A longitudinal epidemiological study reported that factors other than the 
obstructive lung disease itself, such as comorbidities including cardiac arrhythmias, 
were important in linking COPD to causes on the death certificate, as patients may 
die with, rather than of, COPD (Camilli et al., 1991).    
An epidemiological study reported low grade systemic inflammation in subjects 
with moderate to severe airflow obstruction and associations with increased risk of 
cardiac injury; therefore proposed systemic inflammation as a possible explanation 
for the increased rates of CV complications in patients with COPD (Sin and Man, 
2003, Agusti, 2005).   
Smoking has a number of effects that may promote atherosclerosis through 
vascular inflammation and oxidative stress (Perlstein and Lee, 2006).  Systemic 
inflammation and increased insulin resistance, both of which are present in subjects 
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with COPD, are key mechanisms in the development of atherosclerosis and 
therefore increases the prevalence of cardiovascular disease (Bolton et al., 2007, 
Mannino et al., 2006).  It is not yet fully understood whether CV disease leads to 
increased inflammation, increased inflammation contributes to the development of 
CV disease, or if there is another factor that promotes both inflammation and CV 
disease in patients with COPD.   
Some patients with COPD develop right-sided heart failure (RHF) as their condition 
progresses, due to worsening pulmonary arterial hypertension as a result of 
hypoxaemia; however, the incidence of true cor pulmonale appears to be declining.  
This may be because the clinical assessment and prescription services for 
supplemental oxygen therapy has improved, enabling hypoxic patients to receive 
oxygen therapy earlier (Barnes and Celli, 2009).  Structural changes in the right 
ventricle may impact upon the left ventricle, and it has previously been reported 
that COPD patients also have left ventricular diastolic dysfunction (Funk et al., 2008, 
Sabit et al., 2010), and unrecognised heart failure co-exists in patients with COPD 
(Le Jemtel et al., 2007).  One of the major determinants for left ventricular diastolic 
dysfunction in COPD was aortic stiffness (Sabit et al., 2010). 
There is a high prevalence of myocardial injury in COPD, commonly occurring during 
severe acute exacerbations (Patel et al., 2013), with a recent prospective study in 
242 patients with COPD reporting that one in 12 patients admitted to hospital with 
an acute exacerbation of COPD met the current Universal Definition for Myocardial 
Infarction (McAllister et al., 2012).  Using an epidemiological approach it has been 
reported that COPD exacerbations increase the risk of MI and stroke, where acute 
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exacerbations of COPD are associated with a 2.27 fold increased relative risk of MI 
during the 5 day post exacerbation period (Donaldson et al., 2010).   
Studies looking at hard CV endpoints, such as death and MI events, have found 
increased CV disease prevalence in patients with COPD compared to controls (Feary 
et al., 2010, Sin et al., 2006); however, we ideally need a non-invasive measure to 
detect CV risk.  
1.8.2.c Non-invasive measures of CV risk 
There are many methods to non-invasively measure CV risk, including arterial 
stiffness, carotid intima media thickness (CIMT) and endothelial function.   
CIMT is the distance from lumen-intima interface to the media-adventitia interface 
of the artery wall, measured using ultrasonographic images of the carotid arteries 
(Polak et al., 2011).  CIMT has been reported using subjects in the Framingham 
Offspring Study cohort, to be an independent predictor of CV events in subjects 
without a history of CV disease (Polak et al., 2011).  In contrast, a meta-analysis 
reported that CIMT progression was not associated with the risk of subsequent CV 
events (Lorenz et al., 2012) and despite being predictive of CV endpoints CIMT did 
not improve risk classification in the general population (Lorenz et al., 2010).   
Endothelial function can be measured by flow mediated dilation, is predictive of 
future CV events in the general population (Lind et al., 2011), and in patients with 
COPD was associated with severity of airflow obstruction (Clarenbach et al., 2013) 
and systemic inflammation (Eickhoff et al., 2008), although contentious with other 
methods (Maclay et al., 2009).   
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Coronary artery calcium scores, as determined by CT scans, are increased in 
patients with COPD compared to both smoker and never smoker controls, and are 
associated with increased mortality (Williams et al., 2014).   
Carotid  W ĨĞŵŽƌĂů ‘ĂŽƌƚŝĐ ?WtsŝƐƵƐĞĚĂƐƚŚĞŵĞĂƐƵƌĞŽĨĂƌƚĞƌŝĂůƐƚŝĨĨŶĞƐƐďĞĐĂƵƐĞŝƚ
is considered the gold standard measure of arterial stiffness and the most clinically 
relevant measure; due to the aorta being what the left ventricle first  ‘ƐĞĞƐ ?
therefore being responsible for the majority of pathophysiological effects of arterial 
stiffness (Laurent et al., 2006).  Pulse wave velocity is the speed at which a pressure 
wave travels between two points, for example between the carotid and femoral 
pulse points; and is calculated by dividing the distance from the carotid to femoral 
point by the transit time  W being the time of travel of the foot of the wave over the 
distance measured (Laurent et al., 2006).  A systematic review with 17,635 
participants, presenting data from 16 studies reported that aortic PWV enabled 
better identification of those with high CV risk who could therefore benefit from CV 
risk management (Ben-Shlomo et al., 2013). 
Aortic PWV is an independent predictor of CV disease (Laurent et al., 2006), where 
a greater PWV indicates stiffer arteries (Mattace-Raso et al., 2006).  Aortic stiffness 
has been studied as a non-invasive predictor of cardiovascular events in COPD, and 
has been shown to be higher in patients with COPD compared to matched smoker 
controls (Sabit et al., 2007, John et al., 2013).   
1.8.2.d Aortic stiffness and lung function 
The association of aortic stiffness to spirometric measures in COPD was 
demonstrated by Bolton et al., where a strong inverse association in the Caerphilly 
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Prospective study with 800 male participants was reported (Bolton et al., 2009a).  In 
addition, a French study of 194 males without CV disease reported a reduced lung 
function was independently associated with aortic stiffness (Zureik et al., 2001).   
1.8.2.e Aortic stiffness and COPD 
Aortic stiffness is increased in patients with COPD compared to controls (Sabit et 
al., 2007, Maclay et al., 2007), with arterial stiffness relating to emphysema severity 
(McAllister et al., 2007), severity of airflow obstruction, and systemic inflammation 
(Sabit et al., 2007).  Arterial stiffness increases acutely during an exacerbation of 
COPD, with those patients who have frequent exacerbations having a higher aortic 
PWV compared to those with less frequent exacerbations (Patel et al., 2013).   
Augmentation Index (AIx) is a measure of wave reflection, measured as the 
pressure difference between the second and first systolic peaks expressed as a 
percentage of the pulse pressure (Laurent et al., 2006).  A large epidemiological 
cross-sectional study found no difference in AIx between COPD and controls when 
adjusted for CVD risk factors but an inverse relationship between AIx and FEV1 and 
FVC was found  (Janner et al., 2012).  These findings are not unexpected as AIx has 
previously been reported as a less useful marker of arterial stiffness in the age 
group of patients with COPD because it plateaus with age (McEniery et al., 2005).  
The clinical studies of arterial stiffness in COPD are presented in Table 1.3, 
comprising of cross-sectional, cohort, case control and RCT studies.  The literature 
search was performed for English language studies.  With the exception of one 
study, all other literature presented is from 2007 onwards.  
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1.8.2.f Consequences and mechanisms of increased aortic stiffness  
With age there is a progressive increase in arterial stiffness, leading to increased 
pulse pressure (Domanski et al., 1999).  Not only are large arteries a conduit, but 
they also play an important role in buffering the cyclic changes in blood pressure 
caused by intermittent ventricular ejection (EŝĐŚŽůƐ ĂŶĚ K ?ZŽƵƌŬĞ ?  ? ? ? ?).  With 
increased arterial stiffness there is early return of reflected waves during late 
systole (as opposed to diastole), which in turn increases central pulse pressure and 
therefore the load on the ventricle, reducing ejection fraction and increasing the 
myocardial oxygen demand (Boutouyrie et al., 2002).  Increased arterial stiffness 
raises blood pressure and therefore cardiovascular risk, with cardiovascular 
morbidity and mortality being due to systolic hypertension affecting coronary 
perfusion (Laurent et al., 2001). 
1.8.2.g Potential mechanisms for increased arterial stiffness in COPD 
Recent findings using 153 COPD patients enrolled into a multicentre RCT reported 
that the increased aortic PWV seen in patients with moderate to severe COPD could 
be predicted using age, BP and thoracic aortic calcification (Bhatt et al., 2014). 
Systemic inflammation and endothelial dysfunction have been proposed as 
potential explanations for the increased aortic stiffness and CV risk in subjects with 
COPD, where aortic stiffness can be affected by both structural and functional 
aspects of the conduit arteries and vascular beds  (Mills et al., 2008).   
As mentioned earlier, systemic inflammation is thought to provide a mechanistic 
link between COPD and its comorbidities, including CV disease (MacNee, 2013).  
Increased oxidative stress is thought to have a role in activating genes involved in 
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producing an inflammatory response (Alexander, 1995).  The cyclic stress affecting 
arterial wall thickening is a possible reason for the correlation between increased 
arterial stiffness and atherosclerosis (Boutouyrie et al., 2002).  Inflammation and 
arterial wall oxidative stress  W as shown by elevated levels of macrophages and IFN-
y secreting lymphocytes (Yan and Hansson, 2007)  W are central in the pathogenesis 
of atherosclerosis (Alexander, 1995) and comparable to the inflammation seen in 
the peripheral lung of COPD patients (Yan and Hansson, 2007).  In the presence of 
hyperlipidemia this inflammatory response may lead to the formation of 
atherosclerotic plaques (Alexander, 1995).  
42 
 
Table 1.3 Arterial Stiffness and COPD Literature Summary  
Authors Year Study 
Design 
Comparator Significant 
exclusions 
Sample size Primary 
Variable 
Secondary 
Variables 
Device Primary 
Outcome 
Secondary 
Outcome 
Conclusion 
Bartels 
(Bartels et 
al., 2004) 
2004 Single 
blinded, 
crossover 
Suppl. O2  
v. CA 
Abnormal ECG 70 COPD AIx, BRS  T  BRS greater 
following 
suppl. O2 
compared to 
CA 
AIx was 
increased with 
suppl. O2 
compared to CA 
Suppl. O2 
improves BRS 
Sabit (Sabit 
et al., 2007) 
*(Sabit et 
al., 2010) 
2007 Cross-
sectional 
Healthy 
current or 
ex- smokers 
LTOT, OCS, CVD, 
malignancy, cor 
pulmonale, 
inflammatory or 
metabolic 
condition, DM 
75 COPD 
 
42 controls 
aPWV BP, AIx, 
BMD, IL-6, 
TNF-ɲ ? 
S Increased 
aPWV in COPD 
compared to 
controls, 
COPD:11.4 
(2.7) m/s to 
9.0 (1.7)m/s 
Relationship 
between AS and 
airway 
obstruction. 
aPWV related to 
BMD 
 
Increased AS 
compared to 
controls over 
a range of 
COPD 
severities; 
greatest in 
those with 
osteoporosis. 
Relates to 
diastolic 
dysfunction  
McAllister 
(McAllister 
et al., 2007) 
2007 Cohort study None Anti-
inflammatories, 
OCS, systemic 
inflammatory 
disease, recent 
exac. 
157 COPD c-rPWV HRCT S c-rPWV 8.7 
(1.5)m/s 
related to 
emphysema 
severity 
 
c-rPWV higher 
in GOLD stage 
3-4 than 1-2 
Emphysema 
severity is 
associated 
with AS in 
COPD 
Mills (Mills 
et al., 2008) 
2008 Prospective 
case control 
Healthy 
controls 
 
Recent exac, 
ORC, RA, IBS, 
OCS, connective 
tissue disorder, 
malignancy, 
theophylline 
102 COPD 
 
103 controls 
Time to 
reflect 
(ms) 
BP, AIx S Reduced time 
to wave 
reflection 
131(1)ms in 
COPD 
Elevated AIx in 
COPD  
Increased AS 
and BP in 
COPD 
compared to 
controls 
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Maclay 
(Maclay et 
al., 2009) 
2009 Case control Healthy 
males 
ORC, vascular 
function 
conditions or 
medications, 
inflammatory 
conditions 
18 COPD 
 
17 controls 
aPWV AP, AIx, 
VOP 
S aPWV 
increased in 
COPD 11 
(2)m/s 
compared to 
controls 9 
(2)m/s 
AIx increased in 
COPD 
Increased 
aPWV in COPD 
independent 
of smoke 
exposure 
Vivodtzev 
(Vivodtzev 
et al., 2010) 
2010 Case control 
Intervention 
in COPD 
Untrained 
COPD and 
trained 
COPD 
Recent exac., 
DM 
10 trained 
 
7 untrained 
Change 
in  
c-rPWV 
6MWD, 
quadriceps 
muscle 
endurance 
C c-rPWV 
dropped in 
trained 
patients by 
1.1 (0.6)m/s 
from 10.3(0.7) 
to 9.2(0.8)m/s 
Trained patients 
had significant 
improvements 
in 6MWD and 
muscle 
endurance 
AS improves 
after exercise 
training in 
proportion to 
changes in 
exercise 
capacity 
Dransfield 
(Dransfield 
et al., 2011) 
*(Bhatt et 
al., 2014) 
2011 RCT of 
fluticasone 
propionate/ 
salmeterol 
All COPD 
Active v. 
Placebo 
ICS, ICS/LABA, 123 active 
 
126 placebo 
Change 
in aPWV 
AIx S aPWV 
decreases 
post 12 weeks 
intervention 
with FSC 
compared to 
placebo, but 
did not reach 
significance.  
Significant 
change in aPWV 
in active 
compared to 
placebo post- 
treatment in 
highest tertile 
(aPWV 
>10.9m/s). 
No change in 
AIx 
FSC may 
reduce aPWV 
in those with 
the greatest 
abnormality in 
AS 
Janner 
(Janner et 
al., 2012) 
2011 Population, 
cross-
sectional 
None Poor quality AIx, 
missing 
spirometry data 
3374 general 
population 
including 
494 COPD 
AIx BP S AIx higher in 
COPD than 
controls 
AIx not 
increased when 
CVD risk 
adjusted for  
AIx and COPD 
are only 
weakly 
associated 
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Gale(Gale et 
al., 2011) 
2011 Prospective 
cohort study 
Pre- and 
post- rehab 
Healthy 
controls at 
baseline 
only 
Recent exac., 
IHD, cardiac 
failure, DM, 
malignancy, 
inflammatory or 
metabolic 
conditions, OCS 
32 COPD 
 
20 controls 
(baseline only) 
Change 
in aPWV 
with 
rehab 
c-rPWV, 
MAP, PP, 
AIx 
S COPD had 
higher PWV 
than controls. 
Rehab 
lowered 
aPWV from 
9.8 (3.0)m/s 
to 9.3 
(2.7)m/s in 
COPD 
No change in c-
rPWV or AIx 
following 
pulmonary 
rehab, but 
decreased 
central MAP by 
8mmHg  
AS improved 
following 
pulmonary 
rehab - likely 
secondary to 
change in 
MAP 
Albu (Albu 
et al., 2011) 
2011 Cross- 
sectional 
Controls Infection, CVD 38 COPD 
 
36 controls 
Beta 
stiffness 
index, 
Carotid 
PWV 
AC, AIx Ultra 
sound 
COPD had 
higher carotid 
PWV than 
controls 
AS more 
important in 
severe COPD 
than in mild W 
moderate 
disease 
Patients with 
COPD have 
increased 
carotid AS 
independent 
of smoking 
history, and 
more 
pronounced in 
severe disease 
Maclay 
(Maclay et 
al., 2012) 
2012 Cross- 
sectional 
Male ex-
smokers 
Vascular 
disease, 
systemic 
inflammatory 
conditions, 
statins, OCS, 
LTOT 
16 COPD 
 
15 controls 
Skin 
biopsy 
aPWV S Patients with 
COPD have 
increased skin 
elastin 
degradation 
compared to 
controls 
Cutaneous 
elastin 
degradation 
was related to 
both 
emphysema 
severity and AS.  
Systemic 
elastin 
degradation 
may be a 
mechanism 
for 
pulmonary, 
vascular and 
cutaneous 
features of 
COPD 
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Vanfleteren 
(Vanfleteren 
et al., 2013) 
2013 Prospective 
cohort study 
pre- and 
post- rehab 
Healthy 
controls at 
baseline 
Unsuccessful 
aPWV 
measurements 
162 COPD 
 
168 controls 
Change 
in aPWV 
AIx S aPWV 
increased in 
COPD 
10.7(2.7) m/s 
compared to 
controls. 
aPWV did not 
change post 
rehab 
AIx was higher 
in COPD than 
controls 
Increased AS 
in COPD does 
not respond 
to rehab.  No 
change in 
MAP 
Romme(Ro
mme et al., 
2013) 
2013 Cohort None Anti-
inflammatories, 
OCS, systemic 
inflammatory 
disease, recent 
exac. 
119 COPD c-rPWV CAC, TAC S c-rPWV 
8.9(1.6)m/s 
Increased CAC 
was associated 
with increased 
AS and lower 
BMD 
Increase in 
CAC in COPD 
associated 
with higher AS 
and lower 
BMD 
Patel (Patel 
et al., 2013) 
2013 Prospective 
cohort study 
Stable v. 
exac. 
ORC 98 Stable 
COPD 
 
55 COPD with 
exac. 
aPWV MAP, 
Sputum 
V AS related to 
exac freq in 
stable state. 
Frequent exac 
11.8 (2.1)m/s. 
Non frequent 
exacerbators 
10.3 (2.0)m/s. 
Increase in AS 
with exac. 
AS in stable 
state is reliable 
over time  
Frequent 
COPD 
exacerbators 
have greater 
AS 
Stickland 
(Stickland et 
al., 2013) 
2013 Cross-
sectional 
Healthy 
controls 
LTOT, DM, CVD, 
vasoactive 
medication, 
D/A? ? ? ?
inflammatory 
disorders, 
recent  rehab, 
OSA 
33 COPD 
 
10 controls 
c-rPWV VO2max T AS increased 
in COPD. 
Physical 
activity and 
exercise 
tolerance is 
related to c-
rPWV in COPD 
 Physical 
activity and 
exercise 
tolerance is 
significantly 
related to 
PWV in COPD 
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John (John 
et al., 2013) 
2013 Cross-
sectional 
Healthy 
controls 
Alpha-1 
antitrypsin 
deficiency, 
malignancy, 
terminal disease 
52 COPD 
 
34 controls 
UACR in 
relation 
to aPWV 
AIx V aPWV related 
to glomerular 
function 
aPWV greater in 
those with 
micro-
albuminuria  
Glomerular 
damage in 
COPD shown 
by increased 
UACR related 
to aPWV 
Stone 
(Stone et 
al., 2013) 
2013 Prospective - Recent exac., 
LTOT 
23 vicorder 
reproducibility 
33 vicorder 
comparison 
study 
aPWV AIx V, S Vicorder is 
reproducible 
for aPWV 
Vicorder values 
lower, but good 
agreement with 
sphygmocor. 
Sphygmocor 
aPWV 9.5 
(1.5)m/s 
aPWV in COPD 
is 
reproducible 
and not 
affected by 
lung hyper-
inflation 
Cinarka 
(Cinarka et 
al., 2013) 
2013 Prospective 
observation 
Healthy 
controls 
CVD, 
hypertension, 
DM 
62 COPD 
 
22 controls 
aPWV ABG, 
6MWD 
S aPWV level is 
increased in 
COPD 
compared to 
controls 
aPWV is higher 
in severe 
disease 
compared to 
mild disease 
aPWV is 
increased in 
COPD, and 
higher in 
advanced 
compared to 
mild-
moderate 
disease 
Vivodtzev 
(Vivodtzev 
et al., 2013) 
2013 Letter to 
Editor 
- - - aPWV Metabolic 
and inflam. 
markers 
C Baseline 
aPWV 11.1 
(1.9)m/s 
79% of patients 
had abnormal 
aPWV >9.3m/s. 
Good 
reproducibility 
of aPWV. 
aPWV is a 
reproducible 
measure for 
short to 
middle term 
intervention 
in COPD 
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Ives (Ives et 
al., 2013) 
2013 Double blind 
RCT of 
antioxidant 
cocktail 
(vitamin C, E 
ĂŶĚɲ-lipoic 
acid) 
Placebo Current 
smokers, recent 
exac. 
30 COPD 
 
30 controls 
FMD c-rPWV T Patients FMD 
improved with 
antioxidant 
cocktail but 
not controls. 
Antioxidant 
cocktail 
improved          
c-rPWV in 
patients and not 
controls 
Patients with 
COPD exhibit 
vascular 
dysfunction 
which can be 
acutely 
mitigated by 
oral 
antioxidant 
 
Abbreviations  W aPWV: aortic PWV, ABG: arterial blood gas, AC: arterial compliance, AIx: augmentation index, AP: augmentation pressure, AS: arterial stiffness, 
BP: blood pressure, BMD: bone mineral density, BRS: baroreflex sensitivity,  c-rPWV: carotid-radial PWV, CA: compressed air, CAC: coronary artery calcification, 
CVD: cardiovascular disease, DM: diabetes mellitus,  exac.: exacerbation,  FMD: flow-mediated dilation, FSC:  fluticasone propionate/salmeterol, IBS: inflammatory 
bowel disease, IHD: ischaemic heart disease,  LTOT: long term oxygen therapy, MAP: mean arterial pressure, OCS: oral corticosteroids, ORC: other respiratory 
condition, OSA: obstructive sleep apnoea , RA: rheumatoid arthritis, rehab: rehabilitation, suppl. O2: supplementary oxygen, TAC: thoracic aortic calcification, 
VO2max: maximal oxygen consumption, VOP:  venous occlusion plethysmography, 6MWD: 6 minute walking distance  
 
Device Key  W S: sphygmocor, V: vicorder, C: complior, T: other tonometer device 
 
* A further study was published using a subset of subjects 
 
All studies comprise Human subjects, are original studies and published in English Language.  
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1.8.2.h Inflammation and CV disease 
Many secondary comorbidities are a result of chronic systemic inflammation and 
account for a large proportion of the morbidity and mortality in COPD patients  (Sin 
et al., 2006).  CRP is a robust marker of the acute phase response of the innate 
immune response and is associated with CV disease (van Eeden and Sin, 2008).  CRP 
impacts on the initiation, progression and stability of vascular wall atheroma 
through the recruitment of circulating leucocytes into blood vessel walls and 
macrophages uptake of low-density lipoprotein cholesterol  (Torres and Ridker, 
2003).   
 
There is a clear need to address these co-morbidities  ? to improve the 
understanding of their causation, identifying their presence even in mild disease, 
and develop research into therapeutic interventions that might improve morbidity 
and mortality.   
 
1.8.3 Statins 
3-hydroxy 3-methylglutaryl coenzyme A reductase inhibitors, more commonly 
referred to as statins, are routinely prescribed for hypercholesterolemia and 
cardiovascular disease and have been shown in both primary and secondary 
prevention to reduce cardiovascular mortality and morbidity; however there is now 
research to highlight their pleiotropic benefits, as highlighted in a systematic review 
which presented data from nine studies looking at the potential benefits of statin 
therapy in patients with COPD (Janda et al., 2009), and included retrospective 
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cohorts (Blamoun et al., 2008, Keddissi et al., 2007), a case control (Frost et al., 
2007) and a RCT (Lee et al., 2008).  Statins have been shown to have anti-
inflammatory, antioxidant, anti-thrombogenic and have vascular function restoring 
actions, and immune modulating effects; as well as cholesterol lowering properties 
(Davignon and Leiter, 2005).  Elevated high density lipoprotein (HDL) cholesterol 
levels have been reported in patients with severe COPD, with some of this elevation 
attributed to the use of Prednisolone (Reed et al., 2011).   
1.8.3.a Current use of statins 
Statins are currently licensed for the use of lipid lowering and subsequent cardiac 
prevention in subjects with hypercholesterolaemia, CV disease and high risk groups 
such as those with diabetes; and for primary prevention of CV disease in high risk 
populations (NICE, 2010b).   
The Justification for the Use of Statins in Prevention: An Intervention Trial 
Evaluating Rosuvastatin (JUPITER) was a randomised, double-blind, placebo 
controlled, parallel group, primary prevention study, which took place at 1315 sites 
over 26 countries.  From that study it was reported that in healthy people with 
normal lipid levels but increased C-reactive protein (CRP) levels, atorvastatin 
significantly reduced CRP and importantly the incidence of CV events (Ridker et al., 
2008).   
The long term effects of statin therapy has been shown to be cardio-protective in a 
high risk population in a study with a 10 year follow up following an initial study 
with pravastatin.  The West of Scotland Coronary Prevention Study (WOSCOPS) was 
a randomised, placebo controlled trial looking at the use of 40mg pravastatin in 
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hypercholesterolemic men without evidence of myocardial infarction.  During a 
follow up study looking at participants 10 years after the end of the trial there was 
still evidence of reduced risk of major coronary events, thought to be due to the 
stabilisation of plaques (Ford et al., 2007).  
1.8.3.a.i Diabetes 
dŚĞ  ‘ŽůůĂďŽƌĂƚŝǀĞ ƚŽƌǀŽƐƚĂƚŝŶ ŝĂďĞƚĞƐ ^ƚƵĚǇ ?  ?Z^ ) ǁĂƐ Ă ŵƵůƚŝ-centred 
placebo controlled RCT in the UK and Ireland, consisting of 2,838 patients with 
diabetes without CV disease.  It was reported that Atorvastatin 10mg reduced the 
risk of first CV events by 37% and all-cause mortality by 27% in this group of 
patients with type 2 diabetes (Colhoun et al., 2004).  
1.8.3.a.ii CV disease 
The Scandinavian Simvastatin Survival Study (4S) was a double blinded RCT in 4,444 
patients with a history of CV disease.  Over the 5.4 year median follow-up, 
simvastatin was shown to reduce morbidity  W with a risk reduction of 30%, 
attributable to a 42% reduction in CV death.  A reduced risk of CV events was also 
demonstrated in the active group compared to the placebo group.  Simvastatin was 
reported to be beneficial irrespective of previous MI, smoking history and 
hypertension (Kjekshus and Pedersen, 1995). 
A prospective, randomised, single-blind, single-centre study in 93 patients with 
Coronary Artery Disease (CAD) found that fluvastatin had a significant beneficial 
effect on the vascular system after 3 months of treatment; however, arterial 
stiffness was measured using brachial-ankle PWV (baPWV) which does not have the 
same predictive power as aortic PWV (Hongo et al., 2008).   
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The development of aneurysms is associated with a chronic inflammatory response 
and the increased production of matrix metalloproteinases (MMPs) (Wilson et al., 
2005).  The combination of ezetimibe and simvastatin in patients with abdominal 
aortic aneurysms (AAA) has shown a beneficial effect on the inflammatory and 
proteolytic components involved in aneurysm enlargement, with significant 
reductions in aortic wall levels of MMP-9 and IL-6 (Dawson et al., 2011).  A recent 
meta-analysis looking at the effects of statin therapy in patients with AAA suggests 
that statin therapy does not affect AAA enlargement, but mortality rates following 
elective AAA repair are significantly improved with statin therapy (Twine and 
Williams, 2011).   
1.8.3.b Inflammation and statins 
Animal studies in rats have demonstrated statins ? ability to inhibit leukocyte-
endothelial cell adhesion (Kimura et al., 1997) and in in vitro studies cellular 
proliferation (Rudich et al., 1998), reduce oxidative stress, reduce the numbers of 
neutrophils, IL-6 and TNF-ɲ ? ĚĞĐƌĞĂƐĞ d-cell activation and differentiation, and 
increase apoptosis of eosinophils using human cells in vitro.  This may be of benefit 
to COPD patients as cigarette smoking has been shown in in vitro studies to 
enhance the activation of inflammatory cells including neutrophils (Inoue et al., 
2000).   
A double blinded RCT in 125 patients with stable COPD using pravastatin 40mg od 
for 6 months reported an increase in exercise time and a decrease in hs-CRP, with a 
correlation between the decrease in hs-CRP and increased exercise time (Lee et al., 
2008).  Statins have also been shown to reduce inflammation in other chronic 
52 
 
inflammatory conditions (McCarey et al., 2004).  Airway inflammation is discussed 
below.  
1.8.3.c Statins and aortic stiffness in other disease groups 
Previous studies have also looked at the effects of statin therapy in patients with 
rheumatoid arthritis  W another chronic inflammatory condition.  Maki-Petaja et al. 
reported a decrease in aortic PWV, inflammatory markers and disease activity in 
patients with rheumatoid arthritis following simvastatin therapy.  The comparator 
was ezetimibe which showed a similar change.  The study design did not allow for a 
placebo comparator group (Maki-Petaja et al., 2007). 
It has been suggested that statin therapy in COPD could modify non-invasive 
markers of cardiovascular disease, such as arterial stiffness, in the short term.  Pilot 
data looking at sub-therapeutic, low-dose fluvastatin on arterial wall properties has 
shown a decrease in PWV at both 14 and 30 days after starting 10mg fluvastatin 
therapy in a double-blind randomised trial with 50 healthy male subjects.  The 
greatest improvement in PWV was seen after 30 days of treatment in apparently 
healthy males, with a non-significant improvement maintained after 5 months 
(Lunder et al., 2011).   
1.8.3.d Statins and COPD/ Airflow obstruction 
There is limited but supportive evidence for a cardioprotective role for statins in 
COPD: retrospective, observational studies suggest statins confer benefit.  A time-
matched nested case-control study of two population-based retrospective cohorts 
by Mancini et al. reported that statin treatment in patients with COPD may be 
cardio-protective and therefore modify disease prognosis (Mancini et al., 2006).  
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More recently a prospective observational study has reported that long term statin 
use decreases all-cause mortality by 39% in patients with COPD, whilst short term 
statin use reduces respiratory mortality by 64% (Lahousse et al., 2013).  Reduced 
mortality and risk of death from influenza/pneumonia has also been reported 
following statin treatment in patients with COPD (Frost et al., 2007). 
Studies using atorvostatin have also shown a significant reduction in deaths as a 
result of infection and respiratory illness and therefore a reduction in all-cause 
mortality as a result of decreased non-CV deaths (Sever et al., 2011).   
Studies looking at the use of statins in asthma have failed to show any 
improvement in physiological parameters or sputum eosinophils (Menzies et al., 
2007), but a recent RCT by Hothersall et al. in 54 mild to moderate atopic 
asthmatics has reported a decrease in sputum macrophages when atorvostatin was 
used with inhaled corticosteroids over 8 weeks, despite no improvement in lung 
function or FeNO, which also encourages there may be a potential role for statins in 
airways diseases in which activated alveolar macrophages are involved in the 
pathogenesis, such as COPD (Hothersall et al., 2008).   
The potential benefit of these pleiotropic effects of statin therapy in current and ex-
smokers has been suggested in a retrospective study by Keddissi et al. to be 
associated with a reduced rate of decline in lung function, predominantly 
spirometry measurements, and a lower incidence of respiratory related emergency 
hospital admissions, regardless of the underlying lung pathology in a study 
comparing current and ex-smokers to a control group (Keddissi et al., 2007).  In 
2007 Alexeeff et al. reported a reduction in the lung function decline in people 
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concurrently taking statin therapy, based on a population of 803 older males from 
the Veterans Administration Normative Aging Study, with both smoking and non-
smoking backgrounds.  Approximately a third of subjects in the statins group were 
never smokers and there was a pack year history in the statin and not on statin 
groups of 31 and 29 years respectively (Alexeeff et al., 2007).  More recently, 
epidemiologically the presence of airflow limitation was found to be 5 times lower 
in those taking statins compared to people not on statin therapy (Bando et al., 
2012). 
The potential beneficial effects of statin therapy on lung function may be due to 
their anti- inflammatory properties.  The systemic inflammatory mediator CRP has 
been associated with an increased risk of CV disease (Ridker, 2003), inversely 
associated with lung function in people even without respiratory disease (Aronson 
et al., 2006), and elevated in elderly subjects with obstructive lung disease 
compared to age matched controls (Yende et al., 2006), and in COPD populations 
(Pinto-Plata et al., 2006).  Both airway and systemic inflammatory state are thought 
to increase over time in COPD patients, and this heightened inflammatory state 
contributes to the decline in lung function (Donaldson et al., 2005).   
No difference in the rate of decline in FEV1 or FVC was seen between different types 
of statins (Keddissi et al., 2007), however lipophilic statins, such as simvastatin and 
atorvastatin, are thought to have the greatest anti-inflammatory potential (Kiener 
et al., 2001).  The urgent requirement for prospective drug trials in order to 
appropriately assess the impact of statins on clinically relevant outcomes in COPD 
patients has been highlighted (Janda et al., 2009). 
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Studies looking at the use of statins during exacerbations of COPD have been 
reported.  A prospective longitudinal evaluation of statin use on the outcomes of 
245 patients admitted to hospital with COPD exacerbations has shown that patients 
on statin therapy presented a lower total number of exacerbations during the 1 
year follow-up, and also had a longer period before the following exacerbation.  
There was also an improvement in HRQoL post exacerbation hospital discharge in 
those patients on statin therapy, which could be attributable to the reduction in 
exacerbations and longer duration between exacerbations.  There was no short or 
long term survival improvements after hospitalisations with COPD exacerbations 
(Bartziokas et al., 2011).  A more recent observational study supports these findings 
in suggesting statin use reduces the risk of COPD exacerbations (Wang et al., 2013). 
In a retrospective study the use of statins were associated with improved survival 
after exacerbations of COPD.  The use of ICS further increased the survival benefit 
associated with statin treatment (Soyseth et al., 2007).   
Taken together there are a number of studies looking at the use of statins in 
patients with COPD and airflow obstruction through retrospective, population 
based and RCT studies, as summarised in Table 1.4.  Human studies presented were 
published in English between 2006 and 2013. 
1.8.3.d.i Animal studies 
Wright et al. has shown how statins can reverse pulmonary hypertension, which 
can be a serious complication of COPD, and vascular remodelling in female guinea 
pigs.  Smoke induced endothelial dysfunction can also be significantly reversed 
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using statins along with the prevention of emphysema development; but there was 
no protective effect against small airway remodelling (Wright et al., 2010).   
In a study where rats were exposed to cigarette smoke for 16 weeks, simvastatin 
was shown to ameliorate the structural and functional damage to the lungs, 
specifically, lung parenchymal destruction was attenuated, through anti-
inflammatory effects and MMP-9 induction suppression (Lee et al., 2005).  
Consistent with in vitro studies showing statins effect in reducing inflammation, 
namely CRP (Kleemann et al., 2004) using male human CRP transgenic mice, 
unrelated to lipid lowering.    
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Table 1.4 Statins and COPD/ Airflow Obstruction Literature Summary  
Authors Year Study Design Drug 
Dose 
Duration Significant 
exclusions  
Sample size 
 
Primary Outcome Secondary Outcome Conclusion 
COPD  
Mancini 
(Mancini 
et al., 
2006) 
2006 Retrospective 
cohort (nested 
case control) 
Quebec region 
Variable Not 
known 
<65yrs at time 
of surgery, MI 
in previous 5 
years 
946 cases 
18774 
controls 
Hospitalisation 
 
Death Statins were associated 
with reduced COPD 
hospitalisation and 
death irrespective of CV 
risk profile 
Melbye 
(Melbye et 
al., 2007) 
2007 Population 
based study 
Variable Not 
known 
None 
reported 
535 exposed 
3342 
unexposed 
CRP level  No association between 
statin use and CRP 
levels in COPD without 
CVD  
Soyseth 
(Soyseth 
et al., 
2007) 
2007 Retrospective 
cohort 
Variable Not 
known 
None 
reported 
118 exposed 
736 
unexposed 
All- cause mortality  Statin use was 
associated with 
improved survival after 
COPD exacerbation 
Frost 
(Frost et 
al., 2007) 
2007 Retrospective 
cohort 
Variable A? ? ?ĚĂǇƐ None 
reported 
7475 exposed 
to <4mg/d 
11583 expose 
to >4mg/d  
54174 
unexposed 
Mortality  Reduced risk of 
mortality from COPD in 
statin users that was 
more pronounced with 
moderate dose statins 
than low dose statins 
Ishida 
(Ishida et 
al., 2007) 
2007 Population 
based analysis 
Variable - None 
reported 
47 prefectures 
of Japan 
COPD mortality Senility 
Pneumonia 
Accidents 
All-cause mortality 
Statin use was 
associated with 
decreased mortality 
from COPD 
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Keddissi 
(Keddissi 
et al., 
2007) 
2007 Retrospective 
cohort 
Not stated A? ?
months 
Normal 
spirometry, 
asthma, non- 
smokers 
215 exposed 
203 
unexposed 
Respiratory related 
emergency 
department visits 
Decline in FEV1  
Decline in FVC 
Statins were associated 
with a slower decline in 
lung function and 
reduced respiratory 
related emergency 
visits 
Blamoun 
(Blamoun 
et al., 
2008) 
2008 Retrospective 
cohort 
Variable A? ?ǇĞĂƌ Incorrect 
COPD 
diagnosis, 
statins <1year, 
heart failure, 
pneumonia, 
lung surgery, 
OCS, 
FEV1<20% 
predicted 
90 exposed 
95 unexposed 
Exacerbations Intubations 
Morbidity 
Statins may be 
associated with lower 
incidence of 
exacerbations and 
intubation in COPD 
Lee (Lee et 
al., 2008) 
2008 RCT Pravastatin 
40mg 
6 months Allergic 
rhinitis, 
wheeze, PE, 
reversibility 
62 active 
63 placebo 
Increase in exercise 
time on treadmill 
Change in CRP levels The active group had 
increased exercise 
capacity and decrease 
in CRP 
Van Gestel 
(van 
Gestel et 
al., 2008) 
2008 Retrospective 
cohort 
Variable   330 statin 
980 non statin 
Short term mortality 
(30 days) 
Long term mortality  
(10 years) 
Statin use was 
associated with 
improved short and 
long-term survival in 
patients with PAD and 
COPD 
Bartziokas 
(Bartzioka
s et al.) 
2011 Prospective Not stated >30days Other 
respiratory 
condition, no 
spirometry 
data 
74 statins 
171 non 
statins 
All-cause mortality 
within 30days of 
admission and in 
1year follow up 
Composite adverse 
outcome index. 
Number of ECOPD. 
Time to first 
subsequent ECOPD. 
Hospitalisations for 
ECOPD. 
Statins were associated 
with lower risk of 
subsequent ECOPD and 
severe ECOPD, and 
improved QoL in 
patients hospitalised 
for ECOPD 
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Time to first 
subsequent 
hospitalisation 
Sheng 
(Sheng et 
al., 2012) 
2012 Cohort study Not stated - - PP:617 statin 
657 non statin 
SP:292 statin 
151 non statin 
Total cholesterol 
change from baseline, 
CV events 
All-cause mortality Statins were protective 
from CV events and 
mortality in SP; and 
improved all-cause 
mortality in PP and SP 
Lahousse 
(Lahousse 
et al., 
2013) 
2013 Nested case 
control 
Variable 17 year 
follow up 
Asthma 363 cases 
2345 controls 
All- cause mortality Hs-CRP Statin use is associated 
with a beneficial effect 
on all-cause mortality, 
depending on baseline 
systemic inflammation 
ASTHMA  
Menzies 
(Menzies 
et al., 
2007) 
2007 Double-blind 
crossover RCT 
Simvastatin 
20mg/40mg 
1 month Smokers, 
statins, recent 
ECOPD 
 
 
26 FeNO Methacholine 
challenge, sputum cell 
counts, spirometry, 
plethysography, CRP 
Simvastatin did not 
show anti-inflammatory 
activity in asthmatics 
Hothersall 
(Hothersal
l et al., 
2008) 
2008 Double- blind, 
crossover RCT 
Atorvastatin 
40mg 
8 weeks Recent 
ECOPD, atopy, 
smoker, 
statins  
54 Lung function, 
sputum cell counts 
Diary data, exhaled 
nitric oxide, mediator 
levels 
No improvement in 
lung function or other 
markers of asthma 
control. 
Reduction in sputum 
macrophages. 
Braganza 
(Braganza 
et al.) 
2011 Double-blind 
parallel group 
RCT 
Atorvastatin 
40mg 
4 weeks Statins, drugs 
that interfere 
with statins 
36 active 
32 placebo 
PEF QoL score Atorvastatin did not 
change lung function in 
asthmatics 
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All studies comprise Human subjects, are original studies and published in English Language.  
Moini 
(Moini et 
al., 2012) 
2012 Double-blind 
RCT 
Atorvastatin 
40mg 
8 weeks Statins, 
smoking, 
hepatitis, 
myopathy, 
recent ECOPD 
requiring 
hospitalisation 
31 active 
31 placebo 
ACT Lung function 
Eosinophil count 
Atorvastatin not 
effective in mild-
moderate asthma 
Tse  
(Tse et al., 
2013)  
2013 Cohort study Variable  24 
months 
<31yrs age, 
OCS, anti-IgE 
therapy, 
missing 
covariates for 
propensity 
score 
calculation, 
<36 months 
enrolment, 
baseline 
asthma 
therapy other 
than with 
concomitant 
ICS 
14566 statins 
58135 non 
statins 
ICS dispensing Asthma related ED 
visits 
Statin exposure was 
associated with 
decreased OCS 
dispensing and asthma-
related ED visits  
Abbreviations  W  ACT: asthma control test, CVD: cardiovascular disease, ECOPD: exacerbation of COPD, ED: emergency department, FeNO: fraction of exhaled nitric oxide, hs-
CRP: highly sensitive C-reactive protein, OCS: oral corticosteroids, PAD: peripheral artery disease, PE: pulmonary embolism, PEF: peak expiratory flow, PP: primary prevention, 
QoL: quality of life, RCT: randomised control trial, SP: secondary prevention 
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To date, the only published randomised control trial (RCT) looking at aortic PWV as 
a primary endpoint in patients with COPD is a double blind, placebo controlled RCT 
looking at the effect of fluticasone propionate/salmeterol combination inhaler, 
where no significant change in aortic PWV post treatment was seen, however, a 
sub-group analysis looking at those in the highest baseline aortic PWV tertile did 
find a decrease in aortic PWV following treatment (Dransfield et al., 2011). 
 
 
 
The introduction highlights important gaps in our understanding.  There is a huge 
importance of CV disease in COPD, and yet we do not currently perform any routine 
assessment of CV disease at either diagnosis or annual follow-up.  Further, we have 
no COPD management that allows for primary prevention of CV disease.  
In my thesis, I will present 2 studies that will contribute to our understanding of 
these 2 aspects, exploring potential new biomarkers and primary prevention 
therapy. 
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Chapter 2 
Methods 
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2 Methods 
This thesis comprises two core studies  W  ‘dŚĞ ĂƌĚŝŽǀĂƐĐƵůĂƌ ĂŶĚ /ŶĨůĂŵŵĂƚŽƌǇ
Effects of Statin dŚĞƌĂƉǇ ŝŶ KW ? ĂŶĚ  ‘dhe Association of Lung Function and 
Cardiovascular RŝƐŬ ? ?  dŚŝƐ ŵĞƚŚŽĚƐ ƐĞĐƚŝŽŶ ůĂƌŐĞůǇ ƌĞůĂƚĞƐ ƚŽ ƚŚĞ ƐƚĂƚŝŶ RCT, but 
many of the procedures are present in both studies, and are cross-referenced 
accordingly.    
2.1 The Cardiovascular and Inflammatory Effects of Statin 
Therapy in COPD: Trial design  
This study was a randomised, double blind, placebo controlled, parallel group 
clinical trial performed at a single centre.  The objective of the study was to assess 
whether six weeks therapy with simvastatin (20mg) od improves the increased 
arterial stiffness and inflammation seen in COPD patients.   
The primary outcome measure was the difference in change in arterial stiffness as 
measured by aortic pulse wave velocity (PWV) after six weeks of treatment 
between the active statin treatment and placebo group.   
The secondary outcome measures included the change in circulating inflammatory 
mediators, exhaled nitric oxide, induced sputum cell counts, exercise tolerance and 
lung function after six weeks treatment with either the active simvastatin or 
placebo.   
The study was registered on the clinicaltrials.gov website  W ref: NCT01151306. 
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2.1.1 Approvals 
In order to conduct this study approval had to be granted by the National Research 
Ethics Service (NRES), the Medicines and Healthcare products Regulatory Agency 
(MHRA) and Research and Development (R&D).  Approvals were applied for 
through the Integrated Research Application System (IRAS).   
2.1.1.a Ethics 
All documents used in the study i.e. protocol, patient information sheet - see 
appendix 1 p222, consent form  W see appendix 2 p234, poster advert  W see 
appendix 3 p235, questionnaires  W see appendices 8-10 p249-256 and General 
Practitioner (GP) letters (not shown here) were approved by the regional ethics 
committee (REC).  REC reference: 10/H0408/10.  As part of the procedure, there 
was a committee meeting on 22nd February 2010 to discuss the study.  Committee 
members included both medical, such as consultant physicians, pharmacists, 
nurses, co-ordinators, and lay people.  The study was given favourable ethical 
opinion on 20th April 2010 following some minor changes and the submission of an 
external review.  A substantial amendment to invite patients from primary care 
sites across Derby City, Derby County, Nottingham City and Nottingham County 
former Primary Care Trusts was made and accepted in December 2010.  
2.1.1.b MHRA 
The MHRA accepted the study on 12th March 2010.  Documents reviewed by the 
MHRA were the consent form, patient information sheet, protocol, summary of 
product characteristics (SmPC), and the drug bottle label.  Eudra CT 2009-017689-
22, and the local University of Nottingham Sponsor's Protocol Code Number 09105.  
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Annual Development Safety Update Reports were completed as per MHRA 
requirements.  
2.1.1.c R&D 
R&D approval was granted by Nottingham University Hospitals NHS Trust on 6th 
May 2010 following their review of the protocol, patient information sheet (PIS), 
consent form, GP letter, questionnaires and poster advert.  Primary care R&D 
approval for the substantial amendment to allow primary care recruitment was 
received in December 2010.   
2.1.1 Sample Size 
The sample size required to detect a 10% (-1m/s) reduction in aortic PWV with 
intervention, a significance of 0.05 and power of 0.8 was 29 patients in each arm  W 
active and placebo treatment.  A sample size of 35 in each arm was therefore being 
implemented to allow a sample size of 29 fully evaluable subjects to be attained 
after sample attrition.   
Our power calculation was based on a 1m/s drop in aortic PWV as this would be 
considered a significant decrease in aortic PWV.  An increase in aortic PWV of 1m/s 
has been associated with an increase in CV events by 14%, CV mortality by 15% and 
all-cause mortality by 15% (Vlachopoulos et al., 2010).  More recently, a meta-
analysis of 13 studies comprising populations of both known CV disease and 
population based studies, reported a change of 1m/s in aortic PWV was associated 
with a hazards ratio for CV events of 1.07 for a 60 year old non-smoking male 
without traditional CV risk factors (Ben-Shlomo et al., 2013).   
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2.1.2 Inclusion and Exclusion Criteria 
 
Inclusion criteria:  
x Current or ex-smoker with an appropriate smoking history 
x Aged between 45 and 80 years of age with confirmed COPD: FEV1 30-
80% predicted, FEV1/FVC<0.7  
x Salbutamol reversibility <12% or 200mls 
x Able to attend regular clinic appointments and comply with 
requirements of protocol (in the opinion of the investigator)  
x Provide written informed consent 
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Exclusion criteria:   
x Currently taking statins or fibrates,  
x Known hypersensitivity / side effects to statin therapy, 
x HǇƉĞƌĐŚŽůĞƐƚĞƌŽůĂĞŵŝĂ ?A? ? ? ?ŵŵŵŽů ?> ) ? 
x Significant hypoxia (PaO2 <7.3kPa),  
x Lactose intolerance,  
x Alcohol excess (>21 units per week for males or 14 units for females),  
x Clinically significant liver function abnormality,  
x Exacerbation in the last 4 weeks,  
x Condition causing the study to be detrimental to the patient,  
x Co-existing condition: Rheumatoid/collagen vascular disease, diabetes 
mellitus, untreated hypothyroidism, inflammatory bowel disease,  
x Other respiratory disease,  
x Malignancy,  
x History of IHD/cor pulmonale/ congestive heart failure,  
x Known Į1 anti-trypsin deficiency,  
x Elective surgery - recent, or during study period,  
x Therapies including: oral prednisolone for more than 1 week in the last 6 
months, disease modifying drugs e.g. gold/sulphasalazine, 
investigational drugs within 4 weeks of baseline, warfarin, cyclosporine, 
potent CYP3A4 inhibitors, grapefruit juice  
x Pregnancy/ breast feeding/at risk of becoming pregnant (not using a 
medically acceptable form of contraception) 
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2.1.3 Recruitment 
Participants were recruited from both primary and secondary care as well as the 
Nottingham Respiratory Research Unit (NRRU) database.  
NRRU Database: The database had 33 subjects when the study first began.  There 
has been a steady increase, mainly due to ability to liaise with GP surgeries, recruit 
from outpatient clinics and NRRU staff attended pulmonary rehabilitation sessions; 
now there are 448 participants on the COPD database.   
Secondary Care: Patients were recruited from the out-patient clinics of Dr C Bolton 
by personal request as well as posters placed in the out-patient waiting room.  In 
addition, posters were placed in the lung function department, the respiratory 
wards and notice boards around City Hospital, Nottingham.  Other respiratory 
physicians across the Trust were encouraged to inform us if there was a willing 
participant from an outpatient COPD clinic.  NRRU research staff attended 
Pulmonary Rehabilitation groups and Breathe Easy Meetings in a recruitment effort 
in general for the database.  
Primary Care: In December 2010, ethical and R&D permission were gained to liaise 
with GP surgeries as Patient Identification Centres (PICS).  Initially 77 surgeries were 
approached, with 29 positively responding and 18 able to perform searches of 
COPD patients.  Letters were sent out by the practices to the patients meeting an 
abbreviated inclusion / exclusion list, dependent on the surgeries ? software and 
search capability but broadly encompassing  “age ?,  “diagnosis of COPD ?,  “not on a 
statin ?,  “not on warfarin ?,  “no current history of malignancy ?.  Table 2.1 lists the 
ƐĞĂƌĐŚ ǁŚĞƌĞ ƚŚĞ  ‘ƌĞƐƉŽŶƐĞ ? ĐŽůƵŵŶ ŝŶĚŝĐĂƚĞƐ ŚŽǁ ŵĂŶǇƉĂƚŝĞŶƚƐ contacted the 
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research department after being sent an invitation letter by their GP.  In March 
2012 we applied for Primary Care Research Network (PCRN) support to aid 
recruitment from primary care, the study having become adopted; see Table 2.2.  
Figure 2.1 demonstrates the accrual for the statin RCT. 
Posters were also sent to some of these and other surgeries across Nottingham City 
ĂŶĚŽƵŶƚǇWd ?ƐǁŚŽǁĞƌĞǁŝůůŝŶŐƚŽƉƵƚƚŚĞŵƵƉ ?ĨŽƌƚŚĞŵƚŽĚŝƐƉůĂǇŝŶƉĂƚŝĞŶƚ
waiting areas.  
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Table 2.1 GP Recruitment Prior to PCRN Adoption  
 Size of Practicea COPD patientsb Letters sentc Response PIS sent out Consented Completed study 
Tokard Hill Medical Centre 13 255 311 124 18 (15%) 13 9 3 
Stenhouse Medical Centre 12 321 189 85 11 (13%) 7 5 2 
Highcroft Surgery 11 636 214 84 12 (14%) 9 6 4 
Netherfield Medical Centre 8 912 152 44 4 (9%) 4 0 0 
Barnby Gate, Newark 13 238 183 88 5 (6%) 4 3 2 
West End Surgery 6 491 166 29 2 (10%) 0 0 0 
Wilford Grove Surgery 3 317 39 18 2 (11%) 2 1 0 
Church Walk Surgery 11 261 295 133 14 (11%) 6 5 0 
Daybrook Health Centre 9 012 187 *- 5 5 3 2 
Oakenhall Medical Practice 7 067 159 83 12 (14%) 11 3 0 
Hucknall Road Medical Centre 12 428 250 118 20 (17%) 15 9 2 
Zulu Road Medical Centre 2 164 45 15 3 (20%) 3 1 1 
Ruddington Medical Centre *- *- *- 4 2 0 0 
Fairfields Practice 6 165 123 52 4 (8%) 4 3 1 
Melbourne Park Medical Centre 8 153 156 75 7 (9%) 7 2 1 
Leen View Surgery 7 372 192 126 6 (5%) 5 2 1 
Orchard Medical Centre *- *- *- 5 4 3 2 
Rivergreen Medical Centre 8 741 178 70 10 (14%) 5 1 0 
Key - a, b  W according to QoF database 2010 c- according to the Practice Manager *- Not available Abbreviation  ? PIS: patient information sheet 
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Table 2.2 GP Recruitment with PCRN Support 
 Letters 
sent
c 
Patients 
replying 
PIS sent 
out 
Consented Completed 
study 
Blidworth Surgery 37 5 5 4 1 
Moir Medical Centre 14 1 1 1 0 
East Leake Health Centre 31 7 4 2 1 
Churchside Medical Centre 19 2 1 1 0 
Darley Dale Surgery 21 2 2 2 0 
Limes Medical Centre 53 4 3 2 1 
Wollaton Vale Health Centre 5 2 2 1 1 
The Surgery at Wheatbridge  98 14 11 7 3 
Lombard Medical Centre 25 3 3 0 0 
Dronfield Medical Practice 35 1 0 0 0 
Collingham Medical Centre 29 4 4 3 3 
Rosemary Street Health Centre 104 0 0 0 0 
Dr Sood and Partners  40 2 2 0 0 
Newbold Surgery 45 5 5 3 1 
Keyworth Medical Practice 20 0 0 0 0 
Derby Road Health Centre 31 6 5 4 0 
West Oak Surgery 16 4 4 4 2 
Greenwood and Sneinton  37 2 1 0 0 
Key - c- according to the Practice Manager  
Abbreviation  W PIS: patient information sheet 
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Figure 2.1 Cumulative Recruitment for the Statin RCT 
 
Key - A  W Amendment applied for to change reversibility entry criteria, B  W Approached GP practices to aid recruitment 
C  W PCRN started to help with recruitment 
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One of the main reasons for people failing screening was significant reversibility, 
with patients having a significant degree of reversibility to 400mcg of Salbutamol 
via inhaler and spacer.  See Figure 3.2, p101.  Initially the criteria was to exclude 
anybody who reversed by 12% or greater to 400mcg salbutamol.  To coincide with 
guidelines an amendment was made and approved to add >200ml to the 12% as 
the cut-off for a significant bronchodilator response.  The change in reversibility 
criteria did not affect the study design because it was not a primary outcome, and 
although reversibility results can help establish a diagnosis where uncertain, COPD 
guidelines are moving away from this.  Moreover the guidelines recommend the 
use of post-bronchodilator spirometry in the diagnosis of COPD and acknowledge 
day-to-day variability in reversibility (Calverley et al., 2003).  
2.1.4 Patient Information Sheets 
Patient information sheets (PIS) were sent to everyone interested in the study that 
fulfilled the initial requirements, Appendix 1 page 222.  When originally discussing 
the study with prospective patients ? ŝnitial suitability could be assessed following 
simple questions such as checking diagnosis, medication and smoking history.  Once 
a PIS had been sent out patients were phoned back after one week in order to allow 
time to receive the PIS and read it, to see if they were interested, and if they were, 
a consent visit was arranged at a mutually convenient time.  All patient visits were 
in the Clinical Trials Unit (CTU) at City Hospital, Nottingham.   
2.1.5 Consent 
A consent visit was arranged to discuss the study with the patient and obtain 
informed consent.  See appendix 2 page 234.  This provided an opportunity to 
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answer any questions the patient had.  If the patient agreed, a letter was sent to 
their GP to ŝŶĨŽƌŵƚŚĞŵŽĨƚŚĞŝƌƉĂƚŝĞŶƚƐ ?Ɖarticipation in the study.  
2.1.6 Screening 
The patients were then asked to attend a screening visit fasted for 8 hours and 
without having taken their inhaled medication  W short acting bronchodilators 
withheld for 6 hours and long acting bronchodilators withheld for 12 hours.   
They had their height and weight measured (methods 2.2.1 page 78), performed 
spirometry and reversibility (methods 2.2.3 page 82), had venepuncture to send off 
for measurements of their full blood count, fasting lipid profile and glucose levels, 
liver function and renal function (methods 2.2.7 page 87).  Exhaled carbon 
monoxide levels were recorded (methods 2.2.12 page 91) and a capillary blood gas 
sample (methods 2.2.10 page 91) was taken for analysis of oxygen levels on air.   
The most common reasons for subjects failing screening was significant 
reversibility, hypercholesterolaemia and unsuitable spirometry results.   
2.1.7 Drug Preparation 
The active medication (simvastatin) was purchased from Ranbaxy and shipped to 
Bilcare GCS (UK) who prepared the encapsulated statin and placebo.  The 
simvastatin tablet was enclosed within a hard gelatine capsule, with lactose powder 
and magnesium stearate powder, which are excipients of the licensed product, 
used to prevent the tablet rattling within the capsule, and for the production of the 
placebo.  The active treatment and placebo had identical appearance.   
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Disintegration tests on the over-encapsulated product were studied to show that 
the dosage form complied with pharmacopoeial requirements for disintegration.   
Although disintegration testing was performed, it could not be guaranteed that the 
statin works as it would do in its non-capsulated form.    
2.1.8 Dispensing 
Treatment was allocated by an independent pharmacist.  45 tablets were dispensed 
to each patient, whether active or placebo treatment.  Patients were asked to take 
study medication in the evening, because this is when cholesterol biosynthesis is 
most active, hence greater reduction in cholesterol levels (Saito et al., 1991).  The 
researcher did not have access to the randomisation codes.  Pharmacy held them 
and the researcher would contact pharmacy in case of an emergency.    
2.1.9 Randomisation 
Each patient was randomly allocated to either active simvastatin treatment or a 
lactose based placebo treatment via a web based randomisation system.  
Randomisation was performed using a computer generated pseudo-random code, 
which used random permuted blocks of randomly varying size to produce a 
randomisation sequence.  This was created by the Nottingham Clinical Trials Unit 
(NCTU) in accordance with their standard operating procedure (SOP) and held on a 
secure server.  The sequence was generated using the stats package STATA and the 
function RALLOC as per local protocols.  Randomisation was 1:1, stratified according 
to age group with categories 45-62 years and 63-80 years as age is an important 
variable of arterial stiffness (Laurent et al., 2006).     
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2.1.10 Study Visit 1  
Prior to visit 1 the subject was randomised, generating a prescription which was 
processed by the clinical trials pharmacy in preparation for the patient ?s visit.  The 
patients were asked to attend visit 1 fasted for 8 hours and without having taken 
their short or long acting bronchodilator inhaled medication for 6 or 12 hours 
respectively.  With-holding long-acting bronchodilators for 12 hours is not ideal, as 
some drugs have a longer duration of action than this.  Tiotropium bromide 
(Spiriva), for example, has an onset of action of 30 minutes, with peak effect in 3-4 
ŚŽƵƌƐďƵƚĂĚƵƌĂƚŝŽŶŽĨĂĐƚŝŽŶĨŽƌA? ? ? hours (Koumis and Samuel, 2005).  Increasing 
the duration for subjects to with-hold long acting medication could have resulted in 
them taking short acting bronchodilators and therefore not meeting pre-visit 
requirements, or resulted in a bias towards those with milder disease.   
Inclusion and exclusion criteria were re-checked.  Height and weight were 
measured (methods 2.2.1), cardiovascular measurements were made including 
aortic stiffness (sphygmocor) and blood pressure (methods 2.2.2), bronchodilator 
administered; exhaled nitric oxide (FeNO) (methods 2.2.4), bioelectrical impedance 
(BIA) to determine body composition (methods 2.2.13), post-bronchodilator 
spirometry (methods 2.2.3), hand grip strength (methods 2.2.14) and carbon 
monoxide levels (methods 2.2.12) were performed, venepuncture (methods 2.2.7), 
six minute walking test (6MWT) (methods 2.2.9) and questionnaires completed 
(methods 2.2.15), spot urine sample collected, sputum induction (methods 2.2.5) 
and drug dispensed.  Study visits always started with cardiovascular measurements 
and sputum induction was always performed last.     
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2.1.11 During 6 Week Study Period 
Subjects were telephoned twice during the 6 week period, at 2 and 4 weeks post 
visit 1.  This was to check compliance and for side effects.  In addition, all subjects 
had access to a 24 hour a day number to phone and report any side effects or 
change in symptoms according to standard protocol for a Clinical Trial of an 
Investigational Medical Product RCT.   
2.1.12 Study Visit 2  
Study visit 2 was six weeks +/- 3 days post visit 1.  The patients were asked to 
attend study visit 2 fasted and without having taken their inhaled medication as per 
study visit 1.  Tests were performed as per study visit 1.   
In addition the trial medication bottle was checked to count remaining tablets as a 
measure of compliance and related to time period from study visit 1.  We defined 
good compliance as those subjects who took at least 90% of the medication for the 
days that they should have done, i.e. 6 weeks +/- 3days.  
2.1.13 Safety Profile 
A clinically relevant increase in Gamma-glutamyl transferase (gamma GT) and 
alanine transaminase (ALT) was defined as a value greater than 3 times the upper 
limit of normal.  A clinically relevant increase in creatine phosphokinase (CPK) was 
defined as a value greater than 5 times the upper limit of normal.     
Side effects classed as  “musculoskeletal ? included muscle aches and pains, cramps 
and joint aches.   “Gastrointestinal ? side effects included nausea, sickness and 
diahorrea.   
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2.2 Procedures Used in Clinical Studies 
I was the sole member of staff appropriately trained in all procedures for the statin 
RCT and performed all tests according to local standard operating procedures 
(SOPs).   
2.2.1 History and Examination 
For the statin RCT patients were questioned to make sure pre-visit instructions 
were followed, to ensure the patient had withheld inhaled therapy and was fasted.  
The inclusion and exclusion criteria were rechecked.    
dŚĞƐƵďũĞĐƚ ?ƐŚĞŝŐŚƚŝŶŵĞƚƌĞƐ ?ŵ ) and weight in kilograms (kg) were measured on a 
Seca (Hamburg, Germany) dual height and weight station bare-foot without shoes 
and outdoor clothing.  
Smoking pack year history was calculated by dividing the number of cigarettes 
smoked per day by 20, and then multiplying that by the number of years smoked.    
2.2.2 Haemodynamic Measurements 
Prior to commencing the statin RCT, there was a period of operator training.  This 
involved spending 2 days in the Wales Heart Research Institute at the University of 
Wales Hospital, Cardiff, with health care professionals who regularly perform 
arterial stiffness measurements.  After shadowing a few measurements and 
learning how to operate the machine I was observed performing measurements on 
willing subjects and deemed competent by my trainer.  Following this 2 day training 
period I also performed measurements on willing participants before performing 
the tests on study patients.   
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The haemodynamic measurements include peripheral and central blood pressure 
recordings and measurements of pulse wave analysis (PWA) and PWV to assess 
arterial stiffness.  Haemodynamic measurements were made in a quiet room at 
ambient temperature without bright lights.   
2.2.2.a Peripheral Blood Pressure 
Peripheral blood pressure was measured on the right arm using an Omron (705IT, 
UK) electronic sphygmomanometer in duplicate in the seated and supine position.  
Where the two readings exceeded 5mmHg difference a third measurement was 
made.  The average of two repeatable measurements was recorded.  For supine 
recordings, the subject was left to rest in the horizontal position for ten minutes 
prior to measurements.  
Systolic and diastolic blood pressure readings were recorded in mmHg.   
The peripheral mean arterial pressure (MAP) was a computed variable which was 
calculated using:             
(1/3 x systolic blood pressure) + (2/3 x diastolic blood pressure)   
Central MAP was calculated on the machine software.    
Peripheral and central pulse pressure (PP) was calculated using the equation:                             
pulse pressure = systolic blood pressure  W diastolic blood pressure.   
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2.2.2.b Pulse wave analysis and pulse wave velocity 
2.2.2.b.i Sphygmocor 
Measurements for the statin RCT were performed using the sphygmocor® device.  
The sphygmocor® (Atcor medical, Australia) measures central blood pressure, PWA 
and PWV using applanation tonometry to record waveforms (Laurent et al., 2006).   
PWA provides measurements of central blood pressure, mean arterial pressure and 
augmentation index.  Each measurement was recorded and the average of two 
repeatable results used.  
AIx is an indirect measure of arterial stiffness and wave reflection (Laurent et al., 
2006).  To perform the PWA procedure using the Sphygmocor machine the radial 
pulse was first palpated, the probe was then placed over the area where the 
strongest pulse was felt.  After a couple of seconds of repeatable good waveforms 
the data was captured and stored.  See Appendix 5 page 246.  The procedure is 
repeated following 10 minutes resting in the supine position.  Measurements were 
always taken on the right hand side.   
PWV is calculated using the time taken for the arterial waveform to travel through 
vasculature between 2 points of known distance apart.  The gold standard for this 
measurement is carotid  W femoral (aortic) PWV because it has better prognostic 
value (Laurent et al., 2006).  For this study aortic PWV was performed as the 
primary variable and carotid  W radial (brachial) was also recorded.  At least two 
repeatable results were recorded and the average result for each measurement 
was used.  To perform PWV a three lead electrocardiogram (ECG) was performed 
simultaneously with the procedure for PWA firstly at the carotid pulse, followed by 
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the femoral pulse for aortic PWV.  The distance was measured in mm from the 
carotid pulse to suprasternal notch for the proximal distance, and the distance from 
the suprasternal notch to femoral pulse was measured in mm for the distal distance 
which were inputted into the machine prior to starting the test; see Appendix 6 
p247 .   
To perform brachial PWV the same procedure was done using the carotid pulse 
followed by the radial pulse.  Again, two repeatable measurements were made and 
the average recorded.   All PWV measurements were performed after resting in the 
supine position for at least 10 minutes.  
One of the main causes of variation is path length measurements, and the method 
used to determine path length can significantly affect results (Sugawara et al., 
2010).  Differing proposed methods used to determine path length include the 
direct distance between the carotid and femoral pulses, the distance between the 
suprasternal notch (SSN) and femoral pulse with the SSN to carotid pulse distance 
subtracted, and the carotid to femoral pulse distance minus the SSN to carotid 
distance. 
Measurements of arterial stiffness are operator dependent; however, to eliminate 
this all recording made for the RCT were performed by a single operator.   
2.2.2.b.ii Vicorder 
DĞĂƐƵƌĞŵĞŶƚƐ ĨŽƌƚŚĞ  ‘ssociation of lung function and cardiovascular ƌŝƐŬƐƚƵĚǇ ?
were made using the Vicorder (Skidmore Medical, UK), which is another non-
invasive, oscillometric method of performing measurements of PWA, PWV and 
central blood pressure.  Measurements of central blood pressure and PWA are 
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made in the seated and supine position.  In a relaxed seated position a cuff was 
placed around the brachial pulse and inflated.  When a steady trace was detected 
the results were saved and the procedure repeated until at least two 
measurements with an AIx within 5% were recorded.  The average central blood 
pressure, MAP, AIx and HR were then taken.  The procedure was repeated following 
10 minutes rest in the supine position and the same measurements recorded.  With 
this device brachial to femoral and carotid to femoral (aortic) measurements of 
arterial stiffness were made with simultaneous inflating cuffs over the respective 
pulses.  The path length was measured as the distance between the midpoint on 
the brachial cuff to the midpoint on the femoral cuff in cm and the brachial PWV 
recorded, see Appendices 5-6.  After 3 repeatable measures were made, the aortic 
PWV measurements were performed by simultaneously inflating a cuff around the 
carotid pulse with a cuff around the femoral pulse, using the distance measured 
between the mid-point of the carotid cuff and mid-point of the femoral cuff, see 
Appendices 5-6. 
Repeatability of arterial stiffness measurements in patients with COPD using the 
vicorder device (Stone et al., 2013), Sphygmocor in healthy, hypertensive and 
hypercholesterolaemic (Wilkinson et al., 1998), and both vicorder and sphygmocor 
in patients with peripheral arterial disease (Shahin et al., 2013) has been reported.   
2.2.3 Spirometry 
2.2.3.a Standard   
Spirometry was performed on a micro-medical spirometer (MicroLab MK6) in 
accordance with published ATS/ERS guidelines (Miller et al., 2005).  The subject was 
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seated in an upright position with both feet flat on the floor.  The chair did not have 
wheels but had arms for support.  A maximal forced expiration was performed 
through the mouthpiece following maximal inspiration.  Measurements of FEV1, 
FVC, FEV1/FVC ratio and peak expiratory flow (PEF) were recorded.  Three 
repeatable results were recorded, defined as the FEV1 and FVC being within 5% or 
0.15l of each other (BTS/ARTP, 1994).   
The obstructive ventilatory limitation caused by COPD is by definition, minimally or 
not reversible (Raherison and Girodet, 2009); and given the significant day to day 
variation in reversibility (Calverley et al., 2003), routine reversibility has been 
excluded from more recent guidelines (NICE, 2010a).   
Reversibility was assessed during screening for the statin RCT and in the 
 ‘Association of lung function and cardiovascular risk ? study, to identify those 
subjects with significant reversible airways and possible asthma.  Reversibility 
testing should be reserved for cases where asthma and COPD cannot be 
differentiated  W in these cases the National Institute for Clinical Excellence (NICE) 
guidelines recommend a 400ml improvement in FEV1 from the baseline value (NICE, 
2010a), whereas the American Thoracic Society/ European Respiratory Society (ATS 
/ ERS) guidelines state a 12% and 200ml increase in FEV1 and/or FVC from baseline 
shows a significant response (Pellegrino et al., 2005).   
The arbitrary nature of the figures used to classify a significant response highlights 
the unreliability of bronchodilator responsiveness as an improvement to therapy 
(Calverley et al., 2003).  For the statin RCT visits 1 and 2 spirometry was performed 
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post-bronchodilator (400mcg Salbutamol via metered dose inhaler and spacer) 
following the GOLD guidelines for COPD diagnosis and classification (GOLD, 2009).   
Where spirometry was performed on more than one occasion, the same spirometer 
was used.  Spirometers were verified using a 3 litre syringe prior to each testing 
session.  Spirometry predicted values were calculated using the European 
Community of Coal and Steel (ECCS) equations (Quanjer et al., 1993).   
2.2.3.b Bronchodilator reversibility  
Reversibility was measured by performing baseline spirometry i.e. where the 
subject has not had any short acting inhaled bronchodilator medication for 6 hours 
or long acting bronchodilators for 12 hours, then administering 400mcg Salbutamol 
via a Metered Dose Inhaler (MDI) and spacer.  Spirometry was repeated 20 minutes 
after administration, as this is when it will have maximum effect.  Reversibility 
testing was only performed on subjects showing evidence of airflow obstruction on 
baseline spirometry.    
2.2.3.c Grading of airflow obstruction   
To report GOLD stage, the post-bronchodilator FEV1% predicted value were 
categorised: GOLD I (mild): FEV1 A? ? ?A? ? 'K> //  ?ŵŽĚĞƌĂƚĞ ) P  ? ? A? &s1% < 80%, 
'K> ///  ?ƐĞǀĞƌĞ ) P  ? ? A? &s1% < 50% and GOLD IV (very severe) FEV1 <30% 
(Decramer et al., 2013); see Table 1.1.  The statin RCT recruited only GOLD II-III, but 
the  ‘ssociations of lung function and cardiovascular risk study ? recruited all GOLD 
severities. 
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2.2.4 Exhaled Nitric Oxide 
The fraction of exhaled nitric oxide (FeNO) measurement provides a quantitative 
measure of nitric oxide concentrations non-invasively, and is a useful biomarker to 
help distinguish between eosinophilic and non-eosinophilic inflammation (Pavord et 
al., 2008).  Nitric oxide is produced in large and peripheral airways and alveoli by 
epithelial, endothelial and inflammatory cells (Barnes et al., 2010).  NICE guidelines 
are in draft for the use of FeNO is asthma (NICE, 2013), but the potential role of 
FeNO in COPD has not been established yet.   
FeNO was measured by steady exhalations at varying flow rates  W 10, 30, 50, 100 
and 200ml/s on a NIOX flex machine (Aerocrine, Sweden). Multi-flow 
measurements can be used to differentiate between alveolar and bronchial NO 
production and therefore distinguish the type of inflammation  (Lehtimaki et al., 
2001).   
The test is performed by taking a maximal inspiration of NO (nitric oxide) free air 
through the mouthpiece to total lung capacity (TLC), then steadily exhaling at a 
constant rate also through the mouthpiece against a resistance.  In those with 
significant airflow obstruction the test technique was not always possible to 
perform.  Where possible, two measurements were recorded at each flow rate, and 
the mean used for analysis.  The machine was calibrated every 14 days in 
ĂĐĐŽƌĚĂŶĐĞǁŝƚŚŵĂŶƵĨĂĐƚƵƌĞƌ ?ƐŐƵŝĚĂŶĐĞ ? 
Alveolar gradient and bronchial intercept were not measured directly, but 
parameters estimated from a model such as the slope-intercept model (Tsoukias 
and George, 1998).  The alveolar gradient corresponds to the alveolar 
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concentration and the bronchial intercept corresponds to the bronchial nitric oxide 
flux (Malinovschi et al., 2009).  The alveolar gradient and bronchial intercept refer 
to the regression line through the nitric oxide output for each of the flow rates.   
A single flow rate technique can also be performed where measurements are just 
taken at the 50ml/s flow rate as this has been identified as a useful biomarker in 
patients with asthma (Barnes et al., 2010, Olin et al., 2007).  We chose the five-flow 
rate method as little is known about FeNO and COPD it will provide the most 
information.    
2.2.5 Sputum Production and Induction  
Where possible, patients in the statin RCT provided spontaneous sputum samples.  
In those unable to produce an adequate spontaneous sample, sputum induction 
was performed.   
Sputum was induced by inhaling increasing concentrations of saline solution  W 3, 4 
and 5% via a nebuliser (ultrasonic nebuliser NE-U17, Omron).  Following each 
nebulisation FEV1 was measured to check for any resulting bronchoconstriction.  If 
FEV1 dropped by 20% compared to pre-saline nebulisation the test would be 
stopped; if the drop was between 10-20% and the subject remained symptom free 
the test would continue but without increasing the saline concentration.  As per 
departmental protocol, sputum induction was not performed on anyone with an 
FEV1 <50% due to the risk of bronchoconstriction (Pizzichini et al., 2002).    
2.2.6 Sputum Processing 
Sputum plugs were isolated from saliva macroscopically.  The resulting plugs were 
ŵŝǆĞĚ ǁŝƚŚ ƵůďĞĐĐŽ ?Ɛ WŚŽƐƉŚĂƚĞ ƵĨĨĞƌĞĚ ^ĂůŝŶĞ  ? ? P ? ) ĂŶĚ ƉƌŽƚĞĂƐĞ ŝŶŚŝďŝƚŽƌ
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(150µg per gram of isolated sputum) by vortexing (Fisher Scientific FB15012 
TopMix) for 15 seconds before pulse sonicating for a further 15 seconds.  The 
suspension was then filtered and a quota was removed to assess both cell number 
and viability by mixing with Trypan blue (1:1) and analysing using a 
haemocytometer.  The remaining cell suspension was centrifuged (600g for 10 
minutes at 4°C; Eppendorf 5702R) and the supernatant removed was frozen at -
80°C to be used for the potential analysis of markers of airway inflammation.  This 
was performed by GM and HB.  
Differential sputum cell counts were determined manually by counting 400 non-
squamous cells and was reported as relative numbers of eosinophils, neutrophils, 
macrophages, lymphocytes and epithelial cells; and then expressed as a percentage 
of total non-squamous cells.  These were recorded at study visit one and study visit 
two, where possible.   
2.2.7 Venous Blood Sample 
Venepuncture was performed using the aseptic non touch technique with the 
butterfly vacutainer system.   
2.2.7.a Pathology lab samples 
At each study visit of the statin RCT blood samples were taken to check safety 
ŵĞĂƐƵƌĞƐ ?ŝŶĐůƵĚŝŶŐ>&d ?ƐĂŶĚW<.  
Fasting lipids, liver function tests and CPK were measured on the Olympus AU2700 
platform (Beckman Coulter, USA) according to manufĂĐƚƵƌĞƌ ?ƐƐĞƚƚŝŶŐƐ ? 
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2.2.7.b Centrifuging 
Serum separator blood bottles were centrifuged at least 30 minutes after the 
sample was taken at 1300g, 23°C for 10 minutes; and ethylenediaminetetraacetic 
acid (EDTA) blood bottles were centrifuged immediately after taking the blood 
sample at 1000g, 4°C for 15 minutes; ĂůŝƋƵŽƚĞĚĂŶĚƐƚŽƌĞĚĂƚAL ? ? ? ?ůůŵĞƚŚŽĚƐ
had been fully quality controlled prior to analysis in a CPA accredited laboratory.   
2.2.7.c Research bloods Ȃ Statin RCT 
Blood samples were aliquoted and stored at -80oC for later analysis of inflammatory 
mediators.    
2.2.7.c.i Circulating hs-CRP 
High sensitivity CRP (hsCRP) was measured using an immuno-turbidimetric assay 
(Beckman Coulter) on an Olympus AU5400 analyser from a previously frozen (-80°C) 
serum sample and each sample was analysed once.   
2.2.7.c.ii Circulating MMP-9 
Total MMP-9 was measured using a quantikine enzyme-linked immunosorbent 
assay (ELISA) kit (R&D systems, UK) in batches of stored aliquots of serum.  The 
minimum detectable dose of MMP-9 is less than 0.156ng/ml, which was 
determined according to the product datasheet by adding 2SD to the mean optical 
density value of twenty zero standard replicates and calculating corresponding 
concentrations (RnDSystems, 2012).  Each sample was measured in duplicate by 
WC.   
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2.2.7.d Research bloods - Association of lung function and cardiovascular 
risk  
Blood samples were taken and stored for later analysis of serum AGE and serum 
soluble receptor for AGE (RAGE). 
2.2.7.d.i AGE 
Serum AGE was measured using an ELISA kit (Cell biolabs, San Diego, USA) in 
batches of stored aliquots.  Each sample was measured in duplicate by SS. 
2.2.7.d.ii RAGE 
Serum soluble RAGE was measured by WC using an ELISA kit (R&D systems, UK) in 
batches of stored aliquots of serum.  Each sample was measured in duplicate. 
2.2.8 Skin Advanced Glycation End-products (AGE) 
Skin AGE was measured in the  ‘ssociation of lung function and cardiovascular risk ? 
study using a non-invasive AGE Reader (DiagnOptics, Groningen, Netherlands).  See 
Appendix 7 for a picture of the machine.  This measurement was performed on 
Caucasian skin by placing the forearm (free from any creams or tanning lotion, 
bruising, scars or pigmentation) onto the AGE reader.  Triplicate measures were 
made and then the average of the 3 recordings was taken as the final result.   
A 4W UV-A emitting lamp is the light source from the AGE reader that illuminates 
1cm2 of the tissue of the forearm, with an excitation light source of between 300-
420nm  W peak excitation 350nm.  Only light reflected from the skin is measured 
between 300-600nm with a spectrometer using a 200µm glass fibre.  Dark and 
white reference readings were performed before each measurement to correct for 
background light and calculate reflectance; see Appendix 7.  The degree of auto-
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fluorescence (AF) was recorded (Meerwaldt et al., 2004, Mulder et al., 2006).   
Autofluorescence was calculated as:  
AF = average light intensity emitted per nm over the 420-600nm range   
         average light intensity emitted per nm over the 300-420nm range 
 
2.2.9 Six Minute Walking Distance 
Six minute walking distance (6MWD) tests were performed to quantify the distance 
covered in order to assess exercise tolerance (Crapo et al., 2002).  This test was 
performed post bronchodilator along a 10m straight walking course where the 
subject walks up and down a path of known distance, to assess functional ability.  
During the test subjects are not given any indication of the time i.e. how long they 
have walked for or how long they have left.  Encouragement is limited and 
standardised to ensure consistency with each subject.  Many previous studies 
report a practice test followed by a second test, as many subjects improve on the 
second attempt due to the learning effect (Sciurba et al., 2003).  In this study we 
performed a practice walk, until the patient understood the requirements of the 
test, and was able to walk up the path and around the markers adequately.  As the 
6MWD were performed pre- and post-intervention in the statin study there was a 
six week gap between the two tests.  This should have prevented any learning 
effects between the two results because of the time delay.  The distance walked 
was recorded in metres and the pre- and post-exercise heart rate and oxygen 
saturations were also measured using pulse oximetry.   
The current guidelines recommend a walking distance of 30m (Crapo et al., 2002) to 
perform the 6MWD test, however our subjects performed the test on a 10m path 
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due to restrictions within the department.  The shorter walking distance may result 
in lower recorded 6MWD results, as the subjects have to turn around the course 
more often (Crapo et al., 2002).  This was standardised however, as it was 
performed the same way for everyone.       
2.2.10 Capillary Blood Gases 
Capillary blood gases were performed to estimate the arterial oxygen (PaO2) and 
carbon dioxide (PaCO2) levels and pH.  Subjects with hypoxaemia (PaO2 <7.3kPa) 
were excluded.  The earlobe was heated and vasodilated using Raljex® cream to 
increase blood perfusion.  A blood sample was then collected in a capillary tube by 
scratching the earlobe with a lancet.  Blood samples were analysed in the lung 
function department using a Radiometer ABL90 FLEX (Sussex, UK).   
2.2.11 Pulse Oximetry 
Pulse oximetry was performed using a Konica Minolta Pulsox-300 (Tokyo, Japan).  
This provides a measure of oxygen saturation and heart rate.  The probe is placed 
on a finger nail bed free from any nail polish, with adequate circulation.  A single 
measurement was made when there is adequate signal strength and the result is 
stable.   
2.2.12 Carbon Monoxide (CO) Measurements 
Exhaled carbon monoxide (CO) measurements were recorded as a quantifiable 
measure of CO as a combined result of smoking and atmospheric pollution.  The 
measurements are made using a Clement Clarke Smokerlyzer CO monitor (Harlow, 
UK).  To perform the test the subject inhales and breath-holds for 15 seconds, 
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before blowing out into the CO monitor.  A reading was then displayed indicating 
the subjects CO levels.   
2.2.13 Body Composition 
The body mass index (BMI) was recorded from the Seca scales.  Body composition 
measurements were recorded using a Tanita (Illinois, USA) bioelectrical impedance 
machine.  Values of fat mass, percentage body fat, fat free mass percentage, total 
weight and resistance was recorded.  These measurements were being performed 
due to the high reported prevalence of altered body composition in the COPD 
population.  Fat mass index (FMI) was calculated as fat mass/height2 and the fat 
free mass index (FFMI) was calculated as fat free mass/ height2.  Prior to performing 
the measurements the Tanita machine waƐƐĞƚƵƉǁŝƚŚƚŚĞƉĂƚŝĞŶƚ ?ƐĂŐĞ ?ŚĞŝŐŚƚĂŶĚ
weight of clothes to allow for accurate readings.  A standard weight of 0.5kg was 
used to account for clothes.  To perform the test the participant stood with bare 
feet on the machine with a foot on either plate, after the initial weight 
measurement the subject will take hold of the handles, one in each hand for the 
body composition measurements.   
BIA was contra-indicated in anyone with a pacemaker. 
2.2.14 Handgrip Strength 
Upper arm muscle strength was measured with handgrip strength using an 
analogue dynamometer (Takei, Japan).  Three repeatable attempts are recorded 
with the dominant hand and encouragement was given during the test manoeuvre.  
The patients ? dominant side was recorded.  The average measurement for each 
hand was recorded.   
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2.2.15 Patient Questionnaires 
2.2.15.a MRC dyspnoea score 
The MRC score is the subjects ? perception of their breathlessness, and is a score out 
of 5 (Fletcher, 1960), see Appendix 8.  The scale ranges from 1  W  ‘ŶŽƚƚƌŽƵďůĞĚďǇ
breathlessness except on strenuous ĞǆĞƌĐŝƐĞ ? ƚŽ  ? W  ‘ƚŽŽbreathless to leave the 
house, or breathless when dressing ŽƌƵŶĚƌĞƐƐŝŶŐ ?.  The higher the score the more 
severe the subject perceives their breathlessness.    
2.2.15.b COPD Assessment Test (CAT) score 
The CAT score is a self-reported questionnaire with 8 evenly weighted questions 
used to assess the impact of COPD upon the subject (Jones et al., 2009).  Each 
question is scored between 0 (no impact) and 5 (very severe impact), giving CAT 
total scores of between 0 and 40.  The higher the subject scores, the more impact 
COPD is having on their daily lives; see Appendix 9. 
2.2.15.c 
ǯ (SGRQ) 
The impact of disease upon the patient ?ƐƋƵĂůity of life is assessed using the self-
reported St Georges Respiratory Questionnaire (Jones et al., 1992), see Appendix 
10.  SGRQ results were analysed and a score for the domains of symptoms, activity, 
impact and a total score was recorded.   
2.2.16 Funding 
The research presented in this thesis was initially supported by the University of 
Nottingham and the Nottingham Respiratory BRU.  The statin RCT was funded 
through a National Institute for Health Research (NIHR) Research for Patient Benefit 
grant (RfPB).  I was subsequently awarded an NIHR fellowship BRF-2011-012.   
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3 The Cardiovascular Effects of Simvastatin in 
Patients with COPD: A double blind, randomised, 
placebo controlled trial 
3.1 Introduction 
With the recent interest in cardiovascular (CV) disease in subjects with COPD, and 
the prevention and treatment of such comorbidities (Decramer et al., 2013, Fabbri 
et al., 2008), it is surprising that other than smoking cessation, routine COPD 
management is not focused on preventing CV disease.   
Aortic stiffness is an independent predictor of CV risk (Laurent et al., 2001), and is 
increased in COPD subjects, over and above the effects of smoking (Sabit et al., 
2007, Maclay et al., 2009).  Aortic PWV has been reported to predict both future 
fatal and non-fatal CV events, and mortality; even after adjusting for established CV 
risk factors (Ben-Shlomo et al., 2013). 
Aortic PWV is responsive to intervention over a short period of time.  Statins ability 
to modulate arterial stiffness has been shown in people with other chronic illnesses 
(Meng et al., 2009, Maki-Petaja et al., 2007) as described in chapter 1.  
Statins are not currently recommended for primary prevention of CV disease in 
patients with COPD, despite statins being shown in other chronic diseases with an 
increased CV risk to have a role in CV prevention (Colhoun et al., 2004).  In subjects 
with normal LDL-cholesterol levels, but increased CRP levels, rosuvastatin 20mg 
daily significantly reduced CV events in apparently healthy subjects (Ridker et al., 
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2008).  People with diabetes also have an increased risk of CV disease, and a study 
reported that the use of atorvastatin 10mg daily in the diabetic population with 
normal LDL-cholesterol levels and no history of CV disease was effective in reducing 
first CV events, and did so by 37% (Colhoun et al., 2004).  
Statins have been shown through population based retrospective cohort studies to 
be cardio-protective in COPD patients irrespective of individual CV risk and steroid 
use (Mancini et al., 2006).  Other smaller studies have been done which support 
these findings (Soyseth et al., 2007, Lee et al., 2008), but there are no RCT ?Ɛ with CV 
outcomes.  A prospective observational study found that long term statin use, 
defined as at least 2 years, decreases all-cause mortality in COPD by 39%; whilst 
short term statin use, defined as at least 30 days, decreases respiratory mortality by 
64% by modulating the baseline level of systemic inflammation (Lahousse et al., 
2013).  In a matched cohort study, moderate dose statin users  W ĚĞĨŝŶĞĚ ĂƐ A?
4mg/day, were found to have a significantly lower COPD mortality and a reduced 
risk of death from influenza/pneumonia (Frost et al., 2007).   
dŽĚĂƚĞ ?ƚŚĞƌĞĂƌĞŶŽZd ?ƐŽĨƐƚĂtins in COPD with CV outcome measures.  Indeed, 
until recently there have been no RCTs of the effects of medication in COPD on 
primary cardiovascular endpoints, with only observational or retrospective analyses 
ŽĨ Zd ?Ɛ ǁŚŝĐŚ ŚĂĚ ƉƌŝŵĂƌǇ ůƵŶŐ ĞŶĚƉoints.  A recent study by Dransfield et al. 
provides the first RCT evidence of inhaled medication in COPD and CV outcomes 
(Dransfield et al., 2011). 
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Hypothesis:  
Increased aortic stiffness, as measured by aortic PWV, would be lowered 
following 6 weeks treatment of simvastatin 20mg once daily compared to placebo 
in patients with COPD, but without concurrent cardiovascular disease, 
hypercholesterolemia or diabetes.  
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3.2 Methods 
This study was a double-blind, placebo controlled RCT, performed at a single centre 
- the Nottingham Respiratory Research Unit, City Hospital, Nottingham.  All ethical, 
R&D and MHRA approvals were sought prior to commencement  W see methods 
2.1.1.    
3.2.1 Recruitment 
In order to fulfil enrolment requirements 633 subjects expressed an interest from 
our recruitment efforts, with 504 of these appearing suitable following telephone 
conversation and interested in receiving the PIS; see Table 3.1 and Figure 3.1.  
Subjects with COPD were recruited into the study as described in methods 2.1.3 
p68, following detailed inclusion and exclusion criteria:  
Inclusion criteria: as previously described  W see methods 2.1.2 p66, but most 
pertinently a current or ex-smoker with an appropriate smoking history, aged 
between 45 and 80 years of age with confirmed COPD. 
Exclusion criteria: The full exclusion criteria are in the methods chapter, see 
chapter 2 p66. The key exclusion criteria pertinent to the population were not 
currently taking a statin, no hypercholesterolemia, no CV disease and not diabetic.  
The reasons for failing screening are presented in Figure 3.2.  
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Table 3.1 Individual and Cumulative Recruitment for the Statin RCT 
 
Table a: Recruitment figures         Table b: Cumulative Recruitment figures 
 
 Consented Screened Study   Consented Screened Study 
June 2010 4 0 0 June 2010 4 0 0 
July 3 7 0 July 7 7 0 
August 2 2 2 August 9 9 2 
September 5 2 1 September 14 11 3 
October 2 4 0 October 16 15 3 
November 5 5 0 November 21 20 3 
December 0 0 1 December 21 20 4 
January 2011 0 0 0 January 2011 21 20 4 
February 11 10 1 February 32 30 5 
March 4 4 4 March 36 34 9 
April 7 3 0 April 43 37 9 
May 3 5 5 May 45 40 14 
June 3 6 3 June 48 46 17 
July 2 0 3 July 50 46 20 
August 4 6 2 August 54 52 22 
September 7 7 1 September 61 59 23 
October 3 3 1 October 64 62 24 
November 10 11 2 November 74 73 26 
December 6 7 0 December 80 77 26 
January 2012 8 9 5 January 2012 88 86 31 
February 7 4 2 February 94 90 33 
March 5 4 5 March 100 94 38 
April 4 4 2 April 104 98 40 
May 6 8 0 May 110 106 40 
June 4 4 3 June 114 110 43 
July 8 6 1 July 122 116 44 
August 6 6 3 August 128 122 47 
September 10 10 4 September 138 132 51 
October 9 9 3 October 147 141 54 
November 15 15 6 November 162 156 60 
December 4 4 8 December 166 160 68 
January 2013 5 5 2 January 2013 171 165 70 
 
 
 
100 
 
Figure 3.1 Consort Diagram of Study Recruitment, Allocation, Drop-out and 
Completion 
 
 
 ‘KƚŚĞƌ ? ƌĞĂƐŽŶƐ ĨŽƌ ĨĂŝůŝŶŐ ƚŚĞ ƐĐƌĞĞŶŝŶŐ ǀŝƐŝƚ ŝŶĐůƵĚĞĚ ĐĂƌĚŝĂĐ ŚŝƐƚŽƌǇ ? ĂůĐŽŚŽů
excess, maintenance prednisolone/antibiotics, withdrew consent, other respiratory 
diagnosis, never smoker and outside age range.  
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Figure 3.2 Reasons for Failure at Screening Visit (n=failures)            
 
 
                                            
 
  
Significant reversibility
(>12% or >200mls)
FEV1 % predicted <30%
FEV1 % predicted >80%
Not obstructed
spirometry
Medication
Cholesterol >6.5mmol/l
Other
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3.2.2 Consent Visit  
Interested patients, after reading the PIS, were invited for a consent visit to obtain 
informed written consent, see methods 2.1.5 p73. 
3.2.3 Screening  
During the screening visit eligibility was checked.  A full history was taken.  
Spirometry, including bronchodilator reversibility was performed, see methods 
2.2.3 p74.  Fasting lipid profile, liver function test (LFT), renal function, glucose and 
full blood count were measured, see methods 2.2.7 p87.  Carbon monoxide was 
measured, see methods 2.2.12 p91.    
3.2.4 Randomisation 
Eligible subjects that were recruited were then randomised, see methods 2.1.9 p75. 
3.2.5 Study Visit 1 
During study visit one the baseline data was collected.  The primary variable was 
aortic PWV, which was measured to assess aortic stiffness using the sphygmocor, 
see 2.2.2.b p80.  Other tests performed pertinent to this chapter were post-
bronchodilator spirometry, haemodynamic measurements, venepuncture  W safety 
bloods (LFT and creatine phosphokinase (CPK)), lipid profile and high sensitivity C-
reactive protein (hs-CRP); CO and 6MWD.  See methods 2.1.10 p76.  
3.2.6 Treatment Phase 
Telephone calls were made to each patient, see methods 2.1.10   
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3.2.7 Study Visit 2 
Post-treatment results were recorded as per study visit one.  See methods 2.1.10 
p76.  Compliance was checked and recorded.   
3.2.8 Data Analysis 
Data was analysed using Statistical Package for the Social Sciences (SPSS, Chicago, 
IL) version 21.0.  A p<0.05 was considered significant.  The normality of the data 
was checked graphically.  Graphical interpretation was made using frequency 
distribution histograms and Q-Q plots.  Unless otherwise specified, arithmetic mean 
and standard deviation was used to show the measure of central tendency.   
Analysis: The primary outcome measure was aortic stiffness, using the parameter 
aortic PWV and was analysed using a general linear regression model, incorporating 
treatment group.  The aortic PWV was measured in m/s and can be influenced by 
BP and age, and to a lesser extent sex.  Post-treatment measurements were made 
at 6 weeks +/- 3days whilst the patients were still on active/placebo.   
The primary analysis was to compare the difference in the mean difference of the 
active and placebo arms for aortic PWV using an unpaired t-test.   
A secondary stratified analysis was then performed including baseline 
characteristics that were thought to influence the outcome; such as baseline PWV, 
age, sex, change in mean arterial pressure (MAP) and baseline total cholesterol 
levels.  This did not include the age stratification as age is not thought to influence 
the effect of statins on the change in PWV - only the baseline aortic PWV. 
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Secondary variables analysed were seated and supine/peripheral and central 
systolic, diastolic, mean arterial and pulse pressure; plus augmentation index, heart 
rate and carotid-radial PWV.   
A pre-defined subgroup analysis was performed to compare the mean change in 
difference of the active and placebo arms for aortic PWV in the subgroup of 
patients with a baseline aortic PWV measurement of >10m/s.  A value of 10m/s was 
determined prior to data analysis because it was deemed to be the lowest 
acceptable value to use as a cut-off for increased arterial stiffness, and has been 
proposed as the cut-off value for aortic PWV (Van Bortel et al., 2012).  
The 10m/s cut-off point is based on previous guidance to use 12m/s (Mancia et al., 
2007), which has been adapted to account for the new path length measurement 
recommended for use during the aortic PWV procedure which is now of 80% of the 
distance from the common carotid artery to the common femoral artery as 
opposed to 100% as previously used, and has been adopted in the latest ESH-ESC 
guidelines (Mancia et al., 2013).   
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3.3 Results 
Of the 633 subjects that expressed an interest in the study 241 were found to be 
not suitable, for example if they mentioned a pre-existing condition or lack of 
smoking history during initial telephone conversation.  A further 221 were no 
longer interested, or were unable to be re-contacted after receiving the PIS.  This 
left 171 subjects to be consented of whom 165 were screened, see Figure 3.1.   
From this, 72 people were suitable and randomised.  One subject was randomised 
twice as they had repeated acute exacerbation of COPD (AECOPD) post-
randomisation; so whilst fulfilling the criteria, was then unsuitable to start the study 
and subsequently withdrew consent.  Therefore, although 72 subjects were 
randomised, only 70 were prescribed study medication and started the RCT.   
From the 70 subjects that started the study, 33 were randomised into the active 
arm of the study and 37 into the placebo arm.  Of these, 31 subjects in the active 
group completed the study and 33 from the placebo group.   
3.3.1 Demographics 
64 subjects completed the study out of the 70 randomised and starting the study 
medication.  No follow on data is available for those who dropped out of the study.  
Baseline data for those on active treatment are presented in Table 3.2, alongside 
the placebo group.  There was no evidence of significant hypoxemia in either group.   
At baseline the number of subjects in each of the aortic PWV groups (<8m/s, 8-
10m/s and >10m/s) was: <8m/s n=21 (30%), 8-10m/s n=24 (34%) and >10m/s n=25 
(36%).   
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Table 3.2 Baseline Demographics for the Statin RCT 
 ?ŐĞŽŵĞƚƌŝĐŵĞĂŶ   *chi-squared test 
Abbreviations  W FEV1: forced expired volume in 1 second; FVC: forced vital capacity; 
GOLD: Global initiative for chronic Obstructive Lung Disease; CO: carbon monoxide; 
HDL: high density lipoprotein; LDL: low density lipoprotein; SGRQ P ^ƚ 'ĞŽƌŐĞ ?Ɛ
Respiratory Questionnaire; MRC: Medical Research Council; SpO2: oxygen 
saturation levels as measure by pulse oximetry 
Mean (SD) 
Unless otherwise specified 
(t-test unless otherwise specified) 
Active group 
n=33 
Placebo group 
n=37 
Age (years) Median (range) 64 (50-79) 65 (50-79) 
Sex Male n (%) * 26 (79) 24 (65) 
Smoking status (Current:Ex) n(%) * 7(21):26(79) 15(41):22(59) 
Smoking pack years  46 (25) 48 (22) 
FEV1 (L) 1.6 (0.6) 1.4 (0.5) 
FEV1 %predicted 55 (14) 53 (15) 
FEV1/FVC 46 (12) 47 (12) 
GOLD stage n(II, III)  20, 13 22, 15 
Exhaled CO (ppm) 3 (3) 5 (4) 
Total cholesterol (mmol/L)  5.3 (0.8) 5.4 (0.8) 
,>ĐŚŽůĞƐƚĞƌŽů ?ŵŵŽů ?> ? ? 1.6 (1.3) 1.7 (1.3) 
>>ĐŚŽůĞƐƚĞƌŽů ?ŵŵŽů ?> ? ? 2.9 (1.3) 2.9 (1.3) 
SGRQ total  38 (17) 38 (19) 
MRC dyspnoea score Median (range) 2 (1-5) 2 (1-5) 
Resting SpO2 on air (%) Median (range) 95 (92-98) 95 (90-98) 
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3.3.2 Drop Outs   
There were no apparent differences in baseline lung function  W FEV1 and FEV1% 
predicted and aortic PWV between those who dropped out (n=6) and those who 
completed the study (n=64).  For the subjects that dropped out of the study 
baseline mean (standard deviation (SD)) was- FEV1: 1.64 (0.66) L, FEV1% predicted 
56 (13) and aortic PWV 10.1 (3.6) m/s.  
3.3.3 Aortic PWV 
Of the 64 subjects that completed the study, aortic PWV measurements were only 
measured in n=63, but n=70 at baseline.  Central blood pressure measurements 
were in n=62, because accurate results could not be obtained in everyone due to 
technical challenges.   
There was a drop in aortic PWV of -1.0m/s in the active arm, p=0.06 over 6 weeks; 
see Figure 3.3.  Therefore, we did report the required change of what the study was 
powered to, but the placebo group also had a drop in aortic PWV following 
treatment and although there was a larger drop in aortic PWV in the active arm 
compared to placebo, the difference in change between arms was not significant: -
0.7 (-1.8, 0.5)m/s, see Table 3.3.  Adjusting for confounding factors in a secondary 
stratified analysis with the primary variable of the linear regression being change in 
aortic PWV, and the confounding variables which were adjusted for were age, sex, 
change in MAP and then cholesterol levels; using an entered regression model did 
not alter this.  Table 3.3 demonstrates the primary and secondary outcome 
measures pre- and post- treatment for both the active (simvastatin) and placebo 
group.     
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Abbreviations - PWV: pulse wave velocity, HDL: high density lipids, LDL: low density lipids, BP: blood pressure, MAP: mean arterial pressure
Table 3.3 Cardiovascular Measures for all Subjects Pre- and Post-treatment  
Mean (SD) 
n=total (active: placebo) 
Active (simvastatin) group Placebo group Mean difference 
A? ĂĐƚŝǀĞǀĞƌƐƵƐA?
placebo (CI) 
Pre  W
treatment 
Post  W 
treatment 
Post-Pre 
DĞĂŶ ‘A? ? 
Pre  W 
treatment 
Post  W 
treatment 
Post-Pre 
DĞĂŶ ‘A? ? 
Aortic PWV (m/s) n=63 (31:32) 9.9 (3.4) 8.9 (2.2) -1.0 9.1 (2.3) 8.9 (3.0) -0.3 -0.7 (-1.8, 0.5) 
Brachial PWV (m/s) n=31 (12:19) 8.9 (1.8) 8.3 (1.4) -0.4 7.7 (1.4) 7.5 (1.6) -0.2 -0.2 (-1.5, 1.2) 
Total cholesterol levels(mmol/l) n=64 (31:33) 5.2 (0.8) 4.1 (0.8) -1.2 5.4 (0.8) 5.3 (0.9) -0.1 -1.1 (-1.3, -0.8) 
Triglycerides (mmol/l)  n=64 (31:33) 1.2 (0.6) 1.1 (0.5) -0.2 1.5 (1.4) 1.5 (1.2) -0.1 -0.1 (-0.4, 0.2) 
HDL cholesterol (mmol/l) n=62 (31:31) 1.6 (1.3) 1.7 (0.4) 0.0 1.7 (1.3) 1.7 (0.5) 0.0 0.1 (-0.1, 0.2) 
LDL cholesterol (mmol/l) n=62 (31:31) 2.9 (0.7) 1.9 (0.6) -1.1 3.0 (0.8) 2.9 (0.8) 0.0 -1.0 (-1.3, -0.8) 
 
Peripheral 
Seated 
n=64(31:33) 
Systolic BP (mmHg) 147 (22) 144 (18) -3.1 151 (25) 145 (24) -5.5 2.4 (-3.7, 8.6) 
Diastolic BP (mmHg) 90 (12) 87 (11) -3.6 88 (14) 86 (12) -2.4 -1.3 (-4.7, 2.1) 
MAP (mmHg) 109 (14) 106 (12) -3.5 109 (16) 105 (15) -3.4 -0.1 (-3.8, 3.6) 
Pulse pressure (mmHg) 57 (15) 58 (16) 0.6 63 (18) 60 (19) -3.1 3.7 (-1.4, 8.8) 
 
 
Central Seated 
n=62(30:32) 
Systolic BP(mmHg) 137 (18) 135 (22) -1.6 138 (23) 133 (23) -4.9 3.3 (-2.5, 9.0) 
Diastolic BP (mmHg) 91 (12) 86 (12) -4.1 89 (14) 85 (14) -2.2 -1.9 (-5.5, 1.7) 
MAP (mmHg) 111 (14) 108 (12) -3.3 110 (18) 107 (16) -3.3 -0.1 (-4.1, 4.0) 
Pulse pressure (mmHg) 46 (12) 49 (16) 2.5 49 (16) 47 (19) -2.7 5.2 (0.2,10.1) 
Heart rate (bpm) 73 (13) 73 (14) -0.4 74 (15) 76 (17) 2.3 -2.7 (-6.1, 0.7) 
Augmentation Index (%) 27.4 (8.7) 26.6 (8.9) -0.9 27.5 (10.4) 25.9(10.3) -2.3 1.4 (-2.0, 4.9) 
 
Peripheral 
Supine 
n=64(31:33) 
Systolic BP(mmHg) 144 (24) 141 (22) -3.4 144 (24) 142 (23) -1.4 -2.0 (-8.5, 4.4) 
Diastolic BP(mmHg) 86 (12) 84 (12) -1.5 82 (13) 83 (13) 1.7 -3.2 (-6.9, 0.5) 
MAP (mmHg) 105 (15) 103 (14) -2.1 102 (15) 103 (15) 0.7 -2.8 (-7.1, 1.4) 
Pulse pressure (mmHg) 58 (16) 56 (16) -1.9 62 (18) 59 (18) -3.1 1.2 (-3.5, 5.9) 
 
 
Central Supine 
n=58(27:31) 
Systolic BP (mmHg) 136 (21) 135 (22) -0.8 134 (22) 133 (23) -2.0 1.3 (-5.7, 8.2) 
Diastolic BP (mmHg) 87 (13) 86 (12) -1.3 84 (13) 85 (14) 0.8 -2.1 (-6.0, 1.8) 
MAP (mmHg) 108 (16) 107 (15) -0.9 105 (16) 104 (18) -1.1 0.2 (-5.0, 5.4) 
Pulse pressure (mmHg) 49 (13) 49 (16) 0.5 50 (16) 48 (16) -2.9 3.4 (-0.8, 7.6) 
Heart rate (bpm) 68 (11) 68 (12) -0.7 71 (13) 73 (15) 2.2 -2.9 (-6.5, 0.7) 
Augmentation Index (%) 29.7 (8.0) 28.7 (7.5) -1.1 30.2 (9.8) 28.1(10.7) -2.5 1.3 (-2.7, 5.4) 
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Figure 3.3 Change in Aortic PWV After Treatment with Simvastatin or Placebo  
 
 
Mean change in aortic PWV (m/s) from baseline following 6 weeks treatment with 
active (simvastatin) or placebo.  
 
Error bars = standard error. 
 
  
Week 0 Week 6 
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3.3.4 Other Haemodynamic Measures 
There was no difference in change between arms in brachial PWV (n=33), p=0.81 or 
AIx (n=62) in either seated or supine measurements: p=0.40 and p=0.52 
respectively.   There were no significant changes in central or peripheral systolic, 
diastolic or mean arterial blood pressure, or pulse pressure measurements.  See 
Table 3.3.  
3.3.5 Cholesterol Levels 
Total cholesterol and LDL cholesterol levels decreased in the active group compared 
to placebo group post treatment, p<0.001 respectively.  See Table 3.3.  
There was no correlation between baseline total cholesterol or LDL-cholesterol 
level and baseline aortic PWV. 
3.3.6 Compliance 
When accounting for the visit 2 date i.e. 6 weeks from visit one +/- 3 days, the 
active group did not take a mean (SD) of 0.7 (1.0) tablets and the placebo group 1.4 
(2.0) tablets, p=0.06.  When good compliance was defined by taking at least 90% of 
the study medication, there were 15 subjects with poor compliance: placebo n=10, 
active n=5.  All patients took a minimum of 36 tablets. 
3.3.7 Subgroup Analysis: Aortic PWV >10m/s  
A sub-group analysis of subjects with baseline aortic PWV >10m/s was performed.  
This included n=25: active n=12 and placebo n=13.  The active and placebo group 
were well matched for age, sex, smoking history and baseline haemodynamic, lung 
function and cholesterol results; see Table 3.4.   
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Mean (SD) aortic PWV for the total subgroup was 12.6 (2.5) m/s.  In keeping with 
the main group there were a higher proportion of males and ex-smokers in both the 
active and placebo sub-groups.  The sub group was marginally older than the main 
group.  Smoking history, lung function and cholesterol levels were comparable with 
the main group.   
There was a significant difference in the change between the active arm of this 
subgroup n=11 and the placebo arm n=11, p=0.03 for aortic PWV; see Figure 3.4 
and Figure 3.5 and Table 3.5.  This significant difference remained after adjusting 
for age, sex and change in MAP in a stepwise linear regression, p=0.009.   
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Table 3.4 Sub-group Analysis in those with a Baseline Aortic PWV >10m/s: 
Baseline Demographics 
 ?ŐĞŽŵĞƚƌŝĐmean  * chi-squared test 
Abbreviations  W BP: blood pressure; FEV1: forced expired volume in 1 second; FVC: 
forced vital capacity; HDL: high density lipoprotein; LDL: low density lipoprotein; 
PWV: pulse wave velocity; SGRQ: St George ?s Respiratory Questionnaire; SpO2: 
Oxygen saturation levels as measure by pulse oximetry 
Mean (SD) 
Unless otherwise specified 
(t-test unless otherwise specified) 
Active (simvastatin) 
n=12 
Placebo 
n=13 
Age (years) Median (range) 70 (54-77) 64 (52-75) 
Sex Male n (%) * 9 (75) 10 (77) 
Smoking status (Current:Ex) n(%) * 4(33):8(67) 5(38):8(62) 
Pack years  46 (23) 46 (23) 
Aortic PWV (m/s) 13.2 (2.9) 12.0 (2.1) 
Peripheral systolic BP (mmHg) 156 (27) 159 (31) 
Peripheral diastolic BP (mmHg) 94 (14) 90 (18) 
FEV1 (l) 1.4 (0.6) 1.6 (0.7) 
FEV1 %predicted 51 (13) 55 (17) 
FEV1/FVC 41 (8) 48 (10) 
Total cholesterol (mmol/L)  5.3 (0.8) 5.3 (0.8) 
HDL cholesterol (mmol/L)  1.7 (0.4) 1.7 (0.5) 
LDL cholesterol (mmol/L) 3.0 (0.6) 2.8 (0.7) 
SGRQ total  43 (16) 35 (20) 
Resting SpO2 on air (%)  Median (range) 95 (93-98) 95 (90-97) 
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Table 3.5 Subgroup Analysis in those with a Baseline Aortic PWV >10m/s: 
Cardiovascular Markers 
Mean (SD) 
n=total (active: placebo) 
Active Placebo 
 
Mean 
ĚŝĨĨĞƌĞŶĐĞA?
active versus 
A?ƉůĂĐĞďŽ ?/ ? 
Pre-
treatment 
Post- 
treatment 
Pre- 
treatment 
Post- 
treatment 
Aortic PWV (m/s)  
n=22 (11:11) 
13.5 (2.9) 10.6 (2.1) 11.6 (1.5) 11.5 (3.0) -2.8 (-5.2, -0.3) 
Brachial PWV (m/s) n=10 
(4:6) 
9.3 (1.9) 9.2 (1.6) 7.7 (2.1) 6.7 (1.7) 0.9 (-1.3, 3.1) 
Seated AIx (%)  
n=20 (10:10) 
29.8 (7.3) 30.4 (9.2) 23.4 
(10.5) 
20.2 
(10.9) 
3.8 (-2.6, 10.2) 
Peripheral seated MAP 
(mmHg) n=23  (11:12) 
116 (18) 111 (14) 115 (21) 113 (16) -3.0 (-10.2, 
4.3) 
Peripheral supine MAP 
(mmHg) n=23 (11:12) 
111 (17) 108 (18) 105 (19) 110 (20) -8.1 (-16.7, 
0.5) 
Central seated MAP 
(mmHg) n=21 (9:12) 
120 (19) 114 (15) 114 (24) 114 (19) -5.0 (-11.8, 
1.9) 
Central supine MAP 
(mmHg) n=22 (10:12) 
119 (18) 12 (20) 107 (21) 108 (25) -7.2 (-17.2, 
2.9) 
Seated HR (bpm) 
 n=22 (10:12) 
77 (13) 75 (12) 73 (19) 78(21) -6.7 (-12.2, -
1.2) 
Supine HR (bpm) 
 n=22 (10:12) 
74 (12) 72 (8) 71 (16) 74 (20) -5.0 (-11.2, 
1.3) 
 ?ŐĞŽŵĞƚƌŝĐŵĞĂŶ 
Abbreviations- PWV: pulse wave velocity; AIx: augmentation index; MAP: mean 
arterial pressure; HR: heart rate 
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Figure 3.4 Change in Aortic PWV After Treatment with Simvastatin or Placebo in 
the Sub-group with Baseline Aortic PWV >10m/s 
 
 
Abbreviations  W PWV: pulse wave velocity 
Mean change in aortic PWV (m/s) from baseline following 6 weeks treatment with 
active (simvastatin) or placebo in the sub-group with a baseline aortic PWV >10m/s. 
 
Error bar = standard error 
 
 
 
 
Pre-treatment                                                   Post-treatment 
     Week 0       Week 6 
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Aortic PWV values (m/s) for each subject and mean values for active (simvastatin) 
and placebo subjects pre- and post-treatment, in the subgroup with a baseline 
aortic PWV >10m/s. 
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Figure 3.5 Change in Aortic PWV for Individuals in the Subgroup with a Baseline 
Aortic PWV>10m/s 
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3.3.8 Side Effects 
Patient reported side effects were recorded, with adverse events such as 
musculoskeletal and respiratory being the most commonly reported.  
Musculoskeletal problems are commonly reported amongst statin users and were 
anticipated.   
Side effects most commonly reported were respiratory events  W including cough, 
shortness of breath and chest infections, and musculoskeletal  W including muscle 
and joint aches, pain and cramps; less frequent were gastro-intestinal effects.  
There were more musculoskeletal side effects reported in the active group, as 
expected, with the other side effects comparable between the active and placebo 
group.   
There were no severe adverse events and no mortality.  The greatest proportion of 
subjects reported no side effects or adverse events at all.  See Table 3.6.   
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Table 3.6 Safety Issues Reported in the Total Study Group  
 
Abbreviations: ALT: alanine aminotransferase; gamma GT: glutamyltransferase; 
CPK: creatine phosphokinase 
 
  
 Active Placebo 
 
Adverse 
Events 
 
Musculoskeletal 
Muscle cramps 2 0 
Muscle aches 5 2 
Joint aches 0 2 
Respiratory 4 3 
Gastrointestinal 1 1 
Severe 
Adverse 
Events 
Hospital admissions 0 0 
Death 0 0 
Change in 
Liver 
Function 
Tests 
Clinically relevant increase in ALT 0 0 
Clinically relevant increase in gamma 
GT 
1 1 
Clinically relevant increased CPK 0 1 
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3.4 Discussion 
In this double blind, randomised controlled trial of 70 patients with COPD and 
without concurrent heart disease there was no significant difference in the change 
in aortic stiffness, as measured by PWV following 6 weeks, once daily, treatment 
with 20mg simvastatin compared to placebo; despite a reduction in total 
cholesterol of -1.2mmol/l in the active group.  The active group had a change in 
aortic PWV of -1m/s post treatment, but as the placebo group had a drop of 0.3m/s 
the difference between groups was not significant.  This was coupled with no 
significant change in other haemodynamic measurements including blood pressure. 
The baseline results for subjects randomised to simvastatin were well matched to 
those in the placebo group.  To date, this study is the only reported RCT of statins 
on aortic stiffness, or indeed any CV outcome, in patients with COPD.  We used 
aortic PWV as the primary outcome measure because it is the gold standard 
measurement, has been shown to be an independent predictor of CV events 
(Laurent et al., 2001) and is responsive to change over a short period of time (Maki-
Petaja et al., 2007).  Retention in the study was good, with a drop-out rate of 9%.   
Whilst we measured AIx and brachial PWV these are not prognostic like aortic PWV.   
The reported aortic PWV is recurrently lower in recently published studies (John et 
al., 2013, Dransfield et al., 2011) than original reports (Maclay et al., 2009, Sabit et 
al., 2007) on which this RCT was designed.  This is despite aortic PWV 
measurements being recorded using similar devices.  There are no obvious reasons 
why our PWV are lower than the original published results  W baseline demographics 
are similar, with well-matched age, lung function and cholesterol levels.  The 
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previously reported higher results are in a male population with lower blood 
pressure than described here (Maclay et al., 2009), and have a higher proportion of 
current smokers and pack year history (Sabit et al., 2007).  Arguably, the lower than 
previously reported baseline aortic PWV that we observed could be due to the 
improvements in COPD care and medications over the intervening years.  Our 
baseline aortic PWV values are comparable to other interventional studies.  The 
active group had a baseline value of 9.9m/s compared to 10.1m/s (Dransfield et al., 
2011) in a comparable COPD population; and 9.6m/s (Maki-Petaja et al., 2007) in 
patients with Rheumatoid arthritis.  We have shown a decrease in aortic PWV from 
9.9m/s pre-treatment to 8.9m/s post simvastatin treatment, compared to another 
interventional study using simvastatin that showed a decrease from 9.6m/s to 
8.9m/s following treatment (Maki-Petaja et al., 2007), but again this is a 
rheumatoid arthritis population, so although it is a chronic inflammatory condition, 
it is not a COPD study.  
The decrease in aortic PWV in the active group was to a result within the expected 
range for this population, but this drop was not enough to be significant compared 
to the placebo group.  This remained after adjusting for age and sex.   
Multiple linear regression showed seated MAP and age were predictors of baseline 
aortic PWV as one would expect.  This is reassuring as age (McEniery et al., 2005) 
and MAP are known to be the main contributing factors to aortic PWV.   
No other haemodynamic variables had a significant change post-treatment in the 
active compared to placebo group.  As expected there was no change in BP, which 
was an important finding because lowering BP is a significant variable for aortic 
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PWV, and therefore any changes in aortic PWV ideally should be independent of BP 
changes.  Statins have been reported to lower BP through increased NO 
bioavailability and improved arterial compliance, with meta-regression analysis 
showing no difference among different statin types  (Briasoulis et al., 2013), 
however, we did not find such an effect in our study group.      
Surprisingly, the central seated pulse pressure did not follow the same trend and 
was advantageous in the placebo group.  Pulse pressure (PP) has previously been 
used as a surrogate marker of arterial stiffness and a predictor of CV mortality 
(Norata et al., 2013), where a 10mmHg increase in PP was associated with an 
increase in all-cause mortality of 11% (Abernethy et al., 1986, Biere-Rafi et al., 
2013).  We cannot explain this finding, but it may be a result of multiple t-tests, and 
of note it was not repeated in the central supine pulse pressure.    
In the sub-group of those with a baseline aortic PWV >10m/s there was a significant 
difference in the change in aortic PWV between the active and placebo group post 
treatment, which remained after adjusting for age, sex, total cholesterol levels and 
change in MAP; indicating that intervention with statin therapy maybe better 
directed at those with a higher baseline.  Importantly, there were no parallel 
changes in other haemodynamic variables post-treatment in the active compared 
to placebo sub-group.   
There was no obvious way of identifying who would have the higher baseline values 
of aortic PWV, as shown by the similar baseline characteristic between the main 
group and sub-group with aortic PWV >10m/s.  The total group and sub-group with 
a baseline aortic PWV >10m/s had matched baseline and demographic data with 
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the exception of systolic blood pressure and MAP being higher in the sub-group 
compared to the main group.   
Identifying suitable subjects to take part in the study was a challenge; where 165 
subjects were screened to meet the recruitment target, with the main reasons for 
failing screening being hypercholesterolaemia and spirometry/reversibility results.  
The number of inclusion and exclusion criteria made the study population very 
specific, and therefore may reduce the generalizability of the findings to clinical 
settings; however, this was a proof of principle study.  One could question how 
representative our sample was, but we were keen from the outset to establish the 
role of statins in a population where they are not currently indicated.  If we had 
taken all COPD subjects it would then be questioned whether any reported benefit 
was simply because our population met the current licencing requirement for statin 
therapy.   
There is increasing interest in using aortic PWV as an outcome measure, and to 
screen patients for high aortic PWV at baseline.  Current interventional studies in 
patients with COPD are now opting to use aortic PWV as inclusion criteria, such as a 
study by GSK looking at aortic stiffness after 24 weeks fluticasone furoate/vilanterol 
intervention.  We did not because it is not a routine clinical test.  However, 
following the sub-group analysis showing a significant change in aortic PWV in the 
active group compared to the placebo group, it may have been worth considering 
this as an entry criteria.  The exclusion criteria meant that comorbidities such as a 
history of CV disease, hypercholesterolaemia or diabetes mellitus which would 
result in an increased aortic PWV were not present.  Currently, aortic PWV is not 
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measured as part of routine clinical care, but such central haemodynamic measures 
are welcomed by the FDA and undergoing review (Townsend et al., 2010, McEniery 
et al., 2014).   
ĞƐĐƌŝďŝŶŐ  ‘ŶŽƌŵĂů ? ǀĂůƵĞƐ ĨŽƌ ĂŽƌƚŝĐ Wts ŝƐcontentious as there are not well 
defined normal ranges and the variety of devices and techniques that can record 
measurements adds to the variability.  All pre- and post-treatment study 
measurements were made by one person in this trial to standardise technique and 
prevent operator variability.  An aortic PWV cut-off of 12m/s was first proposed in 
the ESH/ESC 2007 guidelines for the management of arterial hypertension (Mancia 
et al., 2007) to determine increased aortic stiffness.  Since then a 10m/s cut off in 
aortic PWV has been proposed to determine increased results (Van Bortel et al., 
2012, Boutouyrie et al., 2010), so we used that for our sub-group analysis; and this 
has since been adopted by the latest ESH/ESC guidelines (Mancia et al., 2013).  
However, adding to the controversy an aortic PWV cut-off of 11m/s was suggested, 
and recent studies have also used this as the cut-off for determining high values 
(Phababpha et al., 2013).   
We have considered why the active group did not have any significant change post-
treatment compared to the placebo group.  There are several possible explanations 
for the lack of response we saw following treatment including compliance, the 
duration of the study, lower baseline results as discussed and co-existent 
medication.  Taking these in turn, the lack of change in results in the active group 
post-treatment compared to the placebo group is unlikely to be due to compliance, 
as on the whole compliance data was good.   
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In retrospect our sample size was too small to detect a significant change in aortic 
PWV after treatment.  As the confidence interval (CI) of mean difference between 
groups includes -1, our findings do not rule out a potential benefit that could be 
seen in an adequately powered study.  
The drop in aortic PWV reported in the placebo group could be attributed to the 
 ‘ƉůĂĐĞďŽĞĨĨĞĐƚ ? ? ƚŚĞĂƉƉĂƌĞŶƚďĞŶĞĨŝƚŽďƐĞrved during study participation, as first 
described by Beecher in 1955 (Beecher, 1955), or as a result of spontaneous 
improvement, fluctuation of symptoms or regression to the mean  W all of which 
have been reported as false impressions of the placebo effect (Kienle and Kiene, 
1997).  It has been stated that altering the therapeutic environment may 
significantly contribute to reducing clinical symptoms (Mayberg et al., 2002) and 
therefore have impacted upon the clinical measures.   
The onset of action of the treatment drugs should not be a factor as a significant 
decrease in cholesterol levels shows medication was taken, and effective.  The 6 
week duration of the intervention period should have been long enough to see an 
effect, as previous studies in other chronic inflammatory conditions have shown a 
reduction in aortic PWV in the same timeframe (Maki-Petaja et al., 2007), and we 
were able to demonstrate the duration was sufficient to decrease cholesterol.   
We used a relatively low dose of simvastatin 20mg od and we cannot exclude the 
possibility that a higher dose of 40mg od may have shown a better response, 
however, in a rheumatoid arthritis population it was sufficient dose and duration to 
exhibit a benefit on aortic PWV (Maki-Petaja et al., 2007).  We selected a dose of 
20mg simvastatin because with a dose of 40mg there are higher risks of 
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musculoskeletal problems and other side effects.  From a patient perspective there 
does not appear to be any undue safety concerns in using statins at this dose in a 
COPD population. 
One placebo controlled RCT with the primary endpoint of aortic PWV has now been 
reported; where 249 patients with COPD were randomised to either fluticasone 
propionate/salmeterol combination inhaler twice daily or placebo, a reduction in 
aortic PWV was not seen.  However, post hoc analysis found a response in the 
subgroup of those patients with higher baseline aortic PWV (Dransfield et al., 2011).  
We excluded medications which were likely to affect aortic PWV such as oral 
steroids but were not able to control for combination inhalers, however, no patient 
knowingly started a new treatment during the six weeks.   
Aortic stiffness can be affected by both structural and functional aspects of the 
conduit arteries and vascular beds.  Systemic inflammation and endothelial 
dysfunction have been proposed as potential explanations for the increased aortic 
stiffness and CV risk in subjects with COPD (Mills et al., 2008).  Endothelial 
impairment has been suggested as a cause of increased arterial stiffness, as seen in 
patients with COPD; however, a recent study suggests that increased arterial 
stiffness is not a result of endothelial dysfunction (Maclay et al., 2009).  Structural 
aspects are less modifiable and include things like calcification, which often arises 
as a result of untreated functional aspects such as hypertension.  Calcification leads 
to decreased compliance and structural changes in the vessel wall.  Both aortic 
stiffness and calcification increases with age (Mills et al., 2008).  By treating 
potentially modifiable factors functional and structural changes can be prevented 
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and we may be able to lower aortic PWV.  Early anti-inflammatory intervention may 
help to modify the functional changes and therefore delay any structural changes.   
All of our subjects had a significant smoking history, as associated with COPD.  
Smoking is a common, well described risk factor for both COPD and CV disease, 
however patients with COPD have increased risk of CV disease over and above the 
effects of smoking (Sin and Man, 2003)  W the cause of which is not entirely 
understood, but may be caused by systemic inflammation.  In moderate-severe 
COPD subjects this low-grade inflammation has been associated with the risk of 
cardiac injury (Sin and Man, 2003).   
3.4.1 Limitations 
Although the planned sample size was reached, in light of the lower baseline aortic 
PWV and wider SD compared to what the power calculation was based on, it was 
underpowered; and a possible cause of the absence of any statistically significant 
changes in primary and secondary outcome measures between active and placebo 
group.  We now know we would need 177 patients in each arm of the study for 90% 
power to detect a -1m/s drop in aortic PWV.  The study was powered to detect a 
1m/s decrease in the active group, but the power calculation did not account for 
changes in the placebo group; therefore the 0.3m/s drop we reported in the 
placebo group was not pre-considered; however, this is in part accounted for by 
looking at the change between groups.  The supportive findings of simvastatin in 
patients with COPD with a higher baseline aortic PWV are encouraging but there 
was some disparity in baseline haemodynamic measures between the active and 
placebo groups. 
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3.4.2 Future Implications 
This was a pilot study to investigate feasibility for future studies.  Any intervention 
that may reduce the risk of CV disease in COPD requires careful evaluation.  Future 
studies could take two directions.  One direction would be a larger and more 
pragmatic study looking at hard end-points such as CV morbidity and/or mortality, 
although these are costly.  Alternatively, to have aortic PWV as the primary 
endpoint, in a larger multi-centre study recruiting those subjects with a high 
baseline aortic PWV. 
There were difficulties in recruitment and these should be considered in the 
planning of future studies.  Intervention with statin therapy appears better directed 
at those with an aortic PWV >10m/s.  Aortic PWV is not routinely performed in the 
clinical setting, therefore further investigation to see if it is practical to use as a 
screening tool to risk stratify and identify those with increased aortic PWV, a 
marker of increased CV risk, hence would benefit from statin treatment or further 
investigation and intervention is required.  
3.4.3 Conclusion 
Despite a significant reduction in total cholesterol there was no significant 
improvement in aortic PWV in patients with COPD taking simvastatin 20mg od 
compared to placebo over 6 weeks.  In the subgroup with a baseline aortic PWV 
value of >10m/s we did however show a significant change in aortic PWV post-
treatment in the active compared to placebo group.  Therefore, subjects with a 
higher baseline aortic PWV are likely to have more benefit from intervention.     
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Statins appear safe to use in this population and this proof of principle study 
supports investigating this further and can be used to assist the design and 
methodology of such a study.  
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Chapter 4 
The Inflammatory Effects of 
Simvastatin in Patients with COPD: 
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4 The Inflammatory Effects of Simvastatin in Patients 
with COPD: A double blind, randomised placebo 
controlled trial 
4.1 Introduction 
Current therapies for patients with COPD, which are routinely inhaled 
bronchodilators to help with airway obstruction, are largely symptom based or 
exacerbation related.  The only current disease modifying intervention is smoking 
cessation (Anthonisen et al., 1994, Decramer et al., 2013).  Whilst there are new 
drugs for COPD in the pipeline, it is a long process which can take years to reach the 
patient; and it has proved difficult to identify new agents which are safe and 
effective (Barnes, 2013).  Therefore, exploring old drugs for new indications is 
advantageous.  
COPD is defined by its airflow obstruction but there is a chronic persisting 
inflammatory process, reflected in increased airway and circulating inflammatory 
markers (McCurdy et al., 2011, Miller et al., 2013, Pinto-Plata et al., 2006).  
Attenuating inflammation has the potential to alter the disease course (Sin et al., 
2004) and the systemic inflammatory process is thought to contribute to the 
comorbidities of COPD (Gan et al., 2004).   
Statins have been proposed as a potential respiratory disease modifier in review 
articles since as far back as 2006 (Hothersall et al., 2006, Dobler et al., 2009, Young 
et al., 2009).  Previous studies have suggested statins as a potential therapy to 
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improve lung function due to their anti-inflammatory and antioxidant effects 
(Alexeeff et al., 2007, Keddissi et al., 2007).  Statins have also been shown to 
decrease specific inflammatory markers such as IL-6 (Inoue et al., 2000), CRP 
(Arnaud et al., 2005) and MMP levels (Bellosta et al., 1998), in other conditions, but 
all clinically relevant mediators in COPD.  
Spirometry, specifically FEV1, is used as one marker of COPD severity; and has been 
shown to be predictive of both CV and total mortality (Hole et al., 1996).  The rate 
of decline of lung function is associated with adverse outcomes, such as mortality 
and COPD related hospital admissions (Mannino and Davis, 2006).  There have been 
long standing discussions regarding statins and their potential to reduce the rate of 
decline in lung function results in both current and ex-smokers with abnormal 
baseline spirometry (Keddissi et al., 2007), and a slower rate of decline in lung 
function has been reported in those concurrently taking statins (Alexeeff et al., 
2007).  
There are several anti-inflammatory agents used in COPD.  Inhaled corticosteroids 
(ICS) have an anti-inflammatory effect in patients with COPD, where those using ICS 
had lower CRP levels than those not using ICS (Pinto-Plata et al., 2006).  In a RCT 
studying patients (non-COPD) admitted to hospital with acute coronary syndromes, 
using statins to lower CRP <2mg/l were associated with improvements in event free 
survival (Ridker et al., 2005a).  
Nitric oxide (NO) is a gaseous signalling molecule produced by three isoenzymes of 
NO synthase (NOS) found in airway epithelial and circulating endothelial cells, as 
well as trafficking inflammatory cells in large and peripheral airways (Barnes et al., 
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2010).  Endothelial nitric oxide synthase is reduced in the peripheral lung of 
subjects with severe stages of COPD due to the emphysematous destruction of 
alveolar walls (Brindicci et al., 2010).     
 
Hypothesis: 
Simvastatin 20mg taken once daily for 6 weeks will reduce airway (sputum and 
exhaled nitric oxide) and circulating (blood) inflammatory markers compared to 
the placebo group in patients with COPD.   
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4.2 Methods 
This study was a double-blind, placebo controlled RCT, see methods p63.   Clinical 
trials identifier: NCT01151306.   
4.2.1 Recruitment 
Subjects with COPD were recruited into the study as described in methods chapter 
(chapter 2 p68) following detailed inclusion and exclusion criteria (methods 2.1.2).  
The inclusion and exclusion criteria were more pertinent to the cardiovascular 
primary outcome measures.   
Following consent and screening as outlined previously, methods 2.1.5 page 73, 
eligible patients were randomised methods 2.1.9 page 75.  
4.2.2 Visit 1 
During visit one the baseline data was collected.  Tests performed pertinent to this 
chapter are post-bronchodilator spirometry - FEV1, FVC, FEV1/FVC ratio, FEV1 % 
predicted and FVC % predicted (methods 2.2.3); FeNO - measured by steady 
exhalations at varying flow rates  W 10, 30, 50, 100 and 200ml/s; see methods 2.2.4.  
The alveolar slope and bronchial intercept were also recorded.  Induced sputum - 
performed by nebulising a hypertonic saline solution (methods 2.2.5) and sputum 
cell counts (see methods 2.2.6); venepuncture  W safety bloods (LFT and CPK), lipid 
profile (see methods 2.2.7.a), circulating MMP-9 and hs-CRP (see methods 2.2.7.c.i 
and 2.2.7.c.ii).  Body composition (see methods 2.2.13) and functional assessment 
was performed using dominant handgrip strength (methods 2.2.14) and 6 minute 
walking distance (6MWD) (methods 2.2.9).  
133 
 
4.2.3 Treatment Phase 
Telephone calls were made to each participant two and four weeks post visit one, 
to check compliance and for any problems.   
4.2.4 Visit 2 
Post-treatment results were recorded as per visit one.  See methods p77.  
Compliance was checked and recorded.  We checked for any clinically relevant 
increases in gamma GT, ALT and CPK as previously described. 
4.2.5 Data Analysis 
Data was analysed using Statistical Package for the Social Sciences (SPSS, Chicago, 
IL) version 21.0.  A p<0.05 was considered significant.  The normality of the data 
was checked graphically.  Graphical interpretation was made using frequency 
distribution histograms and Q-Q plots.  Positively skewed data was 
log10transformed to normalise the data  W sputum neutrophils and macrophages, hs-
CRP and FeNO50, alveolar gradient and bronchial intercept - in order to perform 
parametric analysis.  Unless otherwise specified, arithmetic mean and standard 
deviation was used to show the measure of central tendency.   
Analysis: The difference in the mean change for the active and placebo arms was 
analysed using independent t-test and the mean and 95% confidence intervals 
presented.  This was done for the following: FEV1, FVC, total cholesterol, HDL and 
LDL cholesterol, 6MWD, sputum neutrophils, blood neutrophils, FeNO50, intercept 
and gradient, and serum biomarkers including total MMP-9 and hs-CRP.  The 
difference in change in SGRQ scores, FFM and BMI were also analysed.   
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^ƉƵƚƵŵ ŶĞƵƚƌŽƉŚŝůŝĂ ǁĂƐ ĚĞĨŝŶĞĚ ĂƐ A? ? ?A? ƐƉƵƚƵŵ ŶĞƵƚƌŽƉŚŝůƐ (Spanevello et al., 
2000) ?^ƉƵƚƵŵĞŽƐŝŶŽƉŚŝůŝĂǁĂƐĚĞĨŝŶĞĚĂƐA? ?A?(Pavord et al., 1999). 
A sub-group analysis was performed on subjects with a baseline circulating hs-CRP 
value of >3mg/l, as per the Rotterdam study (Lahousse et al., 2013), to look at the 
change in hs-CRP, sputum neutrophils and macrophages, and FeNO50, bronchial 
intercept and alveolar gradient post-treatment in the active group compared to the 
placebo group.   
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4.3 Results 
4.3.1 Demographics 
64 subjects completed the study out of the 70 randomised and starting the study 
medication, see consort diagram Figure 3.1 p100.  No follow on data is available for 
those who dropped out of the study, see p105. 
Baseline data for those on active treatment are presented alongside the placebo 
group, see Table 3.2 p106.  Groups were well matched for age, sex, smoking pack 
years, lung function and baseline cholesterol levels.   
4.3.2 Missing Data  
Sputum results are not available in all subjects.  Baseline sputum results are only 
available for n=27  W active n=11, placebo n=16; and matched post-treatment data is 
available for n=20  W active n=8, placebo n=12.   
At baseline, of the 43 subjects without results 23 could not perform the induction 
procedure because they had a post-bronchodilator FEV1 of <50% which is a 
contraindication to performing the procedure.  Nine subjects were unable to 
produce a sputum sample following the induction process, 5 produced a sample but 
the slide was uncountable, therefore results could not be obtained and 6 declined 
the sputum induction procedure.  Reasons for the slides being uncountable and 
therefore unable to provide results from the given sputum sample included 
squamous contamination, damaged cells causing poor viability and the sample 
being saliva rather than sputum.     
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Exhaled nitric oxide levels could not be performed in every subject at both visits as 
there were recurrent technical issues and some patients struggled with the test 
technique.  Matched post-treatment results for FeNO50 were available in n=36 with 
17 in the active and 19 in the placebo group. 
4.3.3 Airway Measures 
4.3.3.a Sputum 
There were no significant changes in the difference in change in sputum differential 
cell counts in neutrophils or macrophages, where both were measured as absolute 
number of cells and percentage of the total cells, in the active group compared to 
the placebo group.  See Table 4.1; and Figure 4.1. 
Of the 27 subjects at baseline, 19 (70%) had baseline sputum neutrophilia - active 
ŶA? ? ?ƉůĂĐĞďŽŶA? ? ? ?ĨƵƌƚŚĞƌ ?ƉĞŽƉůĞŚĂĚƐƉƵƚƵŵŶĞƵƚƌŽƉŚŝůƐA? ? ?A?ďƵƚĂůƐŽŚĂĚ
sputum ĞŽƐŝŶŽƉŚŝůƐ A? ?A? ? There were 2 subjects which had baseline sputum 
eosinophilia only.   
Of those with sputum neutrophilia (+/- eosinophilia) there were paired pre- and 
post-treatment results in n=19 (active n=8, placebo n=11).  There was not any 
significant change in sputum neutrophils post treatment in the active compared to 
the placebo group.     
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Key: ?geometric mean Abbreviations: FEV1: forced expired volume in one second; FVC: forced vital capacity; FeNO: fraction of expired nitric oxide; MMP-9: matrix 
metalloprotease-9; CRP: C-reactive protein; 6MWD: six minute walking distance; SGRQ: St GeorŐĞ ?ƐZĞƐƉŝƌĂƚŽƌǇYƵĞƐƚŝŽŶŶĂŝƌĞ ?FFMI: fat free mass index; BMI: body mass 
index 
Table 4.1 Physiological, Airway and Inflammation Markers in the Active (simvastatin) and Placebo Groups 
Mean (SD) 
Unless otherwise specified 
n=active: placebo 
Active group Placebo group  
Mean difference 
A? ĂĐƚŝǀĞǀĞƌƐƵƐA?
placebo (CI) 
Pre -
treatment 
Post - 
treatment 
Post  ?Pre 
Mean 
 ‘A? ? 
Pre - 
treatment 
Post - 
treatment 
Post-Pre 
Mean 
 ‘A? ? 
FEV1 (L) n=31:33 1.59 (0.6) 1.59 (0.6) 0.0 1.41 (0.5) 1.43 (0.6) 0.0 0 (-0.07, 0.05) 
FVC (L) n=31:33 3.40 (0.9) 3.3 (0.9) -0.1 3.06 (1.0) 3.07 (1.0) 0.0 -0.1 (-0.2, 0.2) 
^ƉƵƚƵŵŶĞƵƚƌŽƉŚŝůƐ ?A? ) ?ŶA? ? P ? ? 75.2 (1.5) 75.3 (1.4) -1.9 77.5 (1.3) 61.4 (2.2) -6.3 4.4 (-12.0, 20.8) 
Actual sputum neutrophils (number) ?ŶA? ? P ? ? 306 (2) 310 (1) -2.8 314 (1.2) 246 (2) -27.8 25.0 (-50.1, 101.0) 
^ƉƵƚƵŵŵĂĐƌŽƉŚĂŐĞƐ ?A? ) ?ŶA? ? P ? ? 12.0 (1.6) 6.6 (4.8) 1.7 8.8 (4.1) 10.5 (3.7) 5.7 -4.0(-16.4, 8.4) 
Actual sputum macrophages (number) ? n= 8:12 34 (2) 27 (5) 7.3 32 (4) 42 (4) 20.4 -13.2 (-63.1, 36.8) 
&ĞEK ? ?ŵůƐ ?ƉƉŵ ) 輀 ŶA? ? ? P ? ? 23.6 (1.9) 21.8 (1.9) -2.2 14.5 (1.9) 17.8 (2.1) 6.1 -8.2 (-19.1, 2.6) 
&ĞEKŝŶƚĞƌĐĞƉƚ ? n=16:19  34.4 (2.5) 36.9 (2.5) -0.1 27.7 (2.1) 31.1 (2.2) 4.4 -4.5 (-25.3, 16.4) 
&ĞEKŐƌĂĚŝĞŶƚ ? n=16:19  8.9 (2.5) 8.1 (2.5) -2.0 4.8 (2.1) 5.9 (3.2) 3.8 -5.9 (-13.5, 1.7)  
Circulating MMP-9 (ng/ml) n=31:32 53.1 (16.3) 50.4 (16.8) -2.9 60.4 (17.2) 56.1 (17.8) -3.1 0.2 (-10.8, 11.2) 
Circulating hs-ZW ?ŵŐ ?ů ) ?ŶA? ? ? P ? ? 3.5 (3.1) 2.9 (3.9) 0.7 3.0 (3.0) 3.0 (2.9) 0.2 0.5 (-3.2, 4.1) 
Dominant hand grip strength (kg) n=31:33 35.3 (9.2) 35.3 (8.5) 0.1 32.2 (8.3) 33.0 (8.4) 0.9 -0.8 (-2.6, 0.9) 
6MWD (m) n=30:31 343 (75) 339 (84) -3.6 332 (76) 338 (88) 5.1 -8.7(-23.6,6.2) 
SGRQ total n=31:33 36.8 (15.4) 38.1(16.3) 1.3 35.4 (18.7) 34.3(19.9) -1.1 2.4 (-1.1, 6.0) 
FFMI n=27:29 18.7 (2.5) 18.7 (2.4) -0.6 18.6 (2.8) 18.3 (2.7) -0.6 0 (-0.9, 0.9) 
BMI (kg/m
2
) n=28:30 26.7 (6.7) 26.7 (6.9) 0.1 26.6 (6.8) 26.8 (6.8) 0.1 0 (-0.2, 0.3) 
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Figure 4.1 Individual Sputum Neutrophil Counts Pre- and Post-treatment with 
Active (simvastatin) or Placebo  
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4.3.3.b Exhaled Nitric Oxide 
There were no significant differences in the change of any FeNO measures  W FeNO 
50 (n=36), alveolar gradient (n=35) or bronchial intercept (n=35) post-treatment in 
the active group compared to the placebo group.  Baseline mean FeNO50 was 
23.6ppm for the active group (n=17) and 14.5 for placebo group (n=19).  
4.3.4 Systemic/Circulating Inflammatory Mediators  
4.3.4.a Circulating MMP-9 
There were no significant differences in the change in MMP-9 measurements pre- 
and post-treatment between the active group compared to the placebo group.  See 
Table 4.1.   
4.3.4.b Hs-CRP 
There were no significant differences in the change in hs-CRP measurements pre- 
and post-treatment between the active group compared to the placebo group, see 
Table 4.1.  The mean differences presented in Table 4.1 appear to show an increase 
in hs-CRP result post treatment; however, this has just arisen through using mean 
values; because one result could skew the mean, but the mean differences are 
differences within an individual and then summed, and not the differences of the 
whole population. 
4.3.5 Sub-group Analysis of hs-CRP >3mg/l 
For the whole group, the mean hs-CRP was greater than control data in other 
studies (Pinto-Plata et al., 2006), but there was a range.  The CRP >3mg/l sub-group 
(n=33: 16 active, 17placebo) was comparable to the main group, with similar age, 
proportion of males, smoking pack years, lung function and cholesterol levels.  The 
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CRP >3mg/l sub-group had a higher smoking pack year history (48 pack years) than 
the main group (40 pack years).   
The active and placebo groups of the CRP >3mg/l sub-group were well matched for 
demographic data and sputum and CRP inflammatory markers (see Table 4.2); 
however, there was a significant difference in baseline FeNO50 and bronchial 
intercept, p<0.001, p=0.03 respectively between the active and placebo arms, 
where values were higher in the active arm, as per findings in the total study group.   
In the sub-group analysis of subjects with a baseline circulating CRP value of >3mg/l 
(Lahousse et al., 2013), there was no significant difference in change post-
treatment in hs-CRP  W mean difference and 95%CI 0.26 (-6.6, 7.1)mg/l, MMP-9 -1.2 
(-18.3, 15.8)ng/ml, sputum neutrophils 39.6 (-45.2, 124.5)n or macrophages -34.5 (-
106.9, 37.9)n; or FeNO50 -2.6 (-20.6, 15.4)ppm, bronchial intercept -4.7 (-49.5, 
40.1) or alveolar gradient -2.6 (-11.5, 6.3) in the active group compared to the 
placebo group.   
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Table 4.2 Demographics and Baseline Inflammatory Markers in Sub-group with a 
hs-CRP>3mg/l 
Mean (SD) 
Unless otherwise specified 
(active:placebo) 
(t-test unless otherwise stated) 
Active 
n=16 
Placebo 
n=17 
Age (years) Median (range) (16:17) 65 (50-77) 63 (51-74) 
Sex Male n (%) (16:17) * 13 (82) 10 (59) 
Smoking pack years (16:17) 47 (22) 51 (21) 
FEV1 (l) (16:17) 1.57 (0.50) 1.28 (0.35) 
FEV1 %predicted (16:17) 55 (12) 49 (12) 
FEV1/FVC (16:17) 48 (12) 46 (12) 
Total cholesterol (mmol/L)  (16:17) 5.4 (0.8) 5.2 (0.8) 
hs-ZW ?ŵŐ ?ů ? ?(16:17) 8.2 (2.2) 7.0 (1.7) 
MMP-9 (ng/ml) (16:17) 57.3 (15.2) 66.0 (17.2) 
^ƉƵƚƵŵŶĞƵƚƌŽƉŚŝůƐ ?ĐŽƵŶƚƐ ? ?(6:9) 288 (2) 313 (1) 
FeNO50 (ppm) ?(13:15) 25.5 (1.7) 9.4 (1.9) 
FeNO BroncŚŝĂůŝŶƚĞƌĐĞƉƚ ?(10:14) 39.1 (3.1) 13.3 (4.0) 
FeNO ůǀĞŽůĂƌŐƌĂĚŝĞŶƚ ?(10:14) 7.0 (3.3) 3.6 (1.9) 
 geometric mean   * chi-squared test 
Abbreviations: FEV1: forced expired volume in one second; FVC: forced vital 
capacity; hs-CRP: high sensitivity C-reactive protein; MMP-9: matrix 
metalloprotease-9; FeNO: fraction of expired nitric oxide 
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4.3.6 Other measurements  
There was a significant decrease in total and LDL-cholesterol levels in the active 
group compared to placebo group post treatment (p<0.001 respectively) as 
reported in chapter 3.   
There was no significant difference in change between the active compared to 
placebo arm following treatment in BMI, FFMI, SGRQ, dominant hand grip strength, 
6 MWD or lung function as measured by FEV1 and FEV1% predicted, see Table 4.1.  
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4.4 Discussion 
In this double blind, randomised, placebo controlled trial of 70 patients with COPD 
there was no significant difference in change in any airway or circulating 
inflammatory markers between the active statin group compared to the placebo 
group over 6 weeks.  In addition, there were no changes in spirometric measures, 
or functional tests as measured by dominant handgrip strength and 6MWD.  We did 
show a significant reduction in total cholesterol levels in the active statin group 
compared to placebo group post-treatment. 
4.4.1 Airway Inflammatory Markers 
Patients with COPD have been shown to have increased airway inflammation 
compared to non-atopic healthy subjects, irrespective of whether they are a 
current smoker or not (Rutgers et al., 2000).  Our baseline sputum neutrophils 
results were comparable to those that Rutgers et al. reported where sputum 
neutrophils in patients with COPD had a median (range) of 77 (29-94)%.  
Although 2 subjects were found to have solely eosinophilic sputum at baseline, we 
had excluded anyone reporting a previous diagnosis of asthma, and performed 
reversibility testing at the screening visit to try to eliminate any significant bronchial 
hyper-responsiveness; we did not have sputum cell counts as an inclusion/exclusion 
criteria.  A high proportion of our subjects had sputum neutrophilia, characteristic 
of patients with COPD.  Absolute neutrophil numbers are variable over time and so 
neutrophils as a percentage of total cells are more informative in general for COPD 
subjects (Singh et al., 2010); however for an RCT absolute cell number may have 
merit and so both absolute and percentage of the total were recorded.    
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The use of FeNO in COPD is a contentious issue as it is an unanswered area with 
many outstanding research questions and ongoing debate.  A cautious approach to 
nitric oxide result interpretation is required as it is not as well described in COPD 
populations as in asthma.  We performed FeNO at multiple flow rates as this has 
been reported by Lehtimäki et al. to differentiate between alveolar and bronchial 
NO production and therefore allow large and small airway inflammation to be 
assessed in asthmatics, patients with alveolitis and healthy controls (Lehtimaki et 
al., 2001).  The five-flow method of measuring FeNO has been reported in patients 
with COPD and controls with no significant within- or between-day variability and 
that data from five-flow rates was more reliable than from fewer flow rates (Roy et 
al., 2007). 
A recent study looking at five-flow FeNO levels in COPD sub groups did not find any 
differences in FeNO measurements between their pre-defined sub-groups - severe 
emphysema, chronic bronchitis, frequent exacerbations, loss of lean body mass and 
low fat-free mass index; and the usefulness of FeNO in patients with COPD is still 
questioned  (Bazeghi et al., 2011).  FeNO results are often reported as normal (Clini 
et al., 2000) or increased (Beg et al., 2009) with single flow measurements in 
patients with stable COPD despite significant airflow limitation hence it is a 
controversial measure.  This could be contributable to a number of factors including 
the heterogeneity of the disease, smoking status or the use of ICS (Ansarin et al., 
2001, Barnes et al., 2010).  The factors contributing to increased FeNO levels in 
asthma are thought to be different to the factors influencing FeNO results in COPD 
(Ansarin et al., 2001), this therefore, may be why the tests have currently been 
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shown to be more useful in asthma compared to COPD.  The use of ICS has been 
reported to supress FeNO (Barnes et al., 2010, Jones et al., 2002), although this is 
not universal (Ansarin et al., 2001).   
Smoking status has been shown to influence FeNO results, and may in part explain 
why the evidence for its use in COPD varies so widely.  Both current and past 
smoking has been shown to reduce FeNO results compared to never smoker 
controls (Malinovschi et al., 2006).  Cigarette smoking significantly reduces FeNO 
results due to the down regulation of inducible nitric oxide synthase (iNOS) (Barnes 
et al., 2010, Kharitonov et al., 1995).  Subjects were asked to refrain from smoking 
for 6 hours prior to their visit in an attempt to reduce any acute smoking related 
effects on results and to standardise methodology.     
We were underpowered to detect any changes in FeNO and sputum results as 
these tests could only be performed in a sub-set of patients due to test technique, 
contra-indications to performing the test and technical problems with the 
machines.  
4.4.2 Circulating Inflammatory Markers 
It is recognised that  “inflammation ? covers a wide range of markers and we 
acknowledge that we have chosen specific markers to measure and analyse in this 
proof of principle study.  The alternative would have been to take a blanket 
approach and test for many more markers, but we would then be at risk of finding a 
significant change as a result of multiple endpoints.  Circulating inflammatory 
markers such as hs-CRP (Pinto-Plata et al., 2006) and MMP-9 (Bolton et al., 2009b) 
have been reported to be elevated in patients with COPD, with a potential 
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pathological influence, and these markers have also been shown to be modulated 
following statin treatment in other diseases (Bellosta et al., 1998, Ridker et al., 
2009).   
The main marker of systemic inflammation is hs-CRP which has been associated 
with increased cardiac injury (Sin and Man, 2003) and is available in all of the 70 
baseline subjects and paired results in 63 subjects.  CRP is an acute phase protein 
produced via stimulation of IL-6 released after vascular damage.  It has been 
reported that CRP could affect vasomotor endothelial function through inhibition of 
endothelial nitric oxide (NO) synthase, and therefore inhibit production of NO 
(Maclay and MacNee, 2013).  Hs-CRP results did not show any significant change in 
either the active or placebo group post-treatment.   
Baseline inflammation in patients with COPD, as determined by CRP levels, has 
been shown to influence the benefit seen following statin therapy, where a 
significant drop in CV mortality was seen following statin therapy for greater than 2 
years (Lahousse et al., 2013).  A randomised control trial looking at hs-CRP levels in 
patients with stable COPD, using a different statin  W pravastatin 40mg daily, and for 
a much longer duration (6 months) reported baseline results comparable to the 
baseline results we found with active and placebo hs-CRP of 3.94 and 4.06mg/l 
respectively (Lee et al., 2008), however, despite statin therapy a proportion of 
patients with COPD have persistently elevated hs-CRP levels (Lee et al., 2008, Ridker 
et al., 2005b).  In comparison, Maki-Petaja et al. studied a rheumatoid arthritis 
population with a baseline serum  CRP >6mg/l and found a significant reduction in 
CRP levels post 6 weeks treatment with simvastatin 20mg (Maki-Petaja et al., 2007).  
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A pravastatin 40mg daily dose is comparable to a simvastatin 20mg daily dose 
(Mehra et al., 2002, Keogh et al., 2000). 
CRP has been used to grade the risk for future CV events with a CRP<1mg/l being 
low risk, 1-3mg/l moderate risk and >3mg/l high risk (Pinto-Plata et al., 2006, Ridker 
et al., 2002).  A sub-group analysis was performed on patients with a baseline 
circulating hs-CRP value of >3mg/l, chosen because it has been identified as the 
high risk group and is a well published cut-off point in both general population 
studies (Ridker et al., 2002) and in COPD populations (Lahousse et al., 2013).  When 
a high hs-CRP value is defined as >3mg/l, 51% of our study population would have 
been in the high risk group with 17/36 of those being in the active group and 19/36 
being in the placebo group; but still we could not detect a change in any of our 
inflammatory markers following statin treatment.  This is comparable to the 60% of 
people being in the high risk group reported by Pinto-Plata et al. in a cross-sectional 
study of patients with COPD and current and never smoker controls (Pinto-Plata et 
al., 2006).    
Matrix metalloproteinases (MMPs) are thought to play a role in the pathology of 
COPD including tissue remodelling and repair (Haq et al., 2010).  It has recently 
been reported that MMP-12, which is produced by macrophages and is found on 
chromosome 11q22.3, was a modifier of COPD disease severity (Haq et al., 2010) 
and it has a positive association with lung function in adults who either smoke or 
are at risk of COPD (Hunninghake et al., 2009).  MMP-9 has been shown to have a 
role in the pathogenesis of emphysema and to act outside the lung in the 
development of arterial stiffness and atherosclerosis (Maclay and MacNee, 2013).  
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MMP-9 has been associated with increased arterial stiffness in the general 
population (Yasmin et al., 2005) and features of elastin degradation in the skin of 
patients with COPD (Maclay et al., 2012). 
MMP-9 has been reported to be elevated in patients with COPD compared to 
controls in a matched case control study (Pinto-Plata et al., 2007).  MMP-9 had a 
strong association with lung function, as measured by FEV1 and TLco in patients 
with severe COPD and matched controls (Pinto-Plata et al., 2007).  Our baseline 
MMP-9 results are not consistent with previously published findings, however, 
discrepancies between whether total, pro or active MMP-9 or MMP-9 activity was 
measured is often hard to determine from reported studies.  Our baseline MMP-9 
result for the total group was 61.4(16.1)ng/ml, which is lower than previously 
reported results of 248.2 ±101.0ng/ml in patients with COPD despite being of the 
same nature and similarly being reported as total (pro and active) MMP 
concentration, and measured using the same kit (Brajer et al., 2008).  Circulating 
MMP-9 was shown to be elevated in patients with COPD compared to controls, 
with MMP-9 values of 38.5 (2.2)ng/ml reported, which is closer to our reported 
findings, however pro-MMP-9 was measured using a different ELISA kit (Bolton et 
al., 2009b).   
Fibrinogen is an emerging inflammatory mediator with prognostic value in patients 
with COPD (Gan et al., 2004, Dahl et al., 2001), which has been highlighted more 
recently.  Fibrinogen is elevated in stable subjects who have exacerbations of COPD, 
increases further during exacerbation presence, and may contribute to the 
increased CV morbidity and mortality (Wedzicha et al., 2000).  It has been identified 
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as a potentially useful biomarker to identify those patients at risk of COPD in the 
adult Danish general population (Dahl et al., 2001), who have increased likelihood 
of poor health and may help to determine those with a better chance of responding 
to specific treatments.   
4.4.3 Airway and Functional Assessment 
It is perhaps not surprising that there was no change in spirometry or functional 
assessment given the 6 week time frame of the study.  We did not expect these 
parameters to improve in 6 weeks because other studies of change in lung function 
are over a much longer period of time.  Normal decline in lung function in control 
group of healthy subjects has been reported as a drop in FEV1 of 35mls/year (Peat 
et al., 1987), in comparison to people with COPD who have a mean drop of 
65mls/year (Pauwels et al., 1999).  Statins appear to slow the rate of decline in lung 
function in current and ex-smokers independent of underlying lung disease, over a 
long period of time ŽĨA? ?ŵŽŶƚŚƐ; however, this evidence is retrospective (Keddissi 
et al., 2007).   
The pleiotropic nature of statins, including being anti-inflammatory has been 
demonstrated in animal models.  When rats were given simvastatin either prior to 
and during, or just during tobacco smoke exposure, those who had simvastatin 
prior to smoke exposure had a reduced number of inflammatory mediators 
including neutrophils in the lung and airways (Davis et al., 2012).  The use of statins 
in smoke-induced lung disease has been shown, but the need for primary 
prevention is evident (Davis et al., 2012).  This is reinforced by another clinical study 
showing patients with COPD who have recently been on statin therapy, or those 
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with higher average daily doses have been found to have a decreased risk of COPD 
exacerbation requiring hospitalization (Wang et al., 2013).  As lowering the 
increased inflammation seen in patients with COPD is thought to be disease 
modifying, it is worth exploring the use of other therapeutic drugs that are known 
to lower circulating inflammation, and thus slow disease progression.  
Although there was no improvement in functional tests it was encouraging that 
there was no decline in results in the active group compared to placebo, as 
musculoskeletal side effects are common in those on statin therapy (Bruckert et al., 
2005).   
4.4.4 Limitations  
Airway inflammatory markers could not be performed in all subjects; therefore the 
lack of significance detected in this study could be due to the study ending up being 
underpowered.  The study was underpowered to detect changes in inflammatory 
markers following 6 weeks intervention with a statin compared to a placebo.  It is 
possible that different measures of circulating inflammation may detect a change 
that we did not with the markers we used.  Six weeks is not long enough to detect a 
change in lung function.    
4.4.5 Conclusion 
In this RCT, there was not a detectable change in either the specific airway or 
circulating inflammatory markers we selected, in the active compared to placebo 
group following 6 weeks treatment with active compared to placebo.  Airway 
inflammatory markers were only in a limited number of subjects.  Neither were we 
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able to detect any change in the functional assessments we performed in the active 
compared to placebo group after 6 weeks intervention.  
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Chapter 5 
Relationship of haemodynamics to 
airway and systemic inflammatory 
measures in patients with COPD 
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5 Relationship of haemodynamics to airway and 
systemic inflammatory measures in patients with 
COPD 
5.1 Introduction 
The cardiovascular morbidity associated with COPD has led to a number of in-depth 
studies to determine potential associations and likely mechanisms.  A non-invasive 
predictive measure of cardiovascular disease is aortic stiffness, which has been 
shown to be elevated in patients with COPD compared to controls (Sabit et al., 
2007), in other chronic inflammatory conditions (Wang et al., 2005, Mäki-Petäjä et 
al., 2006), and in those with traditional CV risk factors (Laurent et al., 2001).  
Reasons behind the increased aortic stiffness in patients with COPD have been 
suggested and include systemic inflammation (Sabit et al., 2007), loss of elasticity 
(Maclay et al., 2009), aortic calcification (Bolton et al., 2011) and sympathetic drive 
(Volterrani et al., 1994, Andreas et al., 2005).  Increased arterial stiffness has been 
reported to be influenced by age, blood pressure and thoracic aortic calcification 
(Bhatt et al., 2014). 
There is evidence of increased systemic inflammation in COPD including CRP (Sin 
and Man, 2003) and IL-6 (Ferrari et al., 2013).  Levels of inflammatory markers such 
as fibrinogen are increased in patients with COPD when compared to smoker and 
never smoker controls (Miller et al., 2013).   
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At times of exacerbation, there are further rises in cytokines from this increased 
baseline inflammatory state (Wedzicha et al., 2000, Bhowmik et al., 2000).  The 
cause increased inflammation is not known, but hypotheses such as overspill from 
the lungs into systemic circulation, has been suggested (Gan et al., 2004, Fujii et al., 
2002), but this is controversial (Sevenoaks and Stockley, 2006, Vernooy et al., 2002, 
Sapey et al., 2009).  Whether or not systemic inflammation stems from airway spill-
over, there is a spectrum of airway inflammation in COPD.  This can be measured in 
a number of ways - with pertinent mediators in COPD being neutrophils and 
macrophages.   
CV disease is common in patients with COPD and was associated with increased 
mortality and increased systemic inflammation (Soriano et al., 2005, Fabbri et al., 
2008).  Interestingly in 3,164 COPD patients, 337 smokers and 245 non-smoker 
controls there was no association with CRP and CV comorbidity as self-reported in 
the ECLIPSE study (Miller et al., 2013).   
Increased vascular wall inflammation in patients with COPD has been reported 
indirectly using PET-CT, which may provide more mechanistic direction as to how 
systemic inflammation contributes to the increased CV risk seen in COPD (Coulson 
et al., 2010).   
Results of whether specific isolated circulating inflammatory mediators relate to 
aortic PWV have been variable with Sabit et al. reporting an association with IL-6, 
whilst Maclay et al. found no association with CRP (Sabit et al., 2007, Maclay et al., 
2009).  McAllister et al. also did not find an association between arterial stiffness 
and CRP in patients with COPD, however they used brachial PWV to assess arterial 
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stiffness rather than aortic PWV (McAllister et al., 2007).  That said, CRP is a more 
acceptable measure of inflammation in the CV literature with relationships of CRP 
to aortic stiffness shown in apparently healthy individuals (Yasmin et al., 2004) and 
a general population of older men in the Caerphilly study, however, it is not a 
proven causal relationship (Schumacher et al., 2009).   
Circulating levels of MMP-9 are increased in patients with COPD compared to 
controls, with reports suggesting increased levels particularly in patients with 
osteoporosis (Bolton et al., 2009b).  Maclay et al. tested the hypothesis that 
increased aortic stiffness in COPD might be due to systemic elastin degradation 
(Maclay et al., 2009).  Circulating MMP-9 has been reported as being an enzyme 
that can degrade the elastic component of the arterial wall (Yasmin et al., 2005) and 
therefore contribute to aortic stiffness.  Circulating levels of MMP-9 in COPD have 
not been determined in relation to aortic stiffness; but in other populations, MMP-
9 has been related to aortic stiffness (Yasmin et al., 2005).  A linear correlation 
between circulating MMP-9 and aortic PWV has been shown in patients with never 
treated hypertension (Zhou et al., 2007), isolated systolic hypertension and 
apparently healthy subjects (Yasmin et al., 2005).  Conversely, Vlachopoulos et al. 
reported an inverse relationship between serum MMP-9 levels and aortic stiffness 
as measured by aortic PWV after adjusting for confounding variables, however, the 
population appear to be younger and more healthy as they have lower baseline 
aortic PWV and CRP levels (Vlachopoulos et al., 2007).    
Endothelial NO is a vasoactive substance which influences vascular tone, and basal 
NO production has been shown in animal models to influence large artery 
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distensibility (Wilkinson et al., 2002b).  Supportive findings of increased basal NO 
have been shown in a small double-blinded RCT in 8 healthy males with a mean age 
of 30 years where the vascular measure of basal NO synthesis modulated large 
artery stiffness, as measured by AIx, rather than the preferred method of PWV 
(Wilkinson et al., 2002a).   
We have previously reported that patients with COPD and more purulent sputum as 
self-reported have increased aortic stiffness (John et al., 2012).  That study was 
clinically self-reported based as opposed to having objective measures such as 
sputum cell counts.  Aortic PWV has been related to infection and inflammation in 
patients with COPD at the time of exacerbation, where aortic PWV was strongly 
correlated with airway IL-6, from spontaneous sputum samples (Patel et al., 2012).  
A recent study in 259 participants looking at salivary biomarkers of inflammation 
found a positive correlation between salivary CRP and aortic PWV, and therefore an 
alternative means to assess CV risk (Labat et al., 2013), however, the study was 
performed in a general population and not patients with COPD.  A multivariate 
analysis found an association with both salivary CRP and MMP-9 and carotid intima-
media thickness (CIMT), but not with MMP-9 and PWV (Labat et al., 2013).     
In this chapter we set out to determine whether there was a relationship between 
circulating and airway inflammatory mediators and aortic stiffness in a well-defined 
group of patients with COPD without co-existent hypercholesterolaemia or known 
diabetes mellitus or IHD, in a cross-sectional manner.   
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Hypothesis: 
We hypothesised that the previously reported associations of circulating CRP and 
aortic PWV in a general population would be demonstrated here in clinically 
stable patients with COPD.  Further, we wished to explore the nature of 
circulating to pertinent airway inflammatory markers and aortic stiffness.  
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5.2 Methods 
Data for this chapter was baselinĞƌĞƐƵůƚƐŶA? ? ?ĨƌŽŵƚŚĞƐƚƵĚǇ ‘ardiovascular and 
Inflammatory Effects of Statin TŚĞƌĂƉǇ ŝŶ KW ? ? ĂƐ ƉƌĞǀŝŽƵƐůǇ ĚĞƐĐƌŝďĞĚ, see 
methods 2.1.   
Test methodologies pertinent to this chapter are aortic stiffness as determined by 
aortic PWV (methods 2.2.2), sputum samples (methods 2.2.5), exhaled nitric oxide 
(methods 2.2.4) and venepuncture for circulating inflammatory markers hs-CRP and 
MMP-9 (methods 2.2.7.c).  All subjects gave written informed consent prior to data 
collection. 
Subject recruitment has been previously described, see methods 2.1.3.  There were 
extensive inclusion and exclusion criteria to check eligibility into the study, see 
methods 2.1.1.   
Data was analysed using Statistical Package for the Social Sciences (SPSS, Chicago, 
IL) version 21.0, with p<0.05 considered significant.  Non-normally distributed data 
was log transformed where possible to allow parametric testing to be performed.  
Pearson correlation coefficients were used to investigate the relationship, if any, 
and measure the strength of the linear relationship between two variables.  The 
difference in mean value between 2 groups was analysed using a t-test, and ANOVA 
with post-hoc analysis was used to compare means in 3 or more groups.   
Analysis was performed where subjects were grouped according to their aortic 
PWV values with a value of <8m/s being low, 8-10m/s normal and a value >10m/s 
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regarded as high.  A sub-group analysis looking at subjects with an aortic PWV 
>10m/s was also performed.   
Further associations were explored in a sub-group of subjects with a high hs-CRP, 
defined as >3mg/l. 
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5.3 Results 
Baseline demographics, and airway and circulating inflammatory markers, for the 
total group in the statin RCT are shown in Table 5.1. 
5.3.1 Circulating Inflammatory Markers 
There were no associations between circulating markers of inflammation and aortic 
stiffness; specifically log hs-CRP and aortic PWV, r=-0.19, p=0.12, n=70 and 
circulating MMP-9 and aortic PWV, r=-0.04, p=0.74, n=69.   
When subjects with a high hs-CRP values (>3mg/l) were looked at there was no 
correlation with aortic PWV, r=-0.13, p=0.47, n=36.     
Aortic PWV was compared between those with hs-ZWA? ?ŵŐ ?ůĂŶĚAN ?ŵŐ ?ů ?dŚĞƌĞ
was no significant difference in aortic PWV where those with a hs-CRP A? ?ŵŐ ?ů had 
an aortic PWV of 10.1 (3.0)m/s and those with a hs-CRP >3mg/l had an aortic PWV 
of 9.0 (2.8)m/s, p=0.12.    
When hs-CRP was compared across the 3 groups of aortic PWV (<8m/s (n=21), 8-
10m/s (n=24) and >10m/s (n=25)) there were no significant differences in mean hs-
CRP across any of the aortic PWV groups, p=0.25; however, there was a trend 
suggesting that with lower aortic PWV, surprisingly hs-CRP was higher, see Figure 
5.1. 
When circulating MMP-9 was compared across the 3 groups of aortic PWV (<8m/s, 
8-10m/s and >10m/s) there were no significant differences in mean MMP-9 across 
any of the aortic PWV groups, p=0.19; neither did there appear to be any trend.  
See Figure 5.1. 
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When the group is divided into high and low MMP-9 levels based on median MMP-
9 result of 52.4ng/ml, there was no significant difference in aortic PWV between 
those with a MMP-9 value below the median MMP-9 measurement compared to 
those with a value above the median value, 9.9 (2.8)m/s and 9.2 (3.1)m/s 
respectively, p=0.34 n=69.   
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Table 5.1 Baseline Demographics, Airway and Circulating Inflammatory Markers in 
the Total Group 
Demographics / Inflammatory marker Mean (SD) 
Age (years)  64 (8) 
Gender Male n(%) 50 (71) 
FEV1 (l) 1.5 (0.6) 
FEV1 % predicted 54 (14) 
Smoking pack years 47 (23) 
Aortic PWV (m/s) 9.6 (2.9) 
Peripheral systolic BP (mmHg) 148 (23) 
Peripheral diastolic BP (mmHg) 88 (12) 
AIx (%) 27 (9) 
Total cholesterol (mmol/L) 5.3 (0.8) 
Circulating hs-ZW ?ŵŐ ?ů )ŶA? ? ? ? 3.2 (2.9) 
Circulating MMP-9 (ng/l) n=69 56.9 (17.1) 
Sputum neutrophils 
n=27 
Actual cell count (number) 323 (70) 
Percentage 80 (18) 
Sputum macrophages 
ŶA? ? ? ? 
Actual cell count (number) 35.5 (3.2) 
Percentage 10.2 (2.9) 
FeNO50 (ppb)  ?ŶA? ? ? 15.7 (2.1) 
FeNO Alveolar gradient n=57 8.6 (9.5) 
FeNO Bronchial intercept n=57 35.6 (28.9) 
 geometric mean 
Abbreviations: FEV1: forced expired volume in 1 second, PWV: pulse wave velocity, 
BP: blood pressure, AIx: augmentation index, hs-CRP: high sensitivity C-reactive 
protein, MMP-9: matrix metalloproteinase-9, FeNO: fraction of exhaled nitric oxide  
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Figure 5.1 Baseline Circulating Inflammation for Total Population Grouped by 
Baseline Aortic PWV 
a) hs-CRP 
 
 
 
b) MMP-9 
 
 
Abbreviations: hs-CRP: high sensitivity C-reactive protein, MMP-9: matrix 
metalloproteinase-9, PWV: pulse wave velocity 
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5.3.2 Airway Inflammatory Markers 
There was no correlation in sputum neutrophil or macrophage percentage and 
aortic PWV, r=-0.23 p=0.24, and r=0.21, p=0.30, n=27 respectively.  Neither was 
there any correlation between actual sputum neutrophil or macrophage cell counts 
and aortic PWV, r=-0.19, p=0.36, and r=0.22, p=0.27, n=27 respectively. 
There was no correlation between aortic PWV and any of the exhaled nitric oxide 
measurements  W FeNO50, alveolar gradient and bronchial intercept, r=-0.002, 
p=0.99, n=61, r=-0.01, p=0.97, n=57 and r=-0.14, p=0.31, n=57 respectively.   
Tertile analysis, where the population was divided into thirds and therefore a high, 
middle and low result group, based on FeNO50 measurements, showed no 
difference between different tertiles and aortic PWV, p=0.67.   
5.3.3 Aortic PWV >10m/s Sub-group Analysis 
In those with a baseline aortic PWV >10m/s (n=25) there was no correlation with 
aortic PWV and circulating hs-CRP r=0.04, p=0.85, or between aortic PWV and 
circulating MMP-9, r=0.20, p=0.33.  Further, there were no associations of aortic 
PWV with sputum neutrophils, whether actual cell counts or percentages, r=-0.40, 
p=0.25, n=10 and r=-0.40, p=0.26, n=10 respectively; or between aortic PWV and 
sputum macrophages whether actual cell counts or percentages, r=0.33, p=0.36, 
n=10 and r=0.36, p=0.31, n=10 respectively.  There were no significant correlations 
of aortic PWV and any of the exhaled nitric oxide parameters-FeNO50 r=0.24, 
p=0.29, n=22, alveolar gradient r=0.16, p=0.50, n=20 and bronchial intercept r=0.04, 
p=0.87, n=20.   
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5.4 Discussion 
In this well-defined group of stable patients with COPD, without CV disease or 
diabetes, we could not find any associations between aortic stiffness and either 
airway or circulating inflammatory mediators.  All patients were at clinical stability 
which is important as inflammatory markers (Bhowmik et al., 2000) and aortic PWV 
(Patel et al., 2013) have been shown to increase during exacerbations.   
Airway inflammation was assessed using exhaled nitric oxide measurements and 
sputum samples whilst circulating inflammation was assessed using serum hs-CRP 
and MMP-9.  We were unable to detect any significant difference in aortic PWV 
between those with a high and low hs-CRP where 3mg/l was used as the cut-off 
(Lahousse et al., 2013); similarly we were unable to detect any difference in hs-CRP 
when subjects were grouped according to baseline aortic PWV.   
It was surprising not to find any associations between hs-CRP and aortic PWV.  Both 
CRP (Sin and Man, 2003) and aortic PWV (Sabit et al., 2007) are well described 
markers of cardiovascular risk in patients with COPD.  CRP is a preferred 
inflammatory marker of CV risk and strong, independent associations have been 
shown between CRP and CV disease in the general male population and in a general 
apparently healthy cohort (Ridker et al., 1997, Ballantyne et al., 2004).  Associations 
have also been shown between CRP and aortic PWV as a marker of arterial stiffness 
in the general population (Schumacher et al., 2009, Kullo et al., 2005, Mattace-Raso 
et al., 2004).  In a study of 790 healthy males CRP was shown to be a predictive 
marker of CV risk, but a causal role in the development of arterial stiffness as 
measured by aortic PWV could not be established (Schumacher et al., 2009).  
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Conversely, studies have also reported no association between CRP and aortic PWV 
in a large general population study of 1078 subjects (Nishida et al., 2007), a cross-
sectional study of 157 patients with COPD, however, they used brachial PWV rather 
than aortic PWV which is less predictive of CV risk (McAllister et al., 2007), and in a 
smaller study of 18 males with COPD (Maclay et al., 2009), in keeping with our 
findings.   
The inflammatory markers hs-CRP and MMP-9 measured in this group of 70 
patients with COPD shows an increased inflammatory state.  We chose to divide the 
population based on a CRP value of 3mg/l because there have been lots of 
published studies using this cut-off point, and a value above 3mg/l has been shown 
to relate to CV risk (Lahousse et al., 2013), and although a range, our geometric 
mean hs-CRP was 3.2mg/l, which demonstrates increased circulating inflammatory 
markers in COPD.  This was not a well-defined consensus because there were 
varying cut-off points used and suggested in other publications (Ridker et al., 
2005a).  Hs-CRP was regarded to be more sensitive to determine levels of 
inflammation within the normal range than standard CRP (Ridker, 2001).   
We grouped our subjects using their baseline aortic PWV measurements, based on 
previously reported suggestions for low (<8m/s), normal (8-10m/s) and increased 
(>10m/s) ƌĞĂĚŝŶŐƐ ?ďƵƚĂƐ ‘ŶŽƌŵĂů ?ǀĂůƵĞƐĨŽƌĂŽƌƚŝĐWtsĂƌĞŶŽƚǁĞůůĚĞĨŝŶĞĚ ?ĂŶĚ
higher values such as aortic PWV >12m/s have been suggested for increased aortic 
stiffness (Phababpha et al., 2013, Mancia et al., 2007), the cut-offs we have chosen 
may impact on our findings.  When hs-CRP was compared between the 3 groups of 
aortic PWV there appeared to be a correlation, with a surprising trend towards 
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higher hs-CRP in those in the lowest aortic PWV group, however, this did not reach 
significance.   
MMP-9 has been shown to relate to aortic PWV in healthy individuals (Yasmin et al., 
2006, Yasmin et al., 2005), and in patients with diabetic chronic kidney disease 
(CKD) (Chung et al., 2009) but we could not find the same relationships in our COPD 
group.  Chung et al. reported baseline arterial stiffness in diabetes and CKD of 11.9 
+/- 4.6m/s, which was much higher than the PWV we had in our study group of 
patients with COPD, and 75% of the diabetic CKD patients were taking a statin, 
however, this is a different disease population to our reported patient group 
(Chung et al., 2009).   
There is a wealth of evidence showing endothelial NO affects sympathetic tone, and 
this modulation of vascular compliance has been shown in animal models to be 
independent of BP changes (Fitch et al., 2001), however, exhaled measurements 
have not been explored and it is therefore a leap of faith relating exhaled NO to 
measures of aortic stiffness.  Aortic stiffness is dependent on smooth muscle tone, 
of which the functional regulation of arterial stiffness is reliant on both local and 
circulating vasoactive substances, with NO synthesis shown in vivo to modulate 
large artery stiffness (Wilkinson et al., 2002a). 
Sputum neutrophilia is well defined (Spanevello et al., 2000), and a common 
presentation in patients with COPD which was also demonstrated in our 
population.  Patients with COPD self Wreported increased sputum production has 
been associated with increased aortic PWV (John et al., 2012).  When we looked at 
objective measures such as neutrophil cell counts in sputum samples we did not 
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find the same association.  This could be due to our sputum samples being collected 
at clinical stability, whereas the previously reported subjective measures would 
have been recalled over a longer duration rather than a single sample; and the 
objective measure was neutrophil counts which does not equate to increased 
sputum production and therefore another measure such as sputum volume may be 
more representative.  It has been recently reported that in patients with COPD with 
evidence of airway bacteria or rhinovirus, there was no increase in aortic PWV 
when compared to those at clinical stability; however during infective 
exacerbations of COPD there was a greater rise in aortic PWV from stable clinical 
state compared to those without infection or sputum production  (Patel et al., 
2013).  
dŚĞƌĞ ĂƌĞ ƐĞǀĞƌĂů ƉŽŝŶƚƐ ƚŽ ĐŽŶƐŝĚĞƌ ĂƐ ƚŽ ǁŚǇ ǁĞ ĚŝĚŶ ?ƚ ĨŝŶĚ ĂŶǇ ĂƐƐŽĐŝĂƚŝŽŶƐ
between our airway and circulating inflammatory markers and aortic PWV.  Our 
aortic PWV results were lower than we were expecting.  Results published by 
Schumacher et al. where they found an association between aortic PWV and CRP 
had a higher aortic PWV of 11.5, in a study of 800 men in Caerphilly (2.8)m/s 
(Schumacher et al., 2009), however, despite being in a general population, of key 
importance they did not exclude those with previous CV disease; therefore our 
different population may be a reason for a lack of correlation.  The nature of our 
study means that the study population was a very select group of patients with 
COPD, therefore the results may not be representative of the general COPD 
population.  Importantly subjects with CV disease were excluded from the study; 
therefore the increased inflammation shown was a reflection of the increased 
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inflammatory state seen in patients with COPD and not a result of previous CV 
history.     
A limitation to this study is that a power calculation was not performed based on 
any cross-sectional analysis, as this data was baseline data from an RCT, therefore 
the power calculation was performed based on detecting a change after 
intervention.  It is not known if the analysis is adequately powered, especially given 
FeNO and sputum induction was only performed in a subset of the main group.  
Sputum samples were only available in a subset of patients due to the protocol for 
sputum induction and some patients being unable to produce an adequate sample, 
hence the sample size may impact upon our findings.   
Patients were excluded from the study if they were on oral steroids, however we 
could not control for inhaled steroids.  The inhaled steroids may have dampened 
some of the inflammatory response as it was previously reported that 2 months 
treatment with beclomethasone dipropionate 500µg 3 times daily in patients with 
stable COPD significantly reduced sputum neutrophil cell counts (Confalonieri et al., 
1998), and ICS have important immunomodulatory effects in patients with COPD, 
again reducing neutrophilic inflammation (Jen et al., 2012).  Conversely, a study in 
patients with COPD found that following 4 weeks treatment with fluticasone 
propionate 500 µg twice daily there were no significant changes in inflammatory 
cell counts or neutrophil percentages, and MMP-9 results did not change, when 
compared to the placebo group (Culpitt et al., 1999). 
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In conclusion, we were unable to demonstrate any associations between the 
specific airway or systemic inflammatory markers and aortic stiffness in a group of 
well-defined patients with COPD, without hypercholesterolaemia, IHD or diabetes.   
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Chapter 6 
Advanced Glycation End-products 
 ? a Marker of Cardiovascular 
Status in COPD?   
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6 Advanced Glycation End-products  ? a Marker of 
Cardiovascular Status in COPD?  
6.1 Introduction 
At the moment, we are aware of the increased risk of cardiovascular (CV) disease 
and mortality in COPD but we do not assess the current CV state, predict the CV risk 
or consider preventative CV strategies.  In order to address this increased CV risk in 
COPD patients a multi-dimensional approach is needed.  A shift in patient care is 
required so that rather than just assessing lung function, other measures are made 
to address CV risk (Jones and Agusti, 2006).   
A potential new biomarker for the detection of those patients with COPD at 
increased CV risk is Advanced Glycation End-products (AGE), which are predictive of 
CV risk in other disease groups (Meerwaldt et al., 2004), and as they contribute to 
structural vascular wall changes may be a link between COPD and CV disease 
(Basta, 2008).    
AGEs are markers of glycaemic and oxidative stress, pro-inflammatory and alter 
structure through collagen cross-linking, formed through the Maillard reaction - a 
chemical reaction between an amino acid and a reducing sugar.  Proteins such as 
collagen and elastin are particularly prone to AGE modification (Wu et al., 2011).  
AGEs accumulate with chronological age under normal conditions and have been 
found to contribute to the pathogenesis of multiple age related diseases, for 
example  W established CV disease, diabetes and renal failure.  Semba et al. 
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identified the specific AGE  W plasma carboxymethyl-lysine (CML) as a predictor of 
all-cause CV disease mortality, in a population based study looking at adults over 
the age of 65 years (Semba et al., 2009a).  AGE receptors (RAGE) belong to the 
immunoglobulin super-family and can be found on many cell types, including 
endothelial cells and macrophages.  RAGE can be either membrane bound or 
soluble, with membrane-associated receptors accounting for approximately 80% of 
lung RAGE (Hudson et al., 2008).   
There has been recent interest in AGE and its receptor: RAGE in both the airways 
(Ferhani et al., 2010) and circulating (Smith et al., 2011)  in subjects with COPD.  
Smokers reportedly have increased levels of the membrane bound receptor RAGE 
in their proximal and distal airways (Ferhani et al., 2010).  Whereas a recent study 
by Sukkar et al. reported that a lower systemic soluble RAGE (sRAGE) was 
associated with neutrophilic asthma and COPD (Sukkar et al., 2012).  These subjects 
with neutrophilic COPD or evidence of airway bacterial colonisation also had a 
reported lower mean systemic sRAGE in comparison to those without, suggesting 
sRAGE levels vary with COPD phenotype (Sukkar et al., 2012).  As RAGE contributes 
to tissue inflammation and remodelling, it may impact upon the pathogenesis and 
progression of COPD (Ferhani et al., 2010).  A recent GWAS by Repapi et al. found 
that in a population of 20,288  W including two historical Nottingham based 
populations, over and above the impact of smoking, the single nucleotide (SNP) 
rs2060700 encoding RAGE polymorphism is associated with lung function, 
especially the ratio of FEV1/FVC (Repapi et al., 2010).   
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In studies looking at AGE levels in COPD the interaction between RAGE and AGE is 
thought to contribute to the pathogenesis (Wu et al., 2011).  A case control study 
by Miniati et al. found statistically significant lower sRAGE levels in COPD subjects 
compared to an age and sex matched control group.  A significant inverse 
relationship was also found between sRAGE and the degree of airflow obstruction 
as defined by FEV1 in patients with COPD (Miniati et al., 2011).  These results are 
supportive of the findings previously reported by Smith et al. where it was reported 
that sRAGE was decreased in COPD compared to controls, and decreased further 
during acute exacerbations of COPD, and the same negative association with 
airflow limitation (Smith et al., 2011).  An association between sRAGE and transfer 
factor of carbon monoxide (TLco) and degree of emphysema as defined using a 
Computed Tomography (CT) scan was also reported (Miniati et al., 2011).  sRAGE is 
an anti-inflammatory molecule and as such reduced levels of sRAGE have been 
reported in other chronic inflammatory diseases such as rheumatoid arthritis 
(Pullerits et al., 2005) and coronary atherosclerosis (Falcone et al., 2005).   
Skin autofluoresence (AF) permits a non-invasive measurement of skin AGE, 
validated against the gold standard method of skin biopsies (Meerwaldt et al., 
2004).  These measurements are made using an AGE reader, which measures the 
accumulation of AGE in tissue, providing a quick, non-invasive measure, however 
specific individual ' ?Ɛ ĐĂŶŶŽƚďĞ ŵĞĂƐƵƌĞĚ.  Skin levels reflect accumulation of 
oxidative stress within the tissue, unlike circulating levels which are more variable 
and are affected by smoking (Cerami et al., 1997) and diet (Uribarri et al., 2007).  If 
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a relationship was found, measurements of skin AGE could be easily integrated into 
the clinical setting to assess cardiovascular risk.  
Skin AGE levels have been reported to be significantly increased in type 2 diabetes 
(Lutgers et al., 2006) and renal failure (Hartog et al., 2005).  Previous research has 
found relationships between AGE and other cardiovascular risk measures such as 
arterial stiffness (Ueno et al., 2008).  In a chronic kidney disease population skin 
AGE results have been shown to be independently associated with CV and renal risk 
factors (McIntyre et al., 2011).  A study conducted in Nottingham by McIntyre et al. 
found that in 115 established dialysis patients metabolic stress and hyperglycaemia 
resulted in elevated skin AGE levels compared to an age-matched non Wchronic 
kidney disease database (McIntyre et al., 2009).  Skin autofluorescence (AF) has 
been reported to be a useful clinical adjunct when evaluating both fatal and non-
fatal CV events, and total mortality in type 2 diabetics (Lutgers et al., 2009).  In 881 
stable type 2 diabetics in primary care, it has been reported that skin AGE levels, 
measured by the AGE reader, are predictive of those who developed micro-vascular 
complications, neuropathy and micro-albuminuria; with increased AGE values 
having a positive correlation with increased risk of complications (Gerrits et al., 
2008).   
More recently, in The Netherlands, with a population of 88 patients with COPD and 
55 controls, it was reported that ƐŬŝŶ'ĂŶĚƐŽŵĞƐƉĞĐŝĨŝĐĐŝƌĐƵůĂƚŝŶŐ' ?Ɛare 
higher in patients with COPD compared to controls, and inversely associated with 
disease progression (Gopal et al., 2014).  
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Hypothesis:  
Skin AGE is elevated in patients with COPD compared to controls with a smoking 
history, independent of smoking and age.  Skin AGE is inversely associated with 
spirometric measures of lung function and directly associated with aortic 
stiffness.  
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6.2 Methods 
Personnel: MJ co-ordinated the study and was responsible for the data entry, 
clinical conduct of the study and day-to-day management of the project.  MJ led on 
the preparation for NRES and R&D submissions.  All procedures were performed by 
an appropriately trained member of staff, either MJ or SH, according to local 
standard operating procedures (SOPs).  Enzyme-Linked Immunosorbent Assay 
(ELISA) testing for serum AGE was performed by SS, Department of Immunology, 
University of Nottingham, and for RAGE was performed by WC (see 
acknowledgments).    
6.2.1 Trial Design 
This study is a cross-sectional case control pilot study.  The objective of the study 
was to quantify skin AGE as a potential biomarker.   
Inclusion criteria: 
x Male or female 
x Aged between 40-85 years  
x Caucasian (skin AGE assessment only valid in Caucasian skin)  
x Greater than 10 pack years smoking history  
x Formal diagnosis of COPD (patient group) or no respiratory disease 
(controls)  
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Exclusion criteria: 
x Known alpha 1 antitrypsin deficiency 
x Active or suspected malignancy 
x Terminal disease not likely to survive 6 weeks 
x Any other lung conditions other than COPD where relevant 
There was also a never smoker control group.  The inclusion and exclusion criteria 
were the same with the exception of the smoking criteria. 
6.2.2 Statistics  
All data was analysed using Statistical Package for the Social Sciences (SPSS, 
Chicago, IL) version 21.0.  GraphPad Prism 5 (Graphpad software. San Diego, CA) 
was used for some figures.  Associations between categorical data were analysed 
using chi-ƐƋƵĂƌĞĚ  ?ʖ ? ) test.  Normally distributed continuous variables were 
analysed using an independent t-test. One-way analysis of variance (ANOVA) tests 
were performed if there were more than two sample sets.  Unless otherwise 
specified, arithmetic mean and standard deviation was used to show the measure 
of central tendency.  Where possible, non-parametric data  W serum AGE and serum 
soluble RAGE (sRAGE), was log10 transformed and parametric testing performed. 
Pearson correlation coefficients were used to measure the strength of linear 
relationships between two variables.  Stepwise multivariable linear regression was 
used to estimate the effect of COPD on other variables such as skin AGE and 
presence of comorbidities.  A p<0.05 value is considered statistically significant.  
Bland-Altman plots were used in the analysis of agreement in the validation of 
vicorder operators.  All data was first analysed looking at the COPD and control 
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group together.  In some cases, further sub-group analyses were performed looking 
at the COPD group alone.  
6.2.2.a Power calculation 
A formal power calculation could not be performed as there was no previous pilot 
data of skin AGE in patients with COPD with which to calculate a sample size. 
Pragmatically, we proposed to recruit 60 patients with COPD, 30 smoker controls 
and 30 never smokers; matched for age and gender for this pilot study. 
6.2.3 Approvals 
6.2.3.a Ethics 
Research Ethics Committee (REC) approval was granted on 18th November 2010.  All 
relevant documentation was reviewed by the REC including participant information 
sheets  W Appendix 4, letter of invitation to participant, protocol, consent forms, 
poster advertisements and questionnaires.   
6.2.3.b Research and Development (R&D) 
R&D was granted on 26th November 2010.  All relevant documentation was 
reviewed including protocol, consent forms, participant information sheets, 
advertisements, questionnaires and GP letters.   
6.2.4 Recruitment 
Subjects were recruited from out-patient clinics, poster advertisements across the 
Nottingham University Hospital NHS Trust, University of Nottingham and the local 
newspaper, Nottingham Respiratory Research website, pulmonary rehabilitation 
programmes, the respiratory research unit datĂďĂƐĞĂŶĚƚŚĞ ‘EŽƚƚŝŶŐŚĂŵ ƐŵŽŬĞƌ ?
database (see Figure 6.1).  All subjects were assessed at clinical stability. 
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*Other sources include pulmonary rehabilitation sessions, consultant clinics, other 
departmental studies, friends/relatives, departmental website and Breathe Easy 
meetings. 
Abbreviations- PIS: patient information sheet 
 
 
 
 
  
Other sources* 
Responded  
(n=100) 
PIS sent 
(n=97) 
Recruited 
(n=62) 
Poster adverts 
(including newspaper) 
Responded 
(n=53) 
PIS sent 
(n=50) 
Recruited 
(n=49) 
'smokers' database 
Approached 
(n=23) 
PIS sent 
(n=21) 
Recruited 
(n=20) 
Respiratory research 
unit database 
Approached 
(n=27) 
PIS sent 
(n=23) 
Recruited 
(n=20) 
  
Figure 6.1 Recruitment Source for the 151 who Consented 
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6.2.5 Study Outline 
Informed, written consent was sought from all participants.  All procedures were 
performed during a single study visit in the Clinical Trials Unit, City Hospital, NUH 
NHS Trust.  Where possible, participants were asked to refrain from using short 
acting ɴ2 agonist bronchodilators for 4 hours prior to their study visit and to attend 
fasted for 6 hours.   
6.2.6 Procedures  
6.2.6.a Medical history 
The participants were asked their medication, smoking history, medical conditions, 
physical activity, and occupational history.   
6.2.6.b Haemodynamic measurements 
Peripheral blood pressure was measured in duplicate using an Omron automatic 
sphygmomanometer in the seated and supine position.  All supine measurements 
were made after 10 minutes rest, see methods 2.2.2.a. 
PWA was measured in duplicate to determine AIx using the Vicorder 
(SmartMedical, UK).  When performing PWA the vicorder cuff was placed and 
inflated around the brachial pulse, see methods 2.2.2.b.ii. 
Pulse wave velocity (PWV) was measured in duplicate using the vicorder.  Both 
carotid-femoral (aortic) and brachial-femoral measurements were made; see 
methods 2.2.2.b.ii and Appendix 6.   
182 
 
6.2.6.c Spirometry 
Spirometry was performed on a micro-medical spirometer (MicroLab MK6) to 
assess lung function.  Measurements of Forced Expired Volume in 1 second (FEV1), 
Forced Vital Capacity (FVC) and FEV1/FVC ratio were recorded.  Where evidence of 
airways obstruction was shown on baseline spirometry, reversibility was performed 
and post-bronchodilator spirometry recorded; see methods 2.2.3.  The GOLD COPD 
classification was used (Decramer et al., 2013). 
6.2.6.d Skin AGE 
Skin AGE was measured in triplicate using an AGE Reader (DiagnOptics, Groningen) 
on the forearm of subjects.  The average of the 3 recordings was taken as the final 
result.  See methods 2.2.8 and appendix 7. 
6.2.6.e Blood samples 
Venepuncture was performed.  Patients were asked to fast for 6 hours where 
possible.  Samples were sent to pathology for renal function, glucose and a full lipid 
profile.  Further blood was centrifuged, aliquoted and then stored in a -80ȗC freezer 
for later analysis of circulating AGE (Cell biolabs) and soluble RAGE (R&D systems, 
UK) levels as measured by ELISA see methods 2.2.7.     
6.2.6.f Questionnaires 
The MRC dyspnoea score, CAT score and SGRQ were completed by all subjects; see 
methods 2.2.15 and appendix 8-10. 
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6.2.6.g Body composition 
Height (seca dual station, Hamburg, Germany) was measured.  Weight and body 
composition (Tanita, Illinois, USA) including FM, FFM and total weight.  BMI was 
calculated; see methods 2.2.13. 
6.2.6.h Carbon monoxide 
Exhaled CO levels were measured to assess smoking status using a Clement Clarke 
Smokerlyzer CO monitor (Harlow, UK); see methods 2.2.12. 
6.2.6.i Oxygen saturations (SpO2) 
Oxygen saturation was measured using pulse oximetry with a Minolta Pulsox P300-
P Pulse Oximeter (Tokyo, Japan); see methods 2.2.11. 
6.2.7 Inter Operator Validation of Aortic PWV  
A validation study was performed to determine any inter-operator variability when 
performing measurements of aortic stiffness on the Vicorder.  Both researchers 
performed arterial stiffness measurements on 10 randomly assigned subjects.  
6.2.8 Validation of Skin AGE  
Skin AGE measurements were performed on 20 participants on three separate 
occasions to assess validity.  Measurements were made in triplicate each time.  Two 
sets of measurements were made consecutively on day 1 10 minutes apart, and a 
further set of results were recorded where possible at least 24 hours after the first 
set of measurements.   
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6.3 Results 
In total, 202 people were approached regarding the study, 190 expressed an 
interest and had a PIS sent to them, 180 responded, and 151 consented and were 
entered into the study, see Figure 6.1.  Of these, there were COPD n=84 and smoker 
controls n=39.  The main data analysis is between COPD subjects and an age and 
ŐĞŶĚĞƌŵĂƚĐŚĞĚƐŵŽŬĞƌĐŽŶƚƌŽůŐƌŽƵƉ ?dŚĞ ‘ĐŽŶƚƌŽů ?ŐƌŽƵƉƌĞĨĞƌƐƚŽďŽƚŚĐƵƌƌĞŶƚ
and ex-smoker participants without any lung conditions.  A small number of never 
smokers were also recruited for comparison but not included in the main analysis 
(n=20).  Of the 151, a small number (n=8) were found to have other respiratory 
conditions often detected following spirometry and were excluded from the 
analysis.  Of the subjects recruited, skin AGE measurements were not possible in 3 
subjects - this was because the subjects had a dark sun tan and the machine was 
not able to perform the measurements - all of whom were in the control group.  
These 3 without skin AGE measurements were excluded from data analysis.  The 
number entering the study was COPD n=84 and controls n=36.   
To note, aortic pulse wave velocity (PWV) was a latter addition following an 
amendment to the initial ethical approval so measurements were performed in 52 
of the 84 COPD subjects and 35 of the 36 controls.   
Although they were not excluded, there were 15 subjects with self-reported IHD (12 
in the COPD group) and 13 with self-reported diabetes (9 in the COPD group).   
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The patients with COPD and the control group were matched for age, BMI and 
gender, see Table 6.1.  Similar proportions were current smokers, but the COPD 
group had a great smoking pack year history.   
In the COPD group the majority of subjects were GOLD stage 2.  Resting oxygen 
saturations and carbon monoxide levels were similar across the 2 groups; see Table 
6.1.  The control never smokers are also shown here, though they were not used for 
the main analyses and were significantly younger than the COPD and control group. 
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Table 6.1 Demographic Information of Subjects Recruited 
 
Mean (SD) 
 
(t-test unless otherwise 
stated) 
 
Controls 
n=36 
COPD 
n=84 
 
P values Never 
smoker 
n=20 
Age (years) 65 (12) 68 (9) 0.19 58 (8) 
Male / female (n) * 19/17 51/33 - 9/11 
Smoking status     (n) 
(never/ex/current) * 
 
0/26/10 
 
0/63/21 
-  
20/0/0 
Smoking pack years 28 (17) 46 (27) <0.001 0 (0) 
FEV1 (L) 2.58 (0.7) 1.5 (0.6) <0.001 2.97 (0.7) 
FEV1 % predicted 98 (14) 58 (18) <0.001 103 (13) 
GOLD (1/2/3/4) (n) - 6/54/20/4 - - 
Oxygen saturations (%) 96 (1) 95 (2) <0.001 97 (1) 
CO(ppm) 8 (10) 7 (9) 0.62 2 (2) 
BMI (kg/m
2
) 27.3 (4.0) 27.5 (5.4) 0.89 25.4 (3.6) 
FM (kg) 23.4 (7.3) 24.4 (10.1) 0.63 20.5 (8.0) 
FMI (kg/m
2
) 8.3 (2.4) 8.5 (3.8) 0.72 7.3 (3.1) 
FFM (kg) 54.5 (12.3) 54.0 (11.1) 0.81 52.2 (8.4) 
FFMI (kg/m
2
)  19.0 (2.6) 18.6 (2.6) 0.56 18.1 (2.0) 
Ischaemic Heart Disease n (%) 3 (8) 12 (14) 0.26 0 (0) 
Diabetes Mellitus n (%) 4 (10) 9 (11) 0.94 0 (0) 
 
Key: * chi-squared test 
Abbreviations: BMI body mass index, FEV1 forced expired volume in 1 second, CO 
carbon monoxide, FM fat mass, FMI fat mass index, FFM fat free mass, FFMI fat 
free mass index, GOLD: global initiative for obstructive lung disease.  
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6.3.1 Skin AGE in COPD and According to Lung Function 
Skin AGE was greater in subjects with COPD, 3.0 (0.5) AU, compared to the control 
group, 2.7 (0.6) AU, p=0.04; see Figure 6.2.  The mean skin AGE for each of the 
GOLD stages 1-4 (n=86) and the control group (n=36) is shown in Figure 6.3.  
Although the mean skin AGE of smoker controls is lower than each of the GOLD 
stages, and there is a progressive increase in mean skin AGE levels as the GOLD 
stage increases, there was no statistical difference between any of the GOLD 
categories.  There was only a small number of subjects recruited at GOLD stage 1, 
n=6, and GOLD stage 4, n=4; compared to GOLD stage 2, n=54, and stage 3 n=20.   
There was an inverse relationship between FEV1% predicted and skin AGE r=-0.24, 
p<0.01 across the COPD and smoker control group, as a whole; see Figure 6.4.  In 
the COPD group alone there was no significant correlation between FEV1% 
predicted and skin AGE.   
Data analysis was performed to look at the difference in skin AGE results between 
current and ex-smokers across the COPD and smoker control group.  There was no 
statistical difference in skin AGE results between current or ex-smokers with COPD, 
or between current and ex-smokers in the smoker control group.  A positive 
correlation was found between skin AGE levels and smoking pack years, (r=0.22, 
p<0.05) across the whole group.   
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Figure 6.2 Skin AGE in Controls and Patients with COPD 
 
Abbreviations  ? AGE: advanced glycation end-products 
Key - *: p<0.05 
The bars show the mean skin AGE for the control group and patients with COPD; 
the error bars show 1SD.  
 
 
 
 
* 
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Figure 6.3 Skin AGE Results Across GOLD Stages in Patients and Controls 
 
 
Abbreviations  ? AGE: advanced glycation end-products 
 
 
 
The bars show the mean skin AGE for each of the GOLD categories and the control 
group; the error bars show 1SD.  
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Figure 6.4 Skin AGE and FEV1% Predicted in Patients and Controls 
 
 
 
 
 
 
This figure shows the FEV1 %predicted against mean skin AGE for the COPD and 
control groups, with a line of best fit across the whole group. 
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A stepwise multiple regression was performed in the COPD and control group, with 
skin AGE as the dependent variable and FEV1% predicted, smoking pack years, age, 
BMI and gender entered into the model.  FEV1% predicted and age were 
independent variables p<0.05, see Table 6.2.   
When the same multiple regression analysis was performed in the COPD group 
alone, gender was the single independent variable, p<0.05; see Table 6.3.   
In the total group FEV1% predicted was an independent variable of skin AGE over 
and above the effects of smoking pack years and age, and in the setting of similar 
BMI.   
A priori, it was not our intention to statistically analyse the never smoker group in 
relation to the other smoker groups.  Our never smokers were significantly younger.  
However, the relationship between the three groups is demonstrated in Figure 6.5. 
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Table 6.2 Results of Significant Variables of Stepwise Multiple Regression in COPD 
Patients and Control group 
Dependent variable: skin AGE 
 B 95% CI Adjusted r2 
Constant 2.125 (1.45, 2.8)  
FEV1 % predicted -0.004 (-0.008, 0.000) 13.0% 
Age 0.16 (0.007, 0.025) 9.4% 
 
See text p191 for variables entered. 
 
 
 
Table 6.3 Results of Significant Variables of Stepwise Multiple Regression in COPD 
Patients Alone  
Dependent variable: skin AGE 
 B 95% CI Adjusted r2 
Constant 3.355 (3.0.9, 3.635)  
Gender -0.292 (-0.478, -0.074) 8.0% 
 
See text p191 for variables entered. 
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Figure 6.5 Skin AGE Levels Across All Groups 
 
 
Abbreviations  ? AGE: advanced glycation end-products 
 
The bars represent the mean skin AGE and the error bars show 1 standard 
deviation. 
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6.3.2 Aortic PWV in Patients and Controls 
There was no significant difference in aortic PWV between the COPD (n=52) and 
control group (n=32) who had aortic PWV measurements, p=0.08, see Table 6.4; 
however, there was a trend towards increased aortic PWV in the COPD group.  The 
subgroup who had aortic PWV were not different in age or sex compared to the 
total COPD and control group.  There was no significant difference in aortic PWV 
across the different GOLD stages.  There was no relation between aortic PWV and 
FEV1% predicted across the COPD and the control group, or in the COPD group 
alone (r=-0.101, p=0.36; r=0.111, p=0.435 respectively).  
6.3.3 Other Haemodynamic Measures 
Mean arterial pressure (MAP) was increased in the controls compared to the 
patients, see Table 6.4.    
There was no significant difference in brachial-femoral PWV between the COPD and 
control group, p=0.106, Table 6.4, or across the different GOLD stages.  There was 
no relation of brachial-femoral PWV and FEV1% predicted across the COPD and 
control group, or in the COPD group alone. 
There was no difference in mean AIx between the COPD and control group, Table 
6.4.   
6.3.4 Skin AGE and Haemodynamics 
There was a direct relation between skin AGE and aortic PWV in the total group, 
r=0.26, p<0.05; see Figure 6.6.  This was independent of age, gender and presence 
of comorbidities  W self reported diabetes and CV disease.  There was also a direct 
relation between skin AGE and brachial-femoral PWV in the total group, r=0.26, 
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p<0.01; which was again independent of age, gender and presence of comorbidities 
 W self reported diabetes and CV disease.  
In COPD alone there was a direct relation between skin AGE and brachial-femoral 
PWV, r=0.24, p<0.05; but no relation with aortic PWV, r=0.22, p=0.13. 
There was no correlation between AIx and skin AGE in the total group, r=-0.07, 
p=0.48; or in the COPD group alone r=-0.08, p=0.46.   
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Figure 6.6 Skin AGE and Aortic PWV in all Subjects 
 
Abbreviations  ? AGE: advanced glycation end-products, PWV: pulse wave velocity 
 
Mean skin AGE (AU) and aortic PWV (m/s) correlation in COPD patients (n=52) and 
smoker controls (n=35).  
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Table 6.4 Haemodynamic and AGE Results of Subjects Recruited to Each Group 
 
Mean (SD) 
Unless otherwise stated 
 
 
Controls 
n=36 
 
COPD 
n=84 
 
P values 
 
Never 
smoker 
n=20 
Aortic PWV (m/s) (n=52/35) 10.0 (2.4) 10.8 (1.9) 0.088 9.0 (2.4) 
Brachial-femoral PWV (m/s) 21.8 (8.2) 25.5 (14.7) 0.161 21.1 (11.4) 
AIx (%) 21.0 (6.6) 22.2 (12.8) 0.599 20.9 (5.5) 
Peripheral systolic BP (mmHg) 150 (22) 145 (20) 0.187 143 (21) 
Peripheral diastolic BP (mmHg) 86 (12) 83 (11) 0.263 87 (11) 
Peripheral PP (mmHg) 64 (17) 61 (17) 0.382 56 (14) 
MAP (mmHg) 114 (15) 108 (15) 0.048 110 (13) 
Heart Rate (bpm) 71 (11) 77 (15) 0.025 70 (12) 
Skin AGE (AU) 2.7 (0.6) 3.0 (0.5) 0.009 2.3 (0.4) 
^ĞƌƵŵ'Ɲ ?ƉŐ ?ŵů ?
(n=34/54/14) 
4612.1 
(2.4) 
4525.8 
(2.1) 
0.912 3865.4 
(2.3) 
Serum soluďůĞZ'Ɲ ?ƉŐ ?ŵů ? 1017.0 
(1.7) 
793.6 (1.5) 0.006 1130.0 
(1.5) 
 
Key - ƝA?ŐĞŽŵĞƚƌŝĐŵĞĂŶ ?^ ) 
Abbreviations- PWV: pulse wave velocity, AIx: Augmentation index, BP: blood 
pressure, PP: pulse pressure, MAP: mean arterial pressure, AGE: advanced 
Glycation End-products, RAGE: receptor for AGE.  
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6.3.5 Skin AGE and Comorbidities 
6.3.5.a Diabetes 
When those subjects with self-reported diabetes (n=13) were compared to those 
without diabetes (n=107) there was no significant difference in skin AGE, 3.1 
(0.4)AU, 2.8 (0.5)AU respectively, p=0.06.  
A sub-group analysis was performed in COPD patients alone, where those with self-
reported diabetes (n=9) were compared to those without diabetes (n=75), 3.0 
(0.4)AU and 2.9 (0.5)AU respectively, and there was again no significant difference 
in skin AGE, p=0.6.  
6.3.5.b IHD 
When those subjects with self-reported IHD (n=15) were compared to those 
without IHD (n=105) there was no significant difference in skin AGE, 3.0 (0.5) and 
2.9 (0.5) respectively; p=0.28. 
A sub-group analysis was performed in COPD patients alone, where those with self-
reported IHD (n=12) were compared to those without IHD (n=72) and there was 
again no significant difference in skin AGE, 3.0 (0.5) and 2.9 (0.5) respectively; 
p=0.4.  
6.3.6 Serum AGE and RAGE 
There was no difference in circulating AGE between the patients with COPD and the 
control group, see Table 6.4; but we were able to detect a significant difference in 
soluble RAGE - patients with COPD 793.6 (1.5)pg/ml and controls 1017.0 (1.5), 
p=0.006, see Table 6.4.   
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There was a direct relation between log10 RAGE and both FEV1% predicted and 
FEV1/FVC, r=0.24, p<0.05 and r=0.34, p<0.01 respectively in the COPD patients. 
There was no correlation between sRAGE and aortic PWV, r=-0.26, p=0.18 in the 
total group and r=-0.30, p=0.30 in COPD alone.     
6.3.7 Inter-operator Validation of PWV  
Bland Altman Plots were used to look at aortic and brachial-femoral arterial 
stiffness and both sitting and supine augmentation index in the 10 patients, see 
Figure 6.7.  There was little variability between the two operators for aortic PWV, 
brachial-femoral PWV and sitting and supine AIx, with the majority of 
measurements being within 2SD.   
As all 4 plots have the data clustered around the 0 line there is no evidence of 
proportional error; instead systematic error is shown.   
Systematic error is an error arising from the measuring instrument, often as a result 
of a fault or incorrect use; thus the systematic error could have arisen by the 
measurements of path length being different by the two operators.    
Bland Altman Plots have also been done to look at the same blood pressure results 
from both members of staff performing measurements for the study, see Figure 
6.8.  There was little variability between sitting and supine systolic and diastolic 
blood pressure measurements for both operators with all results within 2SD, adding 
further support that there was no significant difference in measurements 
performed by either staff member.  
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a. Aortic PWV                                                               b. Brachial-femoral PWV 
 
c. Sitting AIx          d. Supine AIx 
 
Abbreviations  ? PWV: pulse wave velocity, AIx: augmentation index  
The lines represent the mean and +/- 2 standard deviations.  
 
Figure 6.7 Bland Altman Plots of Haemodynamic Measurements Between 2 
Operators 
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Figure 6.8 Bland Altman Plots of Blood Pressure Measurements Between 2 
Operators  
 
a. Sitting systolic BP    b. Sitting diastolic BP 
  
 
c. Supine systolic BP    d. Supine diastolic BP 
   
Abbreviations  ? BP: blood pressure 
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6.3.8 Validation of AGE Reader  
Repeated sets of AGE readings were made on 20 different subjects; see Table 6.5.  
In 20 subjects two sets of measurements were made consecutively.  On 11 of these 
subjects an additional set of measurements were made between 24 hours and 1 
week later (measurement 3)  W see Figure 6.9. 
 
Table 6.5 Repeated Skin AGE Results 
 Measurement 1 
n=20 
Measurement 2 
Consecutive 
n=20 
Measurement 3 
>24hrs later 
n=11 
Skin AGE (AU) 
range 
1.8 - 4.9 1.6  W 4.8 1.8-4.6 
Skin AGE (AU) 
mean (SD) 
2.8(0.7) 2.8 (0.7) 2.9 (0.71) 
 
Abbreviations  W AGE: advanced glycation endproduct, AF: autofluorescence 
 
A coefficient of variation analysis was used to test for mean skin AGE differences 
among three different measurements, to see if there was any difference in AGE 
readings made at different time points.  Mean skin AGE did not differ significantly 
across the three measurements, coefficient of variation was less than 10% in all 
cases, with a mean coefficient of variation of 4.6% demonstrating the skin AGE 
measurements are repeatable over time.   
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Figure 6.9  Mean Skin AGE Correlation Plots 
a) Correlation between consecutive skin AGE measurements 
 
 
 
 
 
 
 
 
 
 
Correlation between 2 consecutive measurements of mean skin AGE (AU) (n=20).  
 
b) Correlation between mean skin AGE measurements made >24hrs apart 
 
 
 
 
 
 
 
 
 
 
 
Correlation between 2 mean skin AGE (AU) made at least 24 hours apart (n=11). 
Abbreviations  ? AGE : advanced glycation end-products 
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6.4 Discussion 
Skin AGE using skin autofluoresence were increased in clinically stable patients with 
COPD compared to smoker controls, were inversely related to lung function and 
directly related to aortic stiffness in all subjects, but not in COPD alone,  
comparable to previously reported results in patients with moderate to severe 
COPD (Gopal et al., 2013). 
6.4.1 Lung Function and Skin AGE 
The relationship between reduced lung function and cardiovascular risk has been 
well documented (Sin et al., 2005).  We have shown that increased skin AGE is 
related to a lower lung function however this was only seen in the total population 
and not in the COPD group alone.  Consistent findings were seen in a study 
conducted in The Netherlands, where an inverse relationship between skin AGE and 
lung function was reported in the main group of patients with COPD and controls, 
but not in the COPD patients alone (Gopal et al., 2014). 
6.4.2 Haemodynamic Measurements and Skin AGE 
It has previously been shown that serum AGE levels are associated with aortic PWV 
in the general population (Semba et al., 2009b) and in those with renal disease 
(Ueno et al., 2008).  We have shown a similar association with aortic PWV using skin 
AGE in patients with COPD.    
Given the age of the population in this study it would be expected that the 
relationship between skin AGE and aortic stiffness seen would be with aortic PWV 
as opposed to AIx (Mitchell et al., 2010).  This is due to the differing nonlinear 
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dependency on aortic wall stiffness with PWV and pressure pulsatility, and the 
discordant change with age (Mitchell et al., 2004).  The common risk factors for CV 
disease and COPD have been previously reported (Barnes and Celli, 2009), but the 
association remains over and above this.   
Using the same vicorder machine to measure aortic PWV a study has recently 
published results of 8.9m/s in a COPD population of 23 subjects (Stone et al., 2013) 
which, despite using the same technique, are lower results than we found in our 
population.  There are no obvious reasons why the aortic PWV reported by Stone et 
al. should be different to that found in this study, as baseline lung function, 
smoking history, age and BMI is comparable, with both populations having a higher 
proportion of males; similar to us, they did not exclude those with a cardiac history 
or cardiac risk factors, but they recruited from a COPD and CV database, therefore 
there could be a potential disparity between CV disease prevalence in the study 
group and current medications.    
6.4.3 AGE and Comorbidities 
Many of the common co-morbidities in patients with COPD, such as atherosclerosis 
(Wautier and Schmidt, 2004), osteoporosis (Yamagishi et al., 2005), and diabetes 
(Nin et al., 2011) have been associated with increased AGE levels in their own right.  
The increased CV risk in diabetics has been hypothesised to be due to the increased 
circulating AGE levels, and therefore a similar process may help to explain the CV 
complications in patients with COPD.  A correlation between sRAGE and CV disease 
severity has previously been reported in a Chinese population with coronary artery 
disease (Lu et al., 2011). 
206 
 
The population in our study was inclusive of co-morbidities, and had few exclusion 
criteria.  There was no difference in skin AGE in either the total group or just the 
COPD group, between those with IHD and those without IHD, or between those 
with diabetes and without diabetes; however, there was a disparity between 
numbers.  Our IHD and diabetes record was self-reported and encompasses a wide 
timeframe and range of presentations  W for example, we were not able to 
distinguish between those with a previous MI or current angina, likewise we could 
not distinguish between those with diet controlled diabetes or end-stage diabetes.  
This generic group reflects a typical population as seen in a clinic setting and 
therefore makes the results more representative.  It also means that if patients 
presented with subclinical changes, excluding a subset with a prior diagnosis is 
arbitrary, and may relate to a diagnosis as opposed to presence bias.   
6.4.4 Circulating AGE in Patients with COPD 
Since starting this project, circulating plasma N-(carboxyethyl)lysine (CEL), a well 
characterised AGE, has been reported as increased in patients with COPD compared 
to never/ex-smoker controls (Gopal et al., 2013, Gopal et al., 2014).  The COPD 
population these results were reported in were GOLD stage 2,3 and 4; n=34, n=39 
and n=15 respectively, similar to our population where the majority were GOLD 
stage 2-3; however, we were unable to detect any significant difference in AGE 
levels.  There are several possible explanations for the increased formation and 
levels of systemic AGE including chronic inflammation and oxidative stress (Gopal et 
al., 2013).  The accumulation of AGE is also heightened by hyperglycaemia and 
decreased renal clearance of AGE precursors (Miyata et al., 1997).  
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6.4.5 RAGE in Patients with COPD 
Different studies measure circulating sRAGE through different methods.  The 
ECLIPSE study  W a longitudinal observational study measured circulating sRAGE in 
serum samples, comparable to this study, and found sRAGE levels were significantly 
and inversely associated with disease severity as defined using GOLD stages in 
2,349 subjects from 46 centres in 12 countries (Cheng et al., 2013).  Alternatively, 
the Treatment of Emphysema With a Gamma-Selective Retinoid Agonist study 
(TESRA) which was a phase 2, double-blind, placebo controlled RCT with over 400 
patients with COPD measured sRAGE in baseline plasma samples and reported no 
significant difference in sRAGE between GOLD stages 2 and 3 (Cheng et al., 2013), 
however, this study was in a predefined group of emphysema patients.  It has 
previously been suggested that RAGE cause structural vascular wall changes (Basta, 
2008).    
6.4.6 Lung Function and RAGE 
RAGE has been shown to be significantly increased in COPD patients compared to 
controls, with a rise in mean sRAGE with increasing GOLD stages (Gopal et al., 
2013), and although our study showed a similar trend we did not reach significance.   
6.4.7 Repeatability and Validation 
6.4.7.a Haemodynamic measurements 
The vicorder is a technically easier method to perform compared to other methods 
of measuring arterial stiffness, and it is now becoming a more widely accepted 
method of determining aortic PWV.  During a small validation study there were no 
differences between 2 operators performing measurements on the same subjects, 
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showing the test is not operator dependent.  Recently published studies have 
shown aortic PWV using a vicorder to be highly reproducible when used in patients 
with COPD (Stone et al., 2013), and in the general population (McGreevy et al., 
2013). 
6.4.7.b Skin AGE measurements 
There was good repeatability and no significant inter-observer differences showing 
the AGE reader was consistent over time and did not have significant day to day 
fluctuations.   
6.4.8 Future Utility of Skin AGE 
The recent GOLD guidelines highlight the need to actively look for comorbidities in 
COPD patients (Decramer et al., 2013).  Skin AGE measurements are a potential tool 
that can be easily implemented in a clinical setting to help identify patients that are 
at risk of comorbidities.  Based on this pilot work there are potential clinical 
applications for skin AGE measurements, given the relationship with skin AGE and 
FEV1% predicted and aortic PWV the skin AGE reading may be able to help identify 
patients at risk of CV disease and lung function decline; however, only longitudinal 
studies will be able to fully explore this.  This is of particular relevance as GOLD 
highlights CV disease as being frequent and important (Decramer et al., 2013).    
Skin AGE has greater utility when compared to the measurements of circulating 
AGE levels, and has been validated against the GOLD standard skin biopsy 
measurements (Meerwaldt et al., 2004).  When skin AGE measurements are 
performed the results are available immediately.  It is non-invasive and easy to 
perform, requiring little effort from the subject.  Skin AGE results reflect the 
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accumulation in the body, compared to circulating AGE levels which fluctuate with 
diet (Vlassara et al., 2002) and smoking (Cerami et al., 1997).  Circulating AGE and 
RAGE levels require a blood sample to be taken, a specialised analysis technique, 
and therefore a subsequent delay time for results.   
6.4.9 Limitations and Points for Consideration 
Limitations to the study include the difference in smoking history between the 
COPD and control groups of 46 and 28 pack years respectively.  However, this does 
reflect the nature of COPD and its association with a significant pack year smoking 
history.  Further, all subjects had a greater than 10 pack year smoking history and 
this was adjusted for in regression analysis.  All subjects were of European ancestry, 
as required for the skin AGE reading, and possible effect on haemodynamic results 
(Meerwaldt et al., 2004).  Aortic PWV was only available in a smaller number of 
subjects, and not in the total study population.  
Restrictions to the utility of the skin AGE reader are that the machine is only 
validated for use in Caucasian subjects.  The use of steroids and their effect on skin 
AGE measurements has been questioned; however, research looking at other 
chronic inflammatory disease population has not found any effects with steroid use 
and skin AGE measurements (de Leeuw et al., 2007), and more recently no effect 
on skin AGE was found with either oral steroids or statins in a COPD population 
(Gopal et al., 2013).  Prospective, longitudinal studies are needed to 
comprehensively evaluate the potential influencing factors, such as co-morbidities, 
involved in changes in circulating and skin AGEs in patients with COPD. 
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6.4.10 Conclusion 
There is evidence of increased skin AGE levels in COPD patients compared to 
controls; and a relationship between skin AGE and airways obstruction, and skin 
AGE and aortic PWV.  It is possible that AGE is a linking mechanism between lung 
function and arterial stiffness.  Skin AGE measurements may represent a future 
diagnostic tool that can be implemented in a clinical setting to aid the identification 
of those at risk of comorbidities, particularly CV disease, in accordance with the 
GOLD guidelines; and further studies are warranted.  
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Chapter 7 
Conclusions 
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7 Conclusions 
7.1 Rationale for the Studies in this Thesis 
There is an increasing awareness of the development of extra-pulmonary co-
morbidities in COPD, to the extent that it is now incorporated into the GOLD 
strategy and international definition of COPD.  These extra-pulmonary effects 
include CV disease and have been shown to have an adverse effect on morbidity 
and mortality.   
There is a large gap in therapy options for these extra-pulmonary manifestations 
and research to explore alternatives and attenuate such risk is needed.  In parallel, 
there is a need to identify better biomarkers of the disease, new therapies that 
might address this and how biomarkers alter with therapy.  
Statins are a group of lipid lowering drugs which have been shown in both primary 
and secondary prevention to reduce CV mortality and morbidity in selected patients 
with normal or elevated cholesterol levels.   
It was proposed that statin therapy in COPD, through modulating systemic 
inflammation and lipid lowering effects may favourably modify non-invasive 
markers of CV disease in the short term.  This thesis comprises a randomised, 
placebo controlled, double blind trial investigating the CV and inflammatory effects 
of statins in COPD, and a cross-sectional study investigating the associations 
between CV risk and COPD.   
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7.2 Conclusions 
7.2.1 Cardiovascular Effects of Statin Therapy in Patients with COPD 
A well-defined group of clinically stable patients with COPD, without 
hypercholesterolaemia, known diabetes or IHD, were randomised 1:1 to either 
simvastatin 20mg or placebo for 6 weeks treatment.  Despite a significant reduction 
in total cholesterol there was a non-significant improvement in our primary 
endpoint - aortic stiffness, as measured by aortic PWV  W an independent predictor 
of CV risk, in patients with COPD taking simvastatin 20mg compared to placebo 
over 6 weeks.  There were no significant changes post-treatment in any of the other 
haemodynamic measurements including blood pressure, MAP and AIx.  
Our baseline aortic PWV was lower than we were expecting based on reported 
values at the study set-up, however, the results are in keeping with recently 
published results which are still greater in patients with COPD than in controls.  We 
also reported wider SD than what the power calculation was based on.  This has led 
the study to be underpowered to detect the change we set out to see.  We did 
report a 1m/s drop in aortic PWV in the active group as we set-out to do, but due to 
the placebo effect the difference between active and placebo group was not 
significant.  
In a pre-defined subgroup with a baseline aortic PWV value of >10m/s we did 
demonstrate a significant change in aortic PWV post-treatment in the active 
compared to placebo group.  This was in parallel to a significant drop in total 
cholesterol post-treatment in the active compared to the placebo group.  
Therefore, subjects with a higher baseline aortic PWV may be likely to have more 
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benefit from intervention.  In line with the main group analysis there was no 
significant change in any of the other haemodynamic measurements post 
treatment in the active compared to placebo group. 
7.2.2 Inflammatory Effects of Statin Therapy in Patients with COPD 
In this RCT, there was not a detectable change in either airway or circulating 
inflammatory markers.  We were unable to detect any change in airway 
inflammatory markers of exhaled nitric oxide (FeNO), induced sputum  W neutrophils 
or macrophages; or circulating markers  W hs-CRP and total MMP-9, post treatment 
in the active compared to placebo group following 6 weeks treatment with active 
compared to placebo.  Of importance, airway inflammatory markers were only 
available in a limited number of subjects.   
In a sub-group analysis of patients with a baseline hs-CRP >3mg/l, n=33, 16 active 
and 17 placebo, there were no significant changes in hs-CRP post-treatment in the 
active compared to placebo group.  In addition, there were no changes in airway 
inflammatory markers or total MMP-9 in this sub-group. 
7.2.3 Relationship of Haemodynamics to Inflammatory Measures in 
Patients with COPD 
There were no demonstrable associations between airway or systemic 
inflammatory markers and aortic stiffness in a group of well-defined patients with 
COPD, without hypercholesterolaemia, IHD or diabetes.  Although there was a 
trend towards higher hs-CRP in those in the lowest aortic PWV group this did not 
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reach significance.   Using a variety of pre-defined cut-off points and tertile analysis 
did not allow any relationships to be detected.  
7.2.4 Advanced Glycation End-products (AGE) and CV Risk in Patients 
with COPD 
Skin AGE levels have been validated against skin biopsies and provide a reliable, 
non-invasive method of assessing AGE levels as a potential biomarker of risk of 
comorbidity patients with COPD.  We were able to report increased skin AGE levels 
in COPD patients compared to controls; and a relationship between skin AGE and 
FEV1% predicted and skin AGE and aortic PWV in the total group but not in COPD 
alone.  Skin AGE measurements may be a potential future diagnostic tool for use in 
a clinical setting to aid the identification of those at risk of comorbidities, 
particularly cardiovascular disease, in accordance with the GOLD guidelines 
requirements.  However, larger studies are required, and ideally would include a 
longitudinal element.   
7.3 Summary 
There are numerous co-morbidities seen in COPD and in this thesis I have focused 
on CV disease with statins as a potential therapy to attenuate the CV implications, 
and attention to biomarkers to detect this risk in patients with COPD.  Although we 
were not able to show a significant difference in the change in aortic PWV between 
those taking the active statin treatment compared to placebo post-treatment; we 
did find a significant change in those with a baseline aortic PWV>10m/s and 
therefore treatment may be better aimed at those with a baseline aortic PWV 
>10m/s and warrants further investigation.  I have also explored the role of skin 
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AGE as a potential new biomarker, and the possible association between AGE and 
arterial stiffness.  This is an expanding area of research and one with important 
consequence, given the increasing prevalence of COPD and the projection for it to 
be the third leading cause of death by 2020 having considerable impact on 
morbidity and mortality, quality of life and the economic burden.  These results 
highlight the need for further studies in high risk patients to confirm the impact of 
statin use on the CV outcome of COPD, using death as primary outcome; and give 
an indication of their potential role in this sub-group of patients.   
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8 Future Research Directions 
In order to build upon the research work presented in this thesis there are several 
other areas of research that I feel would be particularly pertinent.  Further studies 
in high risk patients with COPD are needed to confirm the impact of statin use on 
the cardiovascular outcomes.  There are 3 approaches that could be explored. 
x dŚĞ ĨŝƌƐƚ ŝƐ Ă  ‘ŚĂƌĚ ĞŶĚƉŽŝŶƚƐ ? ƐƚƵĚǇ ůŽŽŬŝŶŐ Ăƚ CV morbidity and/or 
mortality.  The results of this RCT may lead onto larger, more pragmatic 
studies with morbidity outcomes as an endpoint in patients with COPD, 
irrespective of lipid levels.  Having studied a specific population to 
deliberately avoid patients who would be eligible for statin treatment based 
on current licensed indications, we cannot generalise our findings to the 
total population of patients with COPD.  A study examining the wider COPD 
population would be more representative of patients presenting in a clinical 
setting.  However these are costly, of long duration and require some 
background supporting information such as this proof of principle RCT.   
x The second approach is a study looking at aortic PWV in either a greater 
number of people, or in those with increased baseline aortic PWV - as we 
have shown a potential benefit in subject with a baseline aortic 
PWV >10m/s, a study looking at this population with a pre-defined 
increased aortic PWV could be performed; but given our recruitment 
difficulties this would need to be a multi-centre study to allow recruitment 
targets to be met.  Alternatively these study options could be performed in 
 ‘Ăůů ? KW ƐƵďũĞĐƚƐ ? ƚŚĞƌĞĨŽƌĞ ŝŶĐůƵĚŝŶŐ ƚŚŽƐĞ ǁŝƚŚs ĚŝƐĞĂƐĞ ďƵƚ ŶŽƚ ŽŶ
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statins already, as this would then be a more representative sample of 
patients with COPD and would be easier to recruit to.   
x This was a pilot study looking at feasibility for future studies.  Any 
intervention that may reduce the risk of CV disease in COPD requires careful 
evaluation.  We selected an intervention that lasted for 6 weeks, 
comparable to timeframes used in previously published work, and also for 
patient retention.  We are unable to exclude the possibility that a longer 
interventional timeframe or a higher dose of statin may have a beneficial 
effect on modifying aortic stiffness.  Further research looking at the effect of 
dose and duration of statin use in patients with COPD should be considered.  
x A third way to build on the research presented in this study is through an 
epidemiological approach, although this would not take the place of the first 
two clinical study options.  Using a large database, for example the GP 
health improvement network (THIN) dataset it could be assessed whether 
CV profiling is routinely performed on patients with COPD, because COPD 
management does not currently include a routine CV assessment or any 
primary prevention, despite the known increased CV risk.  The data can be 
used to look at the proportion of patients with COPD that are on a statin 
and determine whether statin therapy reduces total mortality and CV 
mortality using cox regression analysis.  However, any such results would be 
limited by their speculative nature, as they would be based on retrospective 
cohort analysis and therefore liable to confounding bias.   
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In parallel, there is a need for a major shift in the care of patients with COPD to 
address the cardiovascular risk at diagnosis and at assessments.  Known risk 
factors can be addressed such as smoking cessation and treating hypertension 
and hypercholesterolaemia.  Primary prevention and other therapeutic 
interventions to supplement these endeavours should be prioritised. 
At COPD diagnosis and follow-up assessments, there is not a comprehensive 
review of CV risk.  To build on the work looking at skin Advanced Glycation End-
products as a potential new biomarker to detect those patients with COPD most 
at risk of CV comorbidity, prospective, larger, longitudinal studies are needed to 
fully evaluate potential influencing factors, including co-morbidities which are 
involved in changes in circulating and skin AGEs in patients with COPD.  
However, this should be done in parallel with risk score calculations (e.g. 
Framingham, National Heart Lung and Blood Institute (NHLBI)) to see if the skin 
AGE offers additional benefit to these traditional calculators, as the skin AGE 
reader machine is costly.  Given that the risk of CV disease and death is over and 
above the risk in smokers in epidemiological studies, one could imagine that the 
risk score calculators might not identify the risk in patients with COPD, as the 
current risk score calculator algorithms centre on the modifiable factors of 
blood pressure, lipids and smoking.  However, the risk scores have not been 
fully researched and subtle changes in the parameters might account for any 
differences.  Alternatively, a COPD modified calculator might be necessary.  
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Patient Information Sheet Version 1.3 02-03-10 
The Cardiovascular and Inflammatory Effects of Statin Therapy in Patients with 
COPD 
Chief Investigator: Dr Charlotte Bolton  
REC ref: 10/H0408/10  
Introduction 
We would like to invite you to take part in our research study. It is important for you 
to understand why the research is being done and what it would involve for you, 
before you decide whether or not you would like to take part.  One of our team will 
go through the information sheet with you and answer any questions you have.  
Please take time to read this information sheet carefully and talk to others ± family 
or friends, about the study if you wish.  Part 1 tells you the purpose of this study and 
what will happen to you if you take part. Part 2 gives you more detailed information 
about the conduct of the study.  Ask us if there is anything that is not clear, or if you 
would like more information.  Take time to decide whether or not you wish to take 
part. 
Part 1 of the information sheet 
What is the purpose of the study? 
The research is looking at whether a drug called simvastatin could be used as an 
additional treatment for people with chronic obstructive pulmonary disease.    
Appendix 1  ? Patient Information Sheet for the Statin RCT 
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Chronic obstructive pulmonary disease (COPD) is a condition of the lungs which 
results in breathing difficulties.  This is due to the lungs being damaged.  The lungs 
become inflamed and the breathing tubes (airways) narrowed. In addition, we know 
there is increased inflammation in the blood and patients with COPD are at 
increased risk of heart disease. Current treatments have focused on the narrowed 
airways and attempt to open them up. Statins, simvastatin being one of them, are 
drugs used to lower cholesterol in the blood.  In addition, it may also reduce 
inflammation and lower the risk of heart disease.  This study will explore whether 
simvastatin has a benefit in patients with COPD.  
 
Why have I been invited? 
You have been invited to participate because you have COPD and you   
- Have previously consented to be included on the BRU respiratory database 
- $UHDWWHQGLQJRQHRIWKHUHVHDUFKHUV¶FOLQLFV 
- Have replied to one of the posters seeking volunteers  
 
Do I have to take part? 
It is entirely up to you whether or not you decide to take part.  If you do decide to 
take part you will be given this information sheet to keep and be asked to sign a 
consent form (you will be given a copy of this as well).  If you decide to take part, 
you are still free to withdraw at any time and without giving a reason.  A decision to 
withdraw, or a decision not to take part, will not affect the standard of care you 
receive. 
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What will happen to me if I take part?  
The study involves taking part in a study to explore the effects of simvastatin. It is a 
randomised placebo controlled study which means we will give study participants 
either a 6 week course of simvastatin, or a 6 week course of placebo (a dummy 
treatment which looks like the genuine medicine but contains no active ingredient) 
and then compare the effects of the two treatments at the end. SometimHVZHGRQµW
know which way of treating patients is best. To find out, we need to compare 
different treatments ± in this study we are comparing simvastatin to a placebo. To 
try and make the study as fair as possible each participant will have an equal 
chance of getting simvastatin or placebo, and the trial will be double-blind which 
means neither you nor the people running the study will know which treatment you 
are taking (although if need be we can find this out). The placebo (dummy 
treatment) contains lactose (sugar found in milk), so you will be unsuitable if you are 
lactose intolerant.  
If after reading this information sheet and talking to a member of the research team 
you agree to take part in this study, there will be 3 visits to the Respiratory 
Biomedical Research Unit (BRU) in the Clinical Sciences Building at City hospital. 
We will ask for your consent in writing first.  
 
Consent Visit 
If you agree to take part in the study you will need to sign an informed consent 
sheet so that we have written evidence of your wish to participate in the study.  
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Screening visit 
Please refrain from taking your inhalers before this visit.  Your reliever inhalers 
(usually blue or grey) should be not used for 6 hours before your visit.  Long acting 
inhalers (ones you take just morning and night) should not be taken for 12 hours 
before your visit.  Please fast for 8 hours before coming to this visit ± including 
drinks containing caffeine.  Please do not smoke for 6 hours before coming to this 
visit.   
At the screening visit we will do the following: 
- Take a full medical history including smoking history, and medical 
examination 
- Perform spirometry (a simple breathing test where you blow hard and fast 
into a tube for as long as you can).  Depending on your results we may ask 
you to take an inhaler (salbutamol) and repeat the breathing test again so 
that we can measure any changes in your airways ± this is called a 
reversibility test    
- Measure the level of a gas called carbon monoxide exhaled in your breath.  
This involves blowing into a machine which is a bit like an alcohol 
breathalyser 
- Take a 10ml blood sample (about 2 teaspoons) ± this is required as part of 
the safety monitoring of the trial.  We will measure your blood count, kidney 
and liver function and fasting lipids (e.g. cholesterol). If you are a female and 
there is a possibility you might be pregnant, we will also do a pregnancy test 
as the drug is not indicated in pregnancy.  
- Capillary blood gas sample ± a small scratch on your earlobe to take a few 
drops of blood to measure your oxygen and carbon dioxide levels  
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There will then be a period of about 2 weeks whilst we wait for all your test results. 
 
Visit 1 
Please refrain from taking your inhalers before this visit.  Your reliever inhalers 
(usually blue or grey) should be used for 6 hours before your visit.  Long acting 
inhalers (ones you take just morning and night) should not be taken for 12 hours 
before your visit.  Please fast for 8 hours before coming to this visit ± including 
drinks containing caffeine.  Please do not smoke for 6 hours before coming to this 
visit.   
During visit 1 we will do the following: 
- Measure your height and weight. In addition we will measure the amount of 
fat and muscle in your body using special weighing scales. 
- Issue of study drug (simvastatin) or placebo 
- Take a blood sample (25mls which is about 5 teaspoons) to measure 
inflammatory markers, liver function, a muscle marker and markers of kidney 
and heart function.  In addition we will measure lipid levels (e.g. cholesterol). 
Some of these tests are clinically relevant, some are to aid us in research 
understanding.  
- Spirometry breathing test  
- Take a sputum sample ± to measure the inflammatory cells in the sputum.  If 
\RXFDQQRWSURGXFHVSXWXPUHDGLO\ZHFDQµLQGXFHVSXWXP¶E\DVNLQJ\RXWR
inhale a salt solution called hypertonic saline 
- Measure the level of a gas called nitric oxide exhaled in your breath.  This 
involves blowing into a machine which is a bit like an alcohol breathalyser 
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- Measure the level of a gas called carbon monoxide exhaled in your breath.  
This involves blowing into a machine which is a bit like an alcohol 
breathalyser 
- Measure blood pressure 
- We will then measure artery stiffness by placing an electronic pencil shaped 
device lightly over the artery pulse in your wrist. Following this, you will be 
asked to lie on a bed for 20 minutes where we will take readings from the 
arteries at the wrist (radial), neck (carotid) and upper thigh (femoral).  
- A walking test ± to see how far you can walk in 6 minutes. Before we do this, 
we can let you have a light snack. 
- Measure handgrip strength 
- Complete a breathlessness and quality of life score questionnaire 
-  Provide a urine sample ± about 10mls (2 teaspoon) 
 
In between the 2 visits you will receive 2 telephone calls to see how you are getting 
on and remind you of any forthcoming appointments. 
 
Visit 2 
During visit 2 we will do the same as we did in visit 1.  This will allow us to compare 
your results before and after your 6 weeks on simvastatin or placebo.  
Travel Allowance  
We can reimburse travel costs associated with coming to the BRU.  Please keep 
receipts.  
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What will I have to do? 
We ask that you take the study medication regularly as directed.  You can continue 
to take your other normal medication which will be checked at the screening visit to 
make sure it will not affect the study medication.  It is important that you are not 
involved in any other drug studies whilst taking part in this study.  Please let us 
know if you have taken part in another drug study within the last year.  We also ask 
that you attend the scheduled follow-up study visit ± there is some flexibility in terms 
of the day and time when this is scheduled.  
 
What is the drug, device or procedure that is being tested? 
Simvastatin is a tablet that is commonly used to lower cholesterol in the blood.  It 
will be taken by mouth at a dose of 20mg once a day in the evening for 6 weeks. 
Please let your doctor or pharmacist know that you are taking part in this study if a 
change to your normal treatment is made while you are taking your study 
medication.  
There are a number of drugs that can interact with simvastatin.  If you agree to 
participate we will check your current medication is satisfactory and will not cause 
any interactions.  Such drugs include other cholesterol lowering drugs, an antibiotic 
± clarithromycin; but also grapefruit juice.  
 
What are the alternatives for diagnosis or treatment? 
The alternative is to continue with your current treatment. 
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What are the side effects of any treatment received when taking part? 
Simvastatin is a treatment commonly used to treat people with high cholesterol.  As 
with all medicines some people develop side effects after taking simvastatin.  The 
main side effects that have been reported by people taking simvastatin are 
muscular effects such as aching muscles, tender muscles or muscle weakness 
which are rare but often significant.  Statins can also affect liver function blood tests.  
Rarely they can cause yellow jaundice and headache.  
If you are concerned that you have developed a side effect, such as muscle pain or 
weakness, you can contact the research team on 0115 8231937. 
 
What are the possible disadvantages and risks of taking part? 
Occasionally the inhalation of salt solution to induce sputum can make you wheezy.  
This can be quickly reversed using a salbutamol (Ventolin) inhaler which we will 
have to hand. The test is done frequently in the department by experienced 
members of staff.  
If you have private medical insurance please check with the company, before 
DJUHHLQJWRWDNHSDUWLQWKHWULDOZKHWKHUSDUWLFLSDWLRQLVFRQVLGHUHGDµPDWHULDOIDFW¶
that should be reported.  You will need to do this to ensure that your participation 
will not affect your medical insurance.  
 
What are the possible benefits of taking part?  
There are no short term benefits anticipated with this study.  By participating, you 
will be helping us to collect information to see whether statins, particularly 
simvastatin, could help in the management of patients with COPD, in the future. 
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This completes part 1.  If the information in Part 1 has interested you and you 
are considering participation, please read the additional information in Part 2 
before making any decision. 
 
Part 2 of the information sheet 
What if relevant new information becomes available? 
Sometimes we get new information about the treatment being studied during the 
time you are involved in the study. If this happens, your research doctor will tell you 
about it and discuss whether you should continue in the study. If you decide not to 
carry on, your research doctor will make arrangements for your care to continue. If 
you decide to continue in the study you may be asked to sign an agreement 
outlining the discussion (an updated consent form).  
It is also a possibility that on receiving new information your research doctor might 
consider it to be in your best interests that you should withdraw from the study.  
He/she will explain the reasons and arrange for your care to continue.  
If the study is stopped for any other reason, we will tell you and explain why, and 
arrange your continuing care. 
 
What will happen if I don¶t want to carry on with the study? 
You can withdraw from the study at any time if you no longer wish to take part.  
Information already collected may still be used.  Any stored blood or tissue samples 
that can still be identified as yours will be destroyed if you wish. 
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What if there is a problem? 
Complaints: 
If you have any concerns about the study you should speak with the researchers 
who will do their best to answer your questions (0115 82 31317).  Any concerns or 
complaints about the way you have been treated during the study or any possible 
harm you might suffer will be addressed. If you are unhappy and wish to complain 
formally you can do so through the NHS complaints procedure.  Details can be 
obtained from the hospital.  
Harm: 
In the event that something does go wrong and you are harmed during the research 
study there are no special compensation arrangements. If you are harmed and this 
is due to VRPHRQH¶V QHJOLJHQFH WKHQ \RX PD\ KDYH JURXQGV IRU OHJDO DFWLRQ IRU
compensation against the University of Nottingham but you may have to pay your 
legal costs.  The normal National Health Service complaints mechanism will still be 
available to you.  
 
What happens when the research study stops? 
Throughout the study, your care will remain with your GP.  If you are also under the 
hospital, that care will remain in place.  At the end of the study, all visits to the 
research centre will finish and care will revert to your usual doctor.  When the 
research study stops you will continue to take your normal COPD medication and 
the study medication ± simvastatin ± will stop.  
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Will my taking part in this study be kept confidential? 
Yes.  We will follow ethical and legal practice and all information collected about you 
during the course of the research will be handled in strict confidence.  
 
Involvement of the General Practitioner/Family doctor (GP) 
With your permission we will write to your GP and notify them that you are going to 
be taking part in this study.  
 
What will happen to any samples I give? 
The samples will be collected and analysed and then stored in a secure area, with 
only direct researchers having access.  Samples will be labelled with a code that will 
allow us to work out that the samples came from you when we get the results, but 
will ensure that no one outside the research group can identify you.  If any of these 
results could benefit your treatment outside of this study we would be able to share 
the information with other healthcare professionals involved in your care with your 
agreement.  Samples will be stored until the end of the study and when all analysis 
is complete, and then they will be destroyed in accordance with the Human Tissue 
$XWKRULW\¶Vcode of practice.   
 
Will any genetic tests be done? 
No. 
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What will happen to the results of the research study? 
The results of the paper will be published in a medical journal and may be 
presented at a meeting or conference. It will not be possible to identify individual 
SHRSOH¶V UHVXOWV LQ DQ\ UHSRUW RU SXEOLFDWLRQ  $ VXPPDU\ RI WKH UHVXOWV ZLOO EH
available to you should you wish.  
 
Who is organising and funding the research? 
The study is being funded by the National Institute of Health Research (NIHR) 
Respiratory Biomedical Research Unit, which is part of Nottingham University 
Hospitals NHS Trust and the University of Nottingham.  
Please note the research team are not being paid for including you in this study.  
 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a 
Research Ethics Committee, to protect your interests. This study has been reviewed 
and given favourable opinion by Nottingham Research Ethics Committee.  
 
Further information and contact details 
Michelle John                Charlotte Bolton  
0115  82 31933              0115  82 31317 
michelle.john@nottingham.ac.uk         charlotte.bolton@nottingham.ac.uk  
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Do you have COPD? 
 
Are you interested in taking part in a research 
study? 
We are seeking volunteer men and women aged 45  W 80 years old to 
participate in a study based at Nottingham Respiratory Biomedical 
Research Unit (BRU), City Hospital, Nottingham.  
The Cardiovascular and Inflammatory Effects of Statin therapy in 
patients with COPD 
Chronic obstructive pulmonary disease (COPD) is a common lung 
condition affecting nearly a million people in the UK. COPD is due to the 
lungs being damaged and results in breathing difficulties. Drugs 
currently used for COPD are focused on opening up the narrowed 
airways. We are researching whether Simvastatin (a drug used to lower 
cholesterol in the blood) can be used to lower inflammation and 
therefore lower the risk of heart disease in people with COPD.  
The study involves 3 visits over an 8 week period.  
If you would be interested in more information, please contact Dr 
Bolton or Michelle John at the BRU on:0115 8231933 
Version 1.2 02-03-10 
Appendix 3  ? Statin RCT Poster Adverts 
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Version 2.0 02-09-10 
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Appendix 4  ? Patient Information Sheet ĨŽƌ ‘dŚĞĂƐƐŽĐŝĂƚŝŽŶŽĨůƵŶŐĨƵŶĐƚŝŽŶĂŶĚ
carĚŝŽǀĂƐĐƵůĂƌƌŝƐŬ ?t^udy 
PATIENT INFORMATION SHEET version 1.3 (04/01/2011) 
 
Title: The association of lung function and cardiovascular risk  
Chief Investigator: Dr Charlotte Bolton  
 
Introduction 
You are being invited to take part in a research study. Before you decide, it is 
important for you to understand why this research study is being conducted and 
what it will involve. Please take the time to read the following information carefully 
and discuss it with others if you wish. Please feel free to ask us if there is anything 
that is not clear or if you require any further information. You may keep this 
information for future reference.  
Purpose of the Study 
Previous studies have shown that people with poor lung function (who often have 
chronic lung disease) have an increased risk of cardiovascular disease (problems 
with the blood vessels) over and above the effects of smoking. However, at the 
moment we have a limited understanding of the reasons behind this.  
 
Researchers wish to study people with and without lung disease who currently 
VPRNH RU KDYH VPRNHG LQ WKH SDVW WR H[SORUH SHRSOH¶V ULVN RI GHYHORSLQJ
FDUGLRYDVFXODU GLVHDVH 5HVHDUFKHUV ZLOO PHDVXUH WKH VWLIIQHVV RI SHRSOH¶V EORRG
vessels and also look at levels of inflammation in the blood and compare this with 
SHRSOH¶V OXQJ IXQFWLRQ )LQDOO\ UHVHDUFKHUV ZLVK WR VHH LI SHRSOH¶V NLGQH\V DUH
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affected by the stiffening of the hearts main artery; the aorta. It is hoped that by 
studying SHRSOH¶V blood vessels and lung function, it will lead to a greater 
understanding of why people with poor lung function (who often have chronic lung 
disease) have an increased risk of cardiovascular disease.  
 
Why have I been chosen? 
You have been chosen because you:- 
x Have been diagnosed with COPD and are attending one of the researchers 
Respiratory Out-Patient Clinics. 
x Have previously consented to be included on the Nottingham Respiratory 
Research Database or Professor Ian Halls Volunteer Database and to 
contacted regarding future research studies.  
x Are replying to a poster or advertisement seeking volunteers.  
 
Please note; this study is only available to people of European Ancestry, as the 
tests used in this study are not valid in any other skin type at present.  
 
Do I have to take part? 
It is entirely up to you whether or not you decide to take part. If you do decide to 
take part you will be given this information sheet to keep and be asked to sign a 
consent form (you will be given a copy of this as well). If you decide to take part you 
are still free to withdraw at any time and without giving a reason. A decision to 
withdraw, or a decision not to take part, will not affect the standard of care you 
already receive.  
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What will happen to me if I take part? 
You will be asked to attend for one study visit at the Respiratory Biomedical Unit at 
Nottingham City Hospital. During this time (approximately 90 minutes) you will need 
to have various tests/procedures.  
Visit 1  
If after reading this information sheet and talking to a member of the research team, 
you would like to take part in this study, we would ask you to sign a consent form.  
In addition we would like to conduct the following tests/procedures:- 
x Blood Sample: we would like to take a small amount of blood (25mls or the 
equivalent of 5 teaspoons) from your arm for further analysis. 
x Urine Analysis: we would like to take a sample of urine (10mls or the 
equivalent of 2 teaspoons), to analyse certain molecules.  
x Questionnaires: You will be asked to fill out 3 short questionnaires about 
how your health affects your daily life. 
x Spirometry Test (blowing test); which is used to measure your lung function 
(the size of your lungs and how quickly you can empty them). You will be 
asked to breathe in and then blow out very fast into a mouth piece.  
x Carbon Monoxide Test: we would like to measure the level of a gas called 
carbon monoxide exhaled in your breath. This involves blowing into a 
machine which is a bit like an alcohol breathalyser to record the 
concentration of carbon monoxide. 
x Pulse Oximetry; a simple non-invasive test which measures oxygen 
saturation in your blood. 
x Blood Pressure 
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x Arterial Stiffness Measurements: A non-invasive test which involves 
SODFLQJDEORRGSUHVVXUHFXIIDURXQGWKHSDUWLFLSDQW¶VXSSHUOHJDQGDUPWo 
PHDVXUHWKHVSHHGRISXOVDWLRQGRZQWKHSDUWLFLSDQW¶VERG\ZKLFKLVUHODWHG
to the stiffness of the arteries. Please be aware that all of the tests listed 
above will be performed by competent staff following standard operating 
procedures. Before starting any of the tests we will ensure that there are no 
reasons for the test not to be performed.   
x Skin Elasticity Measurements: A non-invasive test used to measure the 
PHFKDQLFDOSURSHUWLHVRISHRSOH¶VVNLQVNLQHODVWLFLW\6NLQHODVWLFLW\ZLOOEH
measured by applying a small suction force to the skin and measuring how 
the skin responds to this force.  
x Skin AGE Measurements: A non-invasive test used to measure peoples 
skin metabolism. This involves participants placing their arm onto the device, 
which then shines light onto the skin.  The reflected light is then measured 
and analysed.  
 
Please be aware that all of the tests listed above will be performed by competent 
staff following standard operating procedures. Before starting any of the tests we 
will ensure that there are no reasons for the tests not to be performed.   
Finally, we would like to record your past medical history; including your current 
medication and smoking history. 
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Follow-Up (Optional) 
With your consent we would like to contact you in the future to follow you up and 
perform some of these tests again, in order to create a longitudinal study (a study 
over a longer period of time) of cardiovascular risk in patients with and without lung 
disease, dependent on funding. Please be aware that a member of the study team 
will contact your GP to check your ongoing health status before contacting you.  
 
What do I have to do? 
You should continue to carry on with your normal daily activities and take your usual 
medication. We also ask that you attend the scheduled study visit (although there is 
some flexibility in terms of the days and times when this can occur) and complete 
the study paperwork. You may be asked to refrain from eating or drinking for six 
hours prior to your appointment, although your study doctor will advise you before 
you attend for your visit. 
 
Will any genetic tests be carried out? (Optional) 
Yes; it is hoped that the genetics part of the study (looking for differences in 
SHRSOH¶V JHQHV will lead to a greater understanding of the relationship between 
lung function and the blood vessels. Please be aware that the results of any genetic 
testing will be kept strictly confidential and will NOT be sent out to you as they do 
not have any clinical relevance and will not affect any private medical or life 
insurance policies you may have. Please note; this part of the study is optional and 
if you agree to take part in the genetics part of the study you will be asked to sign an 
optional clause on the consent form.  
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What are the possible benefits of taking part? 
You will not benefit directly from taking part in this study, however, it is hoped that 
the results of this study will lead to a greater understanding of the relationship 
between lung function and cardiovascular disease.  
What are the possible disadvantages/risks of taking part? 
As with all tests/procedures some people experience side effects, some of which 
are detailed below:- 
Blood Tests: Occasionally, some people feel faint during a blood test. If this occurs, 
please tell the person doing the test, as you should immediately lie down to prevent 
fainting. Sometimes after donating blood, a bruise develops where the needle was 
inserted.  
Will travel expenses be reimbursed?  
Participants will not be paid an inconvenience allowance to participate in the study. 
However, we will cover the cost of travelling to the hospital (maximum £10 
allowance per visit). 
:KDWZLOOKDSSHQLI,GRQ¶WZDQWWRFDUU\RQZLWKWKHVWXG\" 
You are free to withdraw from this study at any time and without giving a reason. A 
decision to withdraw, will not affect the standard of care you already receive. 
However, please be aware, that should you wish to withdraw, the information 
collected so far cannot be erased and may still be used in the final project analysis. 
Any stored tissue samples that can still be identified as yours will be destroyed if 
you wish. 
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Where will my data be stored and will my details be kept confidential? 
All data collected during the period of the study will be stored securely (password 
protected) on a dedicated trial database. Only the minimum required information for 
the purposes of the study shall be collected and this information will be subject to 
the same degree of confidentiality as your NHS notes. Access to the information will 
be limited to the research team and relevant regulatory authorities.  
Information on the storage and use of tissue samples for research 
Any tissue/blood sample you donate will be stored in a secure research facility at 
the University of Nottingham (Respiratory Biomedical Research Unit), for as long as 
is required for the purposes of this study. Your sample will have your code which is 
unique to yourself, a barcode and date of study. By using these numbers, we can 
trace which sample belongs to you. The analysis of samples will take place within 
the Respiratory Biomedical Research Unit at Nottingham City Hospital. Please note; 
your sample will not be sold for profit or used in any animal research.  
Your tissue/blood sample will be retained for 7 years in accordance with the 
UniYHUVLW\¶V&RGHRI5HVHDUFK&RQGXFWDQGWKHQGHVWUR\HGVKRXOG\RXZLVKWRGR
so. However, with your permission we would like to retain any remaining 
tissue/blood in a link-anonymised form for future laboratory research into respiratory 
disease (as yet unspecified). If you agree, the remaining tissue/blood will be stored 
on University premises under our Human Tissue Authority License.  
Involvement of the General Practitioner/Family Doctor (GP) 
With your permission we will write to your GP to notify them that you are going to 
take part in this study, and also inform them of any abnormal test results (if any) for 
appropriate action.  
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Who is organising and funding this study? 
The research has been organised and funded by the University of Nottingham. 
Please be aware that the research team involved in this study are not being paid for 
including you in this study. 
Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people called a 
Research Ethics Committee, to protect your interests. This study has been reviewed 
and given a favourable ethical opinion for conduct in the NHS by the Leicestershire, 
Northamptonshire & Rutland Research Ethics Committee 1 and will be subject to 
the Data Protection Act.   
What will happen to the results of this study? 
We intend to publish the results of this study in a medical respiratory journal. A 
summary of these results will also be made available on the Nottingham Respiratory 
%LRPHGLFDO 5HVHDUFK 8QLW¶V ZHEVLWH www.nrbru.org.uk). If you wish, you will be 
informed of the study results in clinic by the research nurse or doctor. Furthermore, 
a copy of any published material regarding the study will be made freely available to 
you. 
What if there is a problem? 
If you wish to complain or have any concerns about the way in which you have been 
treated, please get in touch with the research team (see below), who will do their 
best to answer any problems you might have. In addition, the normal NHS 
complaints procedures are also available to you (e.g. Patient Advice and Liaison 
Service ± PALS). Details can be obtained from the hospital. 
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Contact for Further Information 
Dr Charlotte Bolton  
Tel: 0115 82 31317 
E-Mail: charlotte.bolton@nottingham.ac.uk 
Or 
Michelle John  
Tel: 0115 82 31933  
E-Mail: michelle.john@nottingham.ac.uk  
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Appendix 5  ? Waveforms for Augmentation Pressure (AP) and AIx  
  
 
 
 
 
 
 
 
 
P1= first point of inflection 
P2= second point of inflection 
 
D= distance covered by the waves  W measured as the surface distance between the 
two recording sites  
 
T= time measured between the feet of the two waveforms  
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Appendix 6 - Diagram for Path Length Measurements for Arterial Stiffness Tests 
i 
 
  
 
 
 
 
 
Key -        carotid         supra sternal notch           femoral          radial 
Pulse and measurement locations used for sphygmocor arterial stiffness 
measurements  
 
ii       iii
A B 
A 
B 
In picture ii and iii measurements for path length are taken from points A to B  W brachial to 
femoral and carotid to femoral respectively for arterial stiffness measurements using the 
vicorder. 
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  Appendix 7  ? Skin AGE Reader Diagrams  
 
 
 
 
 
 
 
 
AGE Reader Schematic Diagram 
 
 
 
 
 
 
 
 
 
Glass fibre 
To output display 
Arm 
Lamp 
Signal analysis 
Spectrometer 
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Appendix 8  ? MRC Dyspnoea Scale 
Medical Research Council Dyspnoea Scale 
 
1. Not troubled by breathlessness except on 
strenuous exercise  
 
2. Short of breath when hurrying or walking up a 
slight hill  
 
3. Walks slower than contemporaries on the level 
because of breathlessness, or has to stop for 
breath when walking at own pace  
 
4. Stops for breath after about 100 m or after a 
few minutes on the level  
 
5. Too breathless to leave the house, or 
breathless when dressing or undressing 
 
 
  
250 
 
 
 
Appendix 9  ? COPD Assessment Test 
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Appendix 10  ? ^ƚ'ĞŽƌŐĞ ?ƐZĞƐƉŝƌĂƚŽƌǇYƵĞƐƚŝŽŶŶĂŝƌĞ 
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